

- Chandler, G., S2:40
 Chang, S.-K., 259
 Charra, B., 597
 Chauveau, P., 500
 Chazan, J. A., 14
 Chew, S. T. H., 135
 Chiba, S., 894
 Chiu, M. Y., 540
 Choi, J.-S., 259
 Choi, P. C. L., 3:E12
 Choi, Y.-J., 5:E22
 Choudhury, S., 869
 Cline, K. N., 713
 Clutterbuck, E., 155
 Coimbra, T. M., 328
 Collins, A. J., 1065
 Combarnous, F., 839
 Combe, C., 500
 Comerford, S. A., 180
 Compte, T., 264
 Connors, A. F., Jr., 706
 Conrad, K. P., 1142
 Constantini, E. G., 1065
 Constantino, T., 1105
 Contoreggi, C. S., 207
 Contreras, G., 1105
 Cooney, S. K., 918
 Cordido, F., 824
 Cosby, R. L., 304
 Cosio, F. G., 731
 Costa, R. S., 328
 Cosyns, J.-P., 166
 Courteau, S., 486
 Courvoisier, S., 745
 Criswell, L. A., 1040
 Crowley, S. T., 161
 Cunniff, P. J., 349
 Curtis, J. J., 756, 869

 D'Agati, V. D., 184, 588
 Daha, M. R., 344
 Dall'Amico, R., 1048
 Darnell, A., 273
 Daskal, I., 5:E21
 Davis, C. L., 405
 Davis, J. L., 212
 Deacon, A., 155
 De Cavanagh, E. M. V., 445
 Deenitchina, S. S., 279
 DeFranco, P., 65
 Delawari, E., 839
 Delclaux, C., 500
 Delmez, J., 493
 Depner, T. A., 493
 De Précigout, V., 500
 Deteix, P., 633
 Di Cataldo, A., 98
 Dickey, K. W., 752
 Djurdjev, O., 125
 Dolfin, T., 1129
 Domico, J., 228

 Domínguez-Cabrera, C., 508
 Domrongkitchiaporn, S., 29
 Donadio, J. V., Jr., 549
 Dong, Y., 583
 Duley, I., 863
 Dunfee, T. P., 222
 Dunn, S. R., 818
 Dydak, U., 875
 Dysseleer, A., 166

 Ebben, J. P., 1065
 Elinder, C.-G., 1083
 Elston, O., S2:40
 Eltayeb, B. O., 818
 Emerson, S., 688
 Emoto, M., 832
 Engels, K., 228
 Erbas, B., 140
 Ethier, J., 125
 Eto, T., 114
 Everson, S. E., 1065

 Fainaru, M., 438
 Faraggiana, T., 85
 Farina, M., 618
 Fassi, A., 626
 Feigin, M., 1129
 Feinfeld, D. A., 702
 Felsenfeld, A. J., 456
 Ferder, L., 445
 Ferguson, R. M., 731
 Feriozzi, S., 85
 Fernández-Rodríguez, A. M., 508
 Fervenza, F. C., 549
 Fiacco, V., 464
 Fick-Brosnahan, G., 639, 4:E17
 Fink, J. C., 1, 694
 Finkel, K. W., 1:E2, 2:E2, 3:E8,
 4:E15, 5:E19, 6:E24
 Finkelstein, F. O., 752
 Fioretto, P., 1002
 Fischer, F.-P., 678
 Fishbane, S., S2:47
 Fitzwilliam, J., 135
 Flanders, W. D., 1075
 Flores-Suárez, L. F., 364
 Fogo, A. B., 1:E1, 2:E1, 3:E7, 768,
 4:E14, 5:E18, 5:liv, 6:E23
 Forán, M. P., 824
 Fouque, D., 839
 Fraga, C. G., 445
 Frankel, W. L., 731
 Frankenfield, D. L., 721, S2:5, 1075
 Frederick, P. R., 721, 1075
 Freedman, B. I., 254
 Frey, F. J., 569
 Friedman, E. A., 775
 Friedman, G., 65
 Frinak, S., 21
 Fujimoto, S., 114
 Fukushima, M., 279, 1096

 Fukushima, K., 1016
 Furuta, T., 894

 Gabow, P. A., 120, 639, 4:E17, 863
 Gallo, G., 884
 Gan, B. S., 932
 Garcia, C., 264
 García, J., 43
 García-Buela, J., 824
 Garg, K., 120
 Gaughan, W. J., 4:E16
 Geadah, D., 486
 Gelfand, E., 65
 Gerakis, A., 521
 Germino, G. G., 1152
 Ghiggeri, G. M., 1048
 Ghio, L., 1048
 Giacchetti, G., 1002
 Ginevri, F., 1048
 Girgis, I., 1105
 Gitomer, J. J., 1:E2, 2:E2, 3:E8,
 4:E15, 5:E19, 6:E24
 Glynne, P., 155
 Godwin, D. A., 651
 Goffin, E., 166
 Goldsmith, D., 155
 Goldstein, C. S., 588
 Goldstein, S. L., 49
 Gómez-García, L., 338
 González-Roncero, F., 338
 Goto, M., 845
 Goumenos, D., 521
 Grassi, C., 618
 Greevska, L., 911
 Green, M., 438
 Greer, J. W., S1:1
 Grimm, E. M., 1:E2, 2:E2, 3:E8,
 4:E15, 5:E19, 6:E24
 Gruenhagen, S. E., 324
 Gualberti, L., 1105
 Gude, F., 996
 Guignard, J.-P., 2:E3
 Guillemin, L., 633
 Guindeo-Casasús, M. C., 508
 Gulati, S., 646
 Günther, E., 150
 Gupta, A., 646
 Gupta, K. L., 6:E25
 Gürgün, C., 218
 Gutierrez, C., 264

 Ha, K.-S., 259
 Haag-Weber, M., 247
 Haas, M., 69, 540
 Hakim, R., 471
 Halimi, S., 795
 Hamm, L. L., 960
 Hammer, R. E., 180
 Hansen, C., 651
 Hanson, J., S1:1
 Hao, W., 1065

- Hara, S., 926
 Harchowal, J., S2:40
 Hassan, M. H., 4:E16
 Hebert, L. A., 308
 Hegewisch-Becker, S., 5:E20
 Heidland, A., 433
 Heimbürger, O., 947, 1083
 Heinzelmann, M., 384
 Helgersson, S. D., 1075
 Henry, M. L., 731
 Hercz, G., 688
 Hermans, C., 166
 Herzenberg, A. M., 560
 Hess, J. M., 207
 Hino, S., 1016
 Hirakata, E., 1096
 Hirakata, H., 279, 1096
 Hirano, K., 902
 Hirano, T., 279
 Hirth, R., S1:1
 Hisanaga, S., 114
 Ho, C. P., 6:E27
 Hoen, B., S2:30
 Holden, J. K., 560
 Holman, D' A., 1033
 Hong, S.-Y., 259
 Hörl, W. H., 247, S2:25
 Hortal-Cascón, L., 508
 Horvath, F., Jr., 966
 Hosoya, T., 902
 Hossfeld, D. K., 5:E20
 Hotta, O., 894
 Hour, C., 1129
 Hovick, E. T., 1089
 Hudson, B. G., 549
 Hulbert-Shearon, T., S1:1
 Hull, S., 36
 Hunchik, M., 1125
 Huraib, S., 55
 Hyndman, M. E., 669
- Iaina, A., 146
 Ibayashi, S., 1096
 Iijima, K., 854
 Ikizler, T. A., 471
 Imai, H., 902
 Imai, T., 926
 Indridason, O. S., 135
 Inoue, S., 926
 Inoue, Y., 289, 854
 Inserra, F., 445
 Iqbal, A., 55
 Isaacs, R. B., 706
 Ishida, A., 3:E10
 Ishida, I., 1096
 Ismail-Beigi, F., 189
 Itin, P., 745
- Jaber, B. L., 349
 Jacobs, M. G., 65
 Jain, A., S1:1
- Jakob, S., 569
 James, L. R., 932
 Jeffrey, R., 937
 Jha, V., 6:E25
 Jiménez, A., 43
 Jindal, K., 125
 Jirakranont, B., 29
 Johnson, A. M., 120, 639, 4:E17, 863
 Johnson, C. A., 657, S2:5
 Jones, C. A., S1:1
 Josephson, M. A., 69, 540
 Joshi, K., 6:E25
 Juillard, L., 838
 Junaid, S. M. A., 92
- Kahn, S. I., 14
 Kaiser, J. W., 21
 Kaneko, K., 170
 Kaplan, B., 65
 Kara, N., 140
 Kasiske, B., 884
 Katafuchi, R., 279
 Katori, H., 926
 Katz, O., 146
 Katzir, Z., 146, 438
 Kausz, A. T., 651, 688
 Kawahara, H., 170
 Kawamoto, M., 114
 Kawamura, T., 902
 Kay, A., 405
 Keane, W. F., 2:xlili
 Kelley, V. R., 761
 Kew, J., 3:E12
 Khajehdehi, P., 92
 Khaothiar, L., S2:35
 Ki, P. K. T., 3:E12
 Kim, C. W., 1:E3
 Kim, J. S., 3:E13
 Kim, J. Y., 1:E3
 Kinoshita, H., 114
 Kitamura, K., 114
 Kiyohara, Y., 279
 Kleiner, M., 1105
 Kobayashi, S., 3:E10
 Kocak, H., 140
 Kohli, H. S., 6:E25
 Kopp, J. B., 177
 Korbet, S. M., 713
 Korzets, Z., 1129
 Kosorok, M. R., 657
 Kotaki, S., 170
 Kotani, M., 845
 Kovacs, B., 5:E21
 Kovalik, E. C., 135
 Kubo, M.-a., 1096
 Kuhlmann, U., 678
 Kurnik, B. R. C., 1010
 Kurth, S. J., 694
 Kurtzman, N. A., 1137
 Kuzuhara, K., 926
 Kwong, Y. L., 889
- Lafferty, J., 1105
 Lai, F. M.-M., 3:E12
 Lai, K.-N., 235, 380, 1056, 6:E26
 Lai, L.-W., 378
 Lajoie, G., 932
 Lam, C. C. K., 889
 Larroche, C., 633
 Lasne, Y., 839
 Lau, C. S., 315
 Laville, M., 839
 Law, M.-C., 235, 1056
 Leblanc, M., 486
 Lee, H. S., 1:E3
 Lee, H.-A., 259
 Lee, K. C., 355
 Lee, S. M. K., 565
 Lehmann, H., 364
 Leung, C. B., 514, 3:E12, 1056, 1132
 Levey, A. S., 308
 Levin, A., 125
 Levin, N. W., 493
 Levine, D. Z., 759
 Levine, J. S., 3:E11
 Levinsky, N. G., 775
 Lewis, E. J., 308, 809, 818
 Lewis, J. B., 308, 768, 809
 Lewis, R. M., 869
 Li, C. S., 355
 Li, F. K., 6:E26
 Li, P. K. T., 235, 514, 1056, 1132
 Lien, Y.-H. H., 378
 Light, P. D., 694
 Lijima, K., 289
 Lilaj, T., 247
 Lindholm, B., 1083
 Li Volti, S., 98
 Lobo, P. I., 706
 Locatelli, F., 795
 López-Hidalgo, R., 338
 Lui, S. L., 889
 Lynn, M. L., 61
- Ma, J. Z., 1065
 Maaz, D., 14
 Maccario, M., 530
 McClellan, W. M., 721
 McCue, P. A., 4:E16
 McDonald, J. C., 61
 Macdougall, I. C., S2:40
 McGowan, T. A., 818
 MacGregor, G. A., 583
 Macía, M., 43
 McMillan, R. W., 61
 Magil, A. B., 560
 Magnusen, H. M., 324
 Mailloux, L. U., 359
 Maioli, M., 1002
 Malhotra, D., 304
 Manco-Johnson, M., 120
 Manns, B. J., 669
 Manor, Y., 1129

- Mantero, F., 1002
 Markowitz, G. S., 184, 588
 Marks, E. A., 565
 Marti, H.-P., 569
 Martin, B. R., 324
 Martin-Herrera, C., 338
 Martin-Malo, A., 456
 Martinez-Vea, A., 264
 Maruyama, K., 1016
 Maruyama, N., 902
 Matas, Z., 438
 Matos, V., 2:E3
 Matsushita, Y., 926
 Matzke, G. R., 203
 McClellan, W. M., 1075
 McCloughlin, J., 1105
 McGinn, T. G., 1105
 Meehan, S. M., 69
 Mees, E. J. D., 218
 Meier, D., 875
 Meier-Kriesche, H.-U., 65
 Mendelssohn, D., 125
 Mercer-Jones, M. A., 384
 Messana, J. M., 424
 Mettang, T., 678
 Meyers-Purkiss, A., S1:1
 Meysen, T., 433
 Michaux, L., 166
 Mihatsch, M. J., 745, 1146
 Milà, M., 273
 Mir, R., 702
 Mittman, N., 173
 Miwa, M., 289
 Miyazato, H., 1016
 Moberly, J. B., 663
 Modai, D., 146
 Mok, C. C., 315
 Molero-Labarta, T., 508
 Moll, S., 745, 1146
 Mollica, F., 98
 Molony, D. A., 1:E2, 2:E2, 3:E8,
 4:E15, 5:E19, 6:E24
 Montini, G., 1048
 Mora, C., 43
 Morii, H., 832
 Morita, A., 832
 Moriya, H., 3:E10
 Moroni, G., 530
 Muda, A. O., 85
 Mukoyama, M., 845
 Mulgaonkar, S., 65
 Murakami, R., 289
 Myerburg, R. J., 1105

 Nadeau, J., 768
 Nagase, M., 611
 Nakabayashi, I., 3:E10
 Nakagawa, M., 845
 Nakamoto, H., 170
 Nakamura, H., 289, 854
 Nakanishi, K., 854

 Nakao, K., 845
 Nanhau, A., 364
 Nass, K., 955
 Navarro, J. F., 43
 Navarro, M., 338
 Neugarten, J., 884
 Neumayer, H.-H., 556, 3:E9
 Newman, N., 464
 Nickeleit, V., 1146
 Niederer, U., 569
 Nishio, H., 854
 Nishiyama, J.-i., 3:E10
 Nishiyama, K., 289, 854
 Nishizawa, Y., 832
 Nock, S. L., 706
 Nosadini, R., 1002
 Nowack, R., 364

 Oda, K., 611
 Ogawa, Y., 845
 Ojo, A. O., S1:1
 Okada, H., 170
 Okada, M., 1016
 Oliver, J. A., 264
 Omae, T., 1096
 O'Neill, W. C., 955
 Oreopoulos, D. G., 663
 Ornt, D., 493
 Ortner, M.-A., 556
 Orzol, S., 424
 Owen, W., 493
 Owen, W. F., Jr., 721, S2:1, S2:5
 Ozen, S., 140
 Ozenne, S., 500
 Özerkan, F., 218
 Özkahya, M., 218

 Padhi, I. D., 222
 Pak, C. Y. C., 107
 Palmer, R. B., 651
 Palop-Cubillo, L., 508
 Palumbo, M., 98
 Pani, A., 618
 Parekh, R., S1:1
 Parent, D., 486
 Parsons, H. G., 669
 Pasquali, S., 530
 Passerini, P., 618
 Passmore, J. C., 384
 Patel, R. V., 222
 Patruta, S. I., S2:25
 Pauksakon, P., 768
 Pauli-Magnus, C., 678
 Paulson, W. D., 478
 Peck, L. W., 324
 Pegram, S., 254
 Pei, Y., 688
 Peixoto, A. J., 161
 Pelletier, R. P., 731
 Peralta, C., 264
 Pereira, B. J. G., 349

 Perez, G., 1105
 Pérez-Borges, P., 508
 Pérez-Oller, L., 273
 Perico, N., 626
 Pesavento, T. E., 731
 Peterson, D. D., 1089
 Petronis, J. D., 207, 341
 Pfister, M., 569
 Pierratos, A., 597
 Piette, J. C., 633
 Pirsch, J., 869
 Pirson, Y., 166
 Pittalà, D., 98
 Polenakovik, M. H., 911
 Pomeranz, A., 1129
 Ponticelli, C., 530, 618
 Port, F. K., S1:1, 424
 Pozzi, C., 618
 Prabhu, P. N., 937
 Prajapati, D., 932
 Pressman, M. R., 1089
 Pugh, J., 721
 Puhlman, M. E., 918
 Pupim, L. B., 471
 Pusey, C., 155

 Quadri, K., 55
 Quaglini, S., 530
 Quan, A., 1125

 Ragusa, R., 98
 Rahimi, S., 85
 Raj, D. S. C., 597
 Ram, S. J., 478
 Reddy, S. M., 3:E11
 Regan, F., 207, 341
 Rehman, S. U., 471
 Reilly, R. F., 161
 Remuzzi, A., 626
 Remuzzi, G., 626, 951
 Renis, M., 98
 Rennke, H. G., 3:E11
 Richart, C., 264
 Rigalleau, V., 500
 Ritz, E., 150, 795
 Rivabella, L., 1048
 Rocco, M. V., 721, 1075
 Rocha, J. L., 338
 Rodriguez, M., 456
 Rodríguez-Carmona, A., 824
 Rodríguez-Puras, M. J., 338
 Rohde, R., 818
 Rohde, R. D., 308
 Rohdes, R. D., 809
 Romeh, S. A., 55
 Romero, R., 996
 Roth, S., 150
 Rousset, H., 633
 Rovin, B. H., 761
 Roys, E., S1:1
 Rudolph, B., 556

- Ruml, L. A., 107
 Russo, A., 98
 Rychlik, I., 795
 Ryuzaki, M., 170

 Saad, T. F., 1114
 Saatci, U., 140
 Saavedra-Santana, P., 508
 Sagnella, G. A., 583
 St. Pierre, D., 14
 Sakai, O., 902
 Sakhuja, V., 6:E25
 Salinas-Madrigal, L., 92
 Saller, A., 1002
 Samsell, L. S., 228
 Samuels, A., 5:E21
 Sanchez, P., 264
 Sánchez-Guisande, D., 996
 Sardu, C., 1002
 Sauron, C., 633
 Sawaya, D. E., 61
 Sawyer, R., 706
 Scalamogna, M., 1048
 Schaefer, J. P., 669
 Schifferli, J. E., 745
 Schilirò, G., 98
 Schmid, M., 1146
 Schmidt, K.-H., 150
 Schmidt, M., 569
 Schmidt, R. J., 228
 Schmidt-Nowara, W., 739
 Schmitz, P. G., 92
 Schneider, B., 247
 Schultz, J., 464
 Schulze, D. G., 324
 Schwab, S. J., 362, 3:xxxviii
 Schwab, T. R., 549
 Scott, R., 464
 Scott-Douglas, N. W., 669
 Scrivo, D., 445
 Seigle, R. L., 184
 Semenyuk, L., 464
 Sfriso, A., 1002
 Shapiro, J. I., 304
 Sharma, A. P., 646
 Sharma, K., 4:E16, 818
 Sharma, R. K., 646
 Sharp, C. K., 863
 Shaver, M. J., 942
 Shayakul, C., 374
 Shemin, D., 14
 Sherman, R. A., 972
 Sherrard, D. J., 688
 Sheth, A., 5:E22
 Shickle, L. M., 694
 Shih, D., 713
 Shimatsu, A., 845
 Shinn, C., 304
 Shinozaki, M., 279
 Shiozawa, S., 289

 Shirakawa, T., 289, 854
 Shoji, T., 832
 Short, R., 918
 Shortland, J. R., 521
 Shyr, Y., 471
 Sibai-Galland, R., 839
 Silbiger, S., 884
 Simpson, P. M., 207
 Singer, J., 125
 Singh, S., 560
 Sklar, A., 464
 Smetana, S., 438
 Solini, A., 1002
 Sorkin, M. I., 228
 Sorof, J. M., 49
 Soubrier, M., 633
 Soucie, J. M., 254
 Souweine, B., 633
 Späth, P. J., 745
 Spencer, C. E., 706
 Spitalewitz, S., 308
 Stack, A., S1:1
 Stahl, R. A. K., 5:E20
 Stamm, E. R., 120
 Stenvinkel, P., 947, 1083
 Stone, J. H., 1040
 Stone, S. M., 254
 Stopper, H., 433
 Strain, J. D., 639, 4:E17
 Strawderman, R. L., S1:1
 Strife, C. F., 1022
 Sud, K., 6:E25
 Sugahara, S., 170
 Sugar, L., 3:E13
 Sugawara, A., 845
 Sugimori, H., 1096
 Sumino, K., 854
 Sunder-Plassmann, G., S2:25
 Suzuki, H., 170
 Swaminathan, S., 6:E25
 Swartz, R. D., 424
 Szczec, L., S2:5
 Szeto, C.-C., 235, 514, 3:E12, 1056, 1132

 Tabata, T., 832
 Tagami, T., 926
 Taguma, Y., 894
 Takemoto, F., 926
 Takemura, T., 1016
 Tam, J. S., 1132
 Tanaka, I., 845
 Tanaka, K., 845
 Tanaka, R., 289
 Tanaka, S., 926
 Tang, S., 380
 Tanimu, D., 55
 Taylor, C. A., III, 657
 Tedeschi, P. J., S1:1
 Terreros, D., 549

 Tesch, G. H., 761
 Thistlethwaite, J. R., 69, 540
 Thomas, M., 1033
 Thomas, S., 678, 1139
 Thompson, C. R., 125
 To, K. F., 3:E12
 Tobe, S., 125
 Tokura, T., 114
 Tonolo, G., 1002
 Torra, R., 273
 Torres, A., 43
 Torres, V. E., 6: xlv-xlviii
 Touchette, M. A., 222
 Townsend, R. R., 120
 Töz, H., 218
 Tracy, T. S., 228
 Traeger, J., 839
 Trendelenburg, M., 745
 Truong, L. D., 5:E22
 Tsiouris, N., 5:E21
 Tsujimoto, Y., 832
 Tuncbilek, E., 140
 Turner, M. S., 694
 Turney, J. H., 36
 Tuttle, K. R., 918

 Ubara, Y., 926
 Umpleby, S., 36
 Ungkanont, A., 29
 Unsal, I., 140
 Ünsal, A., 218
 Uribarri, J., 493
 Utsunomiya, Y., 902

 Vamvakas, S., 433
 Van Es, L. A., 344
 Van Buren, D. H., 869
 Van der Woude, F. J., 364
 Van Melle, G., 2:E3
 Vardinon, N., 146
 Vega-Díaz, N., 508
 Verburgh, C. A., 344
 Viberti, GC., 1139
 Vidiella, J., 264
 Villa, M., 618
 Volpini, R., 328
 Vonesh, E. F., 713
 Vychytil, A., 247

 Waiser, J., 556, 3:E9
 Wang, A. Y. M., 3:E12
 Wang, T., 1083
 Wang, X.-Q., 706
 Warnock, D. G., 579
 Wassermann, A., 445
 Watkins, S. L., 651
 Weaver, C. M., 324
 Webb, R. L., S1:1
 Weber, J., 678
 Wechsler, B., 633

- Weir, M. R., 1
 Weisberg, L. S., 1010
 Weiss, N. S., 688
 Werner, D., 2:E3
 West, C. D., 1022
 Wheeler, J. R., S1:1
 Whittier, F., 308
 Williams, R. A., Jr., 549
 Wilmer, W. A., 308
 Winchester, J. F., I:xxxvi
 Wisniewska, J., 663
 Wit, E.-J. C., 69
 Wolach, B., 1129
 Wolf, B., 875
 Wolf, G., 5:E20
 Wolfe, R. A., S1:1
 Wong, K. M., 355
 Wong, R. W. S., 315
 Wong, T. Y. H., 235, 514, 1056, 1132
 Woodle, E. S., 69, 540
 Woodrow, G., 36
 Work, J., 61, 478, 597
 Wright, M. J., 36
 Xia, H., 1065
 Xu, H., 289
 Yahata, K., 845
 Yamada, A., 926
 Yamamoto, S., 1016
 Yamamoto, T., 170
 Yan, G., 493
 Yang, D.-H., 259
 Yip, P. S., 6:E26
 Yokota, M., 926
 Yokota, N., 114
 Yokota, S., 228
 Yoshikawa, N., 289, 854
 Yoshioka, K., 1016
 Young, E. W., S1:1
 Yu, A. W. Y., 1056
 Yusa, N., 894
 Yust, I., 146
 Zaltzman, J. S., 3:E13
 Zamorani, E., 1048
 Zeligman, B. E., 863
 Zennaro, C., 1048
 Zhang, J.-Z., 189
 Zibari, G. B., 61
 Zimmerman, S. W., 657
 Ziyadeh, F. N., 818
 Zucchelli, P., 530

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (August 1999) and Supplement 2 (October 1999) are preceded, respectively, by S1: and S2:.

- AAs (amino acids), reabsorption of, in pediatric FS secondary to chemotherapy, 100
 Abbreviations, 1999 USRDS ADR, S1:7-8
 ABD (aluminum-related bone disease), *see* Renal osteodystrophy in ESRD patients on HD
 Abdominal pain, persistent, and prevalence of active CMV in GI tract of RTx recipients, 65-68
 ABO blood group, and RTx for ESRD, USRDS 1999 ADR on, S1:98
 Abstracts citing USRDS data, S1:29
 Abusive end-stage renal disease patients, *see* Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD
 Acceptance into ESRD therapy, S1:162-164
 Access, vascular, *see* Vascular access, HD
 Access to RTx, USRDS 1999 ADR on, S1:96-98
 executive summary of, S1:15-16
 by pediatric patients, S1:109-110
 ACE, *see*: ACE gene; Angiotensin-converting enzyme; Angiotensin-converting enzyme inhibitor(s)
 ACE gene
 in NIDDM siblings, MA and, 1002-1009
 see also Polymorphism of ACE gene
 Acid/base homeostasis
 effects of Pi replacement for hypophosphatemia on, in RTx recipients, 875-883
 see also pH
 Acidosis
 glucocorticoids in, 960-965
 and nutritional status of ESRD patients on HD, 493-499
 ACKD (acquired cystic kidney disease) in ESRD children on CAPD, 242-246
 Acknowledgment for use of USRDS data, S1:35
 Acquired cystic kidney disease (ACKD) in ESRD children on CAPD, 242-246
 Actin, *see* Smooth muscle actin; α -Smooth muscle actin
 Active cytomegalovirus (CMV) infection in GI tract of RTx recipients, persistent abdominal pain, 65-68
 Acute c-anti-neutrophil cytoplasmic-positive vasculitis, MMF for, 3:E9
 Acute interstitial nephritis (AIN), 4:E14
 drug-induced renal allograft, histopathology and course of, 540-548
 Acute rejection
 pulse methylprednisolone for, time course of response to, 304-307
 racial disparities in, 709
 Acute renal failure (ARF)
 bedside renal biopsy for, 956
 CRRT of, *see* Acute renal failure, CRRT of
 due to immersion in seawater polluted by diesel oil, 6:E26
 due to paradoxical embolism, 752-755

- neonatal, due to transplacental transfer of nephrotoxic paraprotein, exchange transfusion for, 1129-1131
- renal AED with, gallium-67 uptake in, 161-165
- with Rosai-Dorfman disease, 3:E12
- streptococcal toxic shock syndrome with desquamating erythema and, 150-154
- see also* Neutrophils in ARF
- Acute renal failure (ARF), CRRT of
- convective clearances with, at various dialysate and ultrafiltration flow rates, 486-492
- see also* Diffusive clearances, and CRRT of ARF
- Acute tubular necrosis (ATN)
- in diabetes mellitus, HD for, 1010-1015
- spontaneous graft rupture due to, 355-358
- Acute vision loss with pediatric ARPKD, 1125-1128
- Acylcarnitine, serum, L-carnitine effects on, 682, 685
- Address of USRDS site on World Wide Web, S1:25
- Adenosine triphosphatase (ATPase) in pediatric FS secondary to chemotherapy, 101
- Adequacy of dialysis
- of CAPD, independent effects of RRF and, on nutritional status of CAPD patients, 1056-1064
- on prolonged slow HD, 599-601
- quality improvement of, ESRD Core Indicators Project report on, 1075-1082
- see also* entries beginning with: Ku/V
- ADH (antidiuretic hormone), secretion of, and etiology of IE, 413
- Adhesion molecules, role of, in neutrophil-induced renal injury in ARF, 391-393
- Adjusted death rates of ESRD patients, USRDS 1999 ADR on, S1:75-77, S1:81-82, S1:153-154
- annual, S1:166-171
- first-year, S1:74-80
- Adjustment
- standard population for, in USRDS 1999 ADR, 1:153
- see also* Adjustment, rate, in USRDS 1999 ADR
- Adjustment (standardization), rate, in USRDS 1999 ADR, S1:10, S1:152, S1:164-166
- see also* Adjusted death rates of ESRD patients, USRDS 1999 ADR on
- Admissions, *see* Hospitalization
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- ADR (Annual Data Report) of USRDS, *see* United States Renal Data System, 1998 ADR of; United States Renal Data System, 1999 ADR of
- Adrenomedullin (AM), plasma and urinary PAMP and, in chronic GN, 114-119
- Adverse effects
- of parenteral Fe therapy, S2:44
- see also* Adverse effects of immunosuppression
- Adverse effects of immunosuppression
- for LN, S25
- of prolonged immunosuppression for FSGS, 623
- Adynamic bone disease, serum Mg and PTH levels in ESRD patients on HD and, 43-48
- AED (atheroembolic disease), renal, with ARF, gallium-67 uptake in, 161-165
- African Americans, *see* Race
- AFS (Annual Facility Survey), S1:157, S1:159
- Age
- of ADPKD patients with colonic diverticular disease, 865
- of bedside renal biopsy patients, 956
- of CAD patients, 920, 922
- of chronic GN patients, 115
- of DM patients, *see* Age of DM patients
- of early renal disease patients, LVH and, 127, 129, 131
- of ESRD patients, *see* Age of ESRD patients on RRT
- of FS patients, 99
- of FSGS patients, 620
- of HTN patients, *see* Age of HTN patients
- of hypokalemic patients, 109
- of IgAN patients, *see* Age of IgAN patients
- of IMN patients, 523
- of LN patients, 317, 319
- of MGN and LMGN patients, 86
- of MPGN patients, 1024
- of nephrotic-range proteinuria patients, 136, 137
- of NS patients, 612
- of POEMS syndrome patients, 634
- of proliferative GN patients, DSG effects and, 895
- of recurrent Goodpasture's syndrome, 554
- of severe ARF patients, 426, 428, 429
- of TINU syndrome patients, 1017
- Age of DM patients
- with ATN, 1012
- and reduced orthostatic cerebral blood flow due to HD, 1097
- see also* Age of IDDM patients with HTN, captopril and; Age of NIDDM patients
- Age of ESRD patients, USRDS 1999 ADR on
- adjusted first-year death rates by, S1:78
- causes of mortality by, S1:88-89, S1:91-93
- expected remaining years of life by, S1:84-85, S1:173
- incidence and prevalence of treated ESRD by, S1:11, S1:42-45, S1:47-49
- Medicare expenditures by, S1:132-135
- of new ESRD patients, S1:64
- patient survival by, S1:172-173
- of pediatric patients, S1:102-107
- RRT modality by, S1:57
- Age of ESRD patients with ADPKD on HD
- ACE gene polymorphism and, 275
- valvular heart disease and, 266
- Age of ESRD patients on HD
- and association between acidosis and nutritional status, 494, 496
- with asymptomatic Al-related renal osteodystrophy, 690
- atherosclerotic vascular disease and, 671, 674
- and CVD, 440
- effects of calcitriol and, on recovery from hypocalcemia, 456-463
- Fe deficiency diagnosis and, 510
- gentamicin pharmacokinetics and, 223
- hyperleptinemic, 825, 827
- leukocyte phagocytic function and viability and, 681
- on long-term maintenance HD, genomic damage to lymphocytes and, 434, 435
- new patients, serum Cr levels and, 696-698
- race and, and outcome of HD, 723, 728
- and relationship between serum Mg and PTH, 44, 45

- rHuEPO and, 24, 1091
- SAEG and, 1107
- serial VABF and, 472
- see also* Age of ESRD patients with ADPKD on HD
- Age of ESRD patients on PD/CAPD
 - with asymptomatic Al-related renal osteodystrophy, 690
 - Cr generation and, 236
 - and effects of aminoglycosides on RRF, 16, 17
 - of new patients, Scr levels and, 696-698
 - NIDDM and, 516, 517
 - nutritional status and, 1058
 - PET measurement of D/P ratio and, 248
 - race and, *see* Age of ESRD patients on PD/CAPD, race and
 - see also* Age of ESRD patients on PD/CAPD, Fe in; Age of ESRD patients on PD/CAPD and IP rHuEPO therapy
- Age of ESRD patients on PD/CAPD, Fe in
 - Fe deficiency diagnosis, 510
 - Fe status, 31
 - Age of ESRD patients on PD/CAPD, leptin and hyperleptinemia, 825, 827
 - and leptin in dialysate, 833
 - and peritoneal leptin clearance, 840
- Age of ESRD patients on PD/CAPD, race and
 - familial aggregation of ESRD in HIVAN and, 248
 - and survival, 714, 716
- Age of ESRD patients on PD/CAPD and IP rHuEPO therapy
 - "dry well" dosing technique and, 659
 - pediatric patients on CCPD, 654
- Age of ESRD patients on RRT
 - serum hyaluronan, survival and, 1084, 1085
 - see also* Age of ESRD patients on HD; Age of ESRD patients on PD/CAPD; Age of RTx recipients
- Age of HTN patients
 - low-renin HTN patients, 581, 584
 - with MA, 997
 - see also* Age of IDDM patients with HTN, captopril and
- Age of IDDM patients with HTN, captopril and
 - captopril effects on IDDM course, 811
 - long-term renoprotection with captopril, 820
 - and NS remission with captopril, 310
- Age of IgAN patients, 906
 - with *PAF-AH* gene mutation, 292
 - with *TCR C α* gene polymorphism, 282
- Age of NIDDM patients
 - on CAPD, 516, 517
 - with MA, *ACE* and *AGN* genes and, 1004
- Age of RTx recipients
 - with CMV infection, persistent abdominal pain and, 66
 - de novo FSGS in renal graft and, 733-735
 - and drug-induced renal graft AIN, 542
 - for FSGS, 1049
 - hypophosphatemic, 876
 - oral CsA versus SGC formulation and, 871
 - parvovirus B19 infection and PRCA and, 1134, 1135
 - quality of life and, 62
 - race, RTx outcome and, 708
- Aggregation size, minimum, in USRDS 1999 ADR analytical methods, S1:154
- Aggressive end-stage renal disease patients, *see* Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD
- Aging-related glomerulosclerosis (GS), sex and, 884-888
- AGN* gene in NIDDM siblings, MA and, 1002-1009
- Agreement for data release, S1:38-39
- AIN, *see* Acute interstitial nephritis
- Al, *see* Aluminum in ESRD patients on HD
- Albumin
 - in LN, 536
 - see also* Albumin in ESRD patients; Microalbuminuria; Plasma albumin; Proteinuria
- Albumin in ESRD patients
 - serum, in RRT patients, *see* Serum albumin in ESRD patients on RRT
 - VLPD and, 501
 - see also* Albumin in ESRD patients on HD; Albumin in ESRD patients on PD/CAPD; Prealbumin in ESRD
- Albumin in ESRD patients on HD
 - L-carnitine effects on, 683
 - CVD and, 440
 - Fe deficiency and, 510
 - and hyperleptinemia, 826, 827
 - in new ESRD patients, 696-698
 - Radix angelicae sinensis* effects on, 350
 - see also* Serum albumin in ESRD patients on HD
- Albumin in ESRD patients on PD/CAPD
 - Fe deficiency and, 510
 - and hyperleptinemia, 826, 827
 - in new ESRD patients, 696-698
 - race, survival and, 716
- Aldosterone, *see* Plasma aldosterone; Renin-aldosterone axis
- Alkaline phosphatase (ALP) in ESRD patients on HD
 - with ADPKD, 266
 - or CAPD, asymptomatic Al-related renal osteodystrophy and, 690
 - relationship between serum Mg and PTH and, 44, 45
- Allergic interstitial nephritis (IN), differentiation between renal AED and, with gallium-67 scan, 161-165
- ALP, *see* Alkaline phosphatase in ESRD patients on HD
- Alpha (α)-smooth muscle actin (α -SMA), expression of mesangial cell, and IgAN progression, 902-910
- Alport's syndrome, X-linked, RT-PCR and direct sequencing in detection of *COL4A5* gene mutations in, 854-862
- Alternate-day prednisone, differences between types I and III MPGN in response to, 1022-1032
- Aluminum (Al) in ESRD patients on HD
 - plasma, asymptomatic ABD and, 688-693
 - and resistance to rHuEPO, 350, 352
 - serum, and relationship between serum Mg and PTH, 44, 45
 - see also* Renal osteodystrophy in ESRD patients on HD
- AM (adrenomedullin), plasma and urinary PAMP and, in chronic GN, 114-119
- Amino acids (AAs), reabsorption of, in pediatric FS secondary to chemotherapy, 100
- Aminoglycosides, effects of, on RRF of PD patients, 14-20
- Amyloidosis
 - de novo amyloid light chain, benign monoclonal gammopathy turning into, after RTx, 166-169

- idiopathic myelofibrosis complicated by, 6:E27
- systemic, as primary diagnosis, 138
- Analgesic nephropathy, as primary disease, 435
- Analysis files, USRDS
 - for researchers, S1:26-35
 - see also* specific analysis files
- Analytical methods used in USRDS 1999 ADR, S1:18-19, S1:152-176
 - for annual mortality, hospitalization, and RTx, S1:166-171
 - database and, *see* Database, USRDS
 - to determine causes of mortality, S1:87-88, S1:153
 - for expected remaining years of life, S1:173
 - for graft survival, S1:152, S1:173
 - intent-to-treat model in, S1:174-176
 - lost-to-follow-up classification methods in, S1:160-162
 - measurement concepts in, S1:162-164
 - for Medicare claims, S1:174
 - for patient survival, S1:152, S1:171-173
 - for rate adjustment, *see* Adjustment, rate, in USRDS 1999 ADR
 - for treatment modalities, S1:173-174
 - what's new in, S1:152-154
- PANCAs, *see* Anti-neutrophil cytoplasmic autoantibody(ies); c-Anti-neutrophil cytoplasmic autoantibody-positive vasculitis
- Anemia
 - of ESRD, *see* Iron deficiency in ESRD patients on HD; Iron deficiency in ESRD patients on PD/CAPD; Recombinant human erythropoietin for anemic ESRD patients
 - and LVH in early renal disease, 125-134
 - in pediatric ARPKD, acute vision loss and, 1125-1128
- ANF (atrial natriuretic factor), levels of, and etiology of IE, 413-414
- Angina in ESRD patients on HD, L-carnitine effects on, 683
- Angioaccess, HD, *see* Vascular access, HD
- Angiography, coronary, in detection of CAD, 918-925
- Angiotensin-converting enzyme (ACE)
 - activity of serum, in NIDDM ESRD patients on CAPD, 514-520
 - see also* ACE gene; Angiotensin-converting enzyme inhibitor(s)
- Angiotensin-converting enzyme (ACE) inhibitor(s)
 - captopril as, *see* Captopril
 - effects of, on progression of renal disease, 626-632
 - enalapril as, antioxidant defense level in ESRD patients on HD treated or not treated with, 445-455
 - in NIDDM ESRD, 802
 - PD patients on, RRF and, 16, 17
 - proteinuria and, *see* Proteinuria, ACE inhibition and
- Anion gap, and SAHS in RTx recipients, 741
- Annual adjusted death rate of ESRD patients, USRDS 1999 ADR on, S1:166-171
- Annual Data Report of USRDS, *see* United States Renal Data System, 1998 ADR of; United States Renal Data System, 1999 ADR of
- Annual Facility Survey (AFS), S1:157, S1:159
- Annual hospitalization for ESRD, USRDS 1999 ADR on, S1:166-171
- Annual renal transplantation (RT; RTx) for ESRD, USRDS 1999 ADR on, 166-171
- ANP (atrial natriuretic peptide), proadrenomedullin N-terminal 20 as, plasma and urinary AM and, in chronic GN, 114-119
- Anterior ischemic optic neuropathy, and acute vision loss in pediatric ARPKD, 1125-1128
- Antibody(ies)
 - aPL antibody syndrome in RTx for ESRD secondary to SLE, 1040-1047
 - monoclonal IgA- κ circulating, recurrent Goodpasture's syndrome due to, 549-555, 565-568
- Anti-C1q autoantibodies in HUVS and SLE, 745-751
- Antidiuretic hormone (ADH), secretion of, and etiology of IE, 413
- Antigens, *see* HLA
- Anti-glomerular basement membrane (GBM) antibody disease, recurrent Goodpasture's syndrome due to monoclonal IgA- κ circulating antibody and, 549-555, 565-568
- Anti-glomerular basement membrane (GBM) nephritis, ANCA-associated pauci-immune GN and, 344-348
- Antihypertensive drugs
 - effects of, on MA in hypertension, 984-985
 - see also* specific classes of antihypertensives; for example: Angiotensin-converting enzyme inhibitor(s)
- Anti-neutrophil cytoplasmic autoantibody(ies) (ANCA), anti-glomerular basement membrane nephritis and pauci-immune GN associated with, 344-348
- c-Anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis, acute, MMF for, 3:E9
- Antioxidants, level of, in ESRD patients on HD treated or not treated with enalapril, 445-455
- Antiphospholipid (aPL) antibody syndrome in RTx for ESRD secondary to SLE, 1040-1047
- Anti-tubular basement membrane (anti-TBM) nephritis, differentiating between partial pediatric FS and, 184-188
- Aortic bacterial endocarditis due *S haemolyticus* catheter infection, inverse paradoxical embolism with, in chronic HD patient, 338-340, 362-363
- APD, *see* Automated peritoneal dialysis for ESRD
- aPL (antiphospholipid) antibody syndrome in RTx for ESRD secondary to SLE, 1040-1047
- Aplasia, pure red cell, parvovirus B19 infection causing, in RTx recipients on tacrolimus, 1132-1136
- Apnea, sleep, effects of rHuEPO for HD patients on HD, 1089-1095
- Apnea hypoapnea syndrome, reversal of sleep, following RTx for ESRD, 739-744
- Apolipoprotein A (apo-A) in ESRD patients on HD, CVD and, 440, 441
- Apolipoprotein B (apo-B) in ESRD patients on HD, CVD and, 440, 441
- ARF, *see* Acute renal failure
- Arginine on HD, indices of activity of, 228-234
- ARPKD (autosomal recessive polycystic kidney disease), pediatric, acute vision loss in, 1125-1128
- Arterial embolization, transcatheter renal, in ADPKD patients with ESRD on HD, 926-931
- Arterial pressure, *see* Blood pressure
- Arteriolar dilation in IE, 408

- Arteritis, *see* Polyarteritis nodosa
- Asia, incidence and prevalence of treated NIDDM ESRD in, 800-801
- Asian Americans, *see* Race
- Aspirin, effects of, on heparin requirements of ESRD patients on HD, 38
- Assessment of abusive and/or aggressive patients and their noncompliance, 781-782
- Asymmetry, renal, in children with ADPKD, 639-645, 4:E17
- Asymptomatic aluminum-related bone disease (ABD) in ESRD patients on HD or CAPD, 688-693
- AT1 receptor gene, and scarring in VUR, 140-145
- ATG gene, and scarring in VUR, 140-145
- Atheroembolic disease (AED), renal, with ARF, gallium-67 uptake in, 161-165
- Atherosclerosis, MA in TNH and, 996-1001
- Atherosclerotic vascular disease, hyperhomocyst(e)nia and prevalence of, in ESRD patients on HD, 669-677
- Atlas of renal pathology, 1:E1, 2:E1, 3:E7, 4:E14, 5:E18, 6:E23
- ATN, *see* Acute tubular necrosis
- ATPase (adenosine triphosphatase) in pediatric FS secondary to chemotherapy, 101
- Atrial natriuretic factor (ANF), levels of, and etiology of IE, 413-414
- Atrial natriuretic peptide (ANP), proadrenomedullin N-terminal 20 as, plasma and urinary AM and, in chronic GN, 114-119
- Augloid light chain amyloidosis, de novo, benign monoclonal gammopathy turning into, after RTx, 166-169
- Autoantibodies
anti-C1q, in HUVS and SLE, 745-751
see also Anti-neutrophil cytoplasmic autoantibody(ies); c-Anti-neutrophil cytoplasmic autoantibody-positive vasculitis
- Automated literature search in online features of *AJKD*, 1137-1138
- Automated peritoneal dialysis (APD) for ESRD
aminoglycosides and RRF on, 17
influence of preceding exchange on PET results on, 247-253
- Automated spring-loaded gun device, percutaneous renal biopsy using ultrasound-guided, effects of, on bleeding, and implications for early hospital discharge, 92-97
- Autosomal dominant polycystic kidney disease (ADPKD) without ESRD, colonic diverticular disease with, 863-868
extrarenal manifestations of, 6: xlv-xlviii
see also Autosomal dominant polycystic kidney disease, ESRD patients on HD with; Cyst(s) in ADPKD
- Autosomal dominant polycystic kidney disease (ADPKD), ESRD patients on HD with, 264-278
- ACE gene polymorphism and progression of renal failure in, 273-278
echocardiography of cardiac complications in, 264-272
transcatheter renal arterial embolization in, 926-931
- Autosomal recessive polycystic kidney disease (ARPKD), pediatric, acute vision loss in, 1125-1128
- Availability of kidneys, RTx and, USRDS 1999 ADR on, S1:95-96
- Azathioprine, effects of prednisolone and, on progression of IMN, 521-529
- Azide, tissue exposure to, and glucose transport regulation by hypoxia, 189-202
- Bacteremia associated with tunneled, cuffed, permanent HD catheters, 1114-1124
- Bacterial endocarditis, aortic, due *S haemolyticus* catheter infection, inverse paradoxical embolism with, in chronic HD patient, 338-340, 362-363
- Bacterial virulence, Fe effects on, S2:48-49
- Bartter's syndrome, Gitelman's syndrome as subtype of, R642C missense mutation of TSC gene in, 845-853
- BD (bullous dermatoses) in ESRD patients on CAPD, 155-160
- Bedside renal biopsy, ultrasound guidance for, 955-959
- Benign monoclonal gammopathy turning to de novo augloid light chain amyloidosis after RTx, 166-169
- Berger's disease, *see* IgA nephropathy
- Beta (β) cells, function of, in NIDDM patients on CAPD for ESRD, homeostasis model analysis of, 514-520
- Beta₂-microglobulin, *see* β_2 -Microglobulin
- BF (blood flow), *see* Vascular access blood flow, HD
- Bicarbonate, *see* NaHCO₃
- Bilateral hydronephrosis without obstruction, reversibility of, in HBV infection-associated PAN, 3:E11
- Bilateral renal infarction secondary to paradoxical embolism, 752-755
- Bilirubin, total, in severe ARF, 427-430
- Bioavailability of oral CsA versus SGC formulation, 869-874
- Biochemistry
of NIDDM patients on CAPD for ESRD, relationship between insulin requirements and, 514-520
see also specific biochemical data
- Biocompatible membranes, *see* High-flux biocompatible membranes, HD for ESRD with
- Biological marker of Fe status, *see* Serum ferritin
- Biomedical Scientific Advisory Committee (B-SAC), USRDS, S1:5
- Biopsy
bone, of renal osteodystrophy, 4:1x
see also Histopathology; Renal biopsy
- Black Americans, *see* Race
- Bleeding due to percutaneous renal biopsy, effects of using ultrasound-guided automated spring-loaded gun device on, 92-97
- Blood flow
velocity of orthostatic cerebral, HD for diabetes mellitus and reduction of, 1096-1104
see also Vascular access blood flow, HD
- Blood group, ABO, and RTx for ESRD, USRDS 1999 ADR on, S1:98
- Blood pressure (BP)
in chronic GN, 115
in doxorubicin-induced nephropathy, NaHCO₃ effects on, 331, 334
in ESRD patients on CAPD, NIDDM and, 516, 517, 802;
see also Blood pressure of ESRD patients on HD
in Gitelman's syndrome, 846
in IE, 416
in IgAN, 282, 906

- in IMN, 523
- in MGN and LMGN, 86
- in proliferative GN, DSG effects on, 895
- and remission of NS with captopril in IDDM, 310
- in severe ARF, 427-430
- see also* Hypertension; Hypotension
- Blood pressure (BP) of ESRD patients on HD
 - with ADPKD, valvular heart disease and, 266
 - and CVD, 440, 441
 - intradialytic serial VABF and, 471-477
 - in NIDDM ESRD, 802
 - on prolonged slow HD, 602-603
 - SAECG and, 1108
 - venous, of HD access grafts, monitoring of, at high blood flow, and graft failure prediction, 212-217
- Blood urea nitrogen, *see* BUN
- BMI, *see* Body mass index
- Body composition of ESRD patients on VLPD, DEXA in assessment of outcome of, 500-507
- Body fat, total, in ESRD patients, VLPD and, 501, 503-504
- Body mass index (BMI)
 - of CAD patients, 920
 - of ESRD patients, *see* Body mass index of ESRD patients
 - of HTN patients, *see* Body mass index of HTN patients
 - of NIDDM patients with MA, ACE and AGN genes and, 1004
- Body mass index (BMI) of ESRD patients
 - on RRT, serum hyaluronan and survival and, 1084; *see also* Body mass index of ESRD patients on HD;
 - Body mass index of ESRD patients on PD/CAPD VLPD and, 501
- Body mass index (BMI) of ESRD patients on HD
 - acidosis, nutritional status and, 495, 496
 - cardiac complications in patients with ADPKD, 266
 - and hyperleptinemia, 826, 827
 - of new ESRD patients, 696-698
- Body mass index (BMI) of ESRD patients on PD/CAPD
 - Cr generation and, 236
 - of new ESRD patients, 696-698
 - nutritional status and, 1058
 - see also* Body mass index of ESRD patients on PD/CAPD, leptin and
- Body mass index (BMI) of ESRD patients on PD/CAPD, leptin and
 - with hyperleptinemia, 826-828
 - and leptin in dialysate, 833, 834
 - and peritoneal leptin clearance, 840
- Body mass index (BMI) of HTN patients
 - with low-renin HTN, 581-584
 - with MA, 997
- Body temperature in severe ARF, 427-430
- Body weight (BW)
 - of DM patients, *see* Body weight of DM patients
 - of ESRD patients, VLPD and, 501; *see also* Body weight of ESRD patients on HD; Body weight of ESRD patients on PD/CAPD
 - of hypokalemic patients, 109
 - of hypophosphatemic RTx recipients, 876
 - of IE patients, morning-evening differences in, 416
 - of renal insufficiency patients, LVH and, 127, 129, 131
 - of severe ARF patients, 427-430
- Body weight (BW) of DM patients
 - on HD, and orthostatic hypotension and, 1100
 - and remission of NS with captopril in IDDM, 310
- Body weight (BW) of ESRD patients on HD
 - acidosis, nutritional status and, 496
 - and Fe status, 31
 - gentamicin pharmacokinetics and, 223
 - and HTN, 220
 - race and, and HD outcome, 728
 - SAECG and, 1108
- Body weight (BW) of ESRD patients on PD/CAPD
 - Cr generation and, 236
 - effects of aminoglycosides on RRF and, 16, 17
 - and IP rHuEPO administration, 659
 - NIDDM and, 516, 517
 - nutritional status and, 1058
 - race, survival and, 715
- Bone disease, *see* Renal osteodystrophy in ESRD patients on HD
- Bone marrow of ESRD patients on CAPD, Fe content of, 29-35
- BP, *see* Blood pressure
- Breast cancer, scleroderma renal crisis and sclerosis associated with, 937-941
- Bromocriptine in IE, 416
- B-SAC (Biomedical Scientific Advisory Committee), USRDS, S1:5
- Bullous dermatoses (BD) in ESRD patients on CAPD, 155-160
- BUN (blood urea nitrogen)
 - and bleeding due to percutaneous renal biopsy, 93
 - in DM patients on HD, orthostatic hypotension and, 1100
 - in MGN and LMGN, 86
 - in nephrotic-range proteinuria, 136, 137
 - in proliferative GN, DSG effects on, 895
 - and RTx, 741
 - in severe ARF, 427-430
 - see also* BUN in ESRD patients on HD; BUN in ESRD patients on PD/CAPD
- BUN (blood urea nitrogen) in ESRD patients on HD
 - acidosis, nutritional status and, 495, 496
 - gentamicin pharmacokinetics and, 223
 - in new ESRD patients, 696-698
 - in pediatric ESRD patients, 53
- BUN (blood urea nitrogen) in ESRD patients on PD/CAPD
 - in new ESRD patients, 696-698
 - race, survival and, 715
- BW, *see* Body weight
- C difficile* (*Clostridium difficile*), IgAN associated with, 4:E16
- C1q (complement 1q), autoantibodies against, in HUVS and SLE, 745-751
- C3 (complement 3)
 - serum, in LN, 317
 - in types I and III MPGN, 1022-1032
- C4 (complement 4), serum, in LN, 317
- Ca (calcium)
 - in DM patients on HD, and orthostatic hypotension, 1100
 - in nephrotic-range proteinuria, 136, 137
 - in recurrent Goodpasture's syndrome, 551

- in renal insufficiency, LVH and, 127, 129
 serum, *see* Serum Ca
see also Ca acetate; Ca in ESRD patients on HD; Ca in RTx recipients
- Ca (calcium) acetate, as phosphate binder, ferrihydrite versus, 324-327
- Ca (calcium) in ESRD patients on HD
 with ADPKD, cardiac complications and, 266
 and CVD, 440
 hypocalcemic patients, age and calcitriol effects on recovery from hypocalcemia, 456-463
 or PD, asymptomatic Al-related renal osteodystrophy and, 690
Radix angelicae sinensis effects on, 350
 SAECG and, 1108
 serum, relationship between serum Mg, PTH and, 44, 45
- Ca (calcium) in RTx recipients
 hypophosphatemic, effects of Pi replacement on, 875-883
 and SAHS, 741
- CAD (coronary artery disease), microalbuminuria and insulin as predictors of, 918-925
- Calciphylaxis due to UV light in CAPD patients with ESRD secondary to SLE, 932-936
- Calcitriol [$1,25(\text{OH})_2\text{D}_3$; $1,25\text{-dihydroxyvitamin D}_3$], effects of age and, on recovery from hypocalcemia in ESRD patients on HD, 456-463
- Calcium, *see* Ca
- Caloric intake, and acidosis in ESRD patients on HD and, 495, 496
- Cancer, *see* Malignancy
- CAPD, *see* Continuous ambulatory peritoneal dialysis for ESRD
- CAPD and Peritonitis Rates Study, USRDS, S1:31
- Capillary permeability, abnormal, IE etiology and, 417-418
- Capitation payments by Medicare, S1:130
- Captopril
 IE and, 413
see also Captopril in IDDM
- Captopril in IDDM
 correlation of long-term renoprotection in IDDM and effects of, on serum TGF- β 1, 818-823, 951-954
 with HTN, effects of, on IDDM course, 809-817
 NS remission with, 308-314
- Carbon dioxide (CO_2) in nephrotic-range proteinuria, 136, 137
- Cardiac complications in ESRD patients with ADPKD on HD, echocardiography of, 264-272
- Cardiac dilatation, time factor and, in HTN therapy of ESRD patients on HD, 218-221, 359-361
- Cardiovascular disease (CVD)
 MA and, in hypertension, 982-983
 microalbuminuria and insulin as predictors of CAD, 918-925
see also Cardiovascular disease in ESRD patients on RRT
- Cardiovascular disease (CVD) in ESRD patients on HD
 hemostatic factors and serum MDA as predictive factors for, 438-444
 hyperhomocyst(e)nia and prevalence of atherosclerotic vascular disease in ESRD patients on HD, 669-677
 in new patients, USRDS 1999 ADR on, S1:66-68
 parenteral Fe therapy and, S2:18-24
 on prolonged slow HD, 602-603
- Cardiovascular disease (CVD) in ESRD patients on RRT
 on CAPD, nutritional status and, 1058
 on PD, race, survival and, 716
 serum hyaluronan and survival and, 1084-1086
see also Cardiovascular disease in ESRD patients on HD
- L-Carnitine (γ -trimethyl-ammonium- β -hydroxybutyrate), effects of, on leukocyte phagocytic function and viability in ESRD patients on HD, 678-687
- Case-Mix Adequacy Study (CMAS), USRDS, S1:32
 available on CD, S1:34
- Case-Mix Severity Study (CMSS), USRDS, S1:31
- Catheters, HD
 bacteremia associated with tunneled, cuffed, permanent, 1114-1124
 inverse paradoxical embolism with aortic bacterial endocarditis due to *S haemolyticus* infection of, in chronic HD, 338-340, 362-363
 transcatheter renal arterial embolization in ADPKD patients with ESRD, 926-931
- Caveats on USRDS data release, S1:36-37
- CC (Coordinating Center) University of Michigan, USRDS, S1:4-5
- CCPD, *see* Continuous cycling peritoneal dialysis for ESRD
- CD(s), USRDS
 current price structure of, S1:34
 DMMS and CMAS, S1:34
 hospitalization, S1:33
 transplant, S1:32-33
- CD-ROM, core SAF, S1:27-28, S1:30
- CD-ROM drive needed to use SAFs, S1:35
- Cell energetics, and glucose transport regulation by hypoxia, 189-202
- Cell-mediated immune dysfunction in NS and, serum and urinary NP and, 611-617
- Cellulose membranes
 polyethylene glycol-grafted, thrombogenicity of, and heparin requirements of ESRD patients on HD, 36-42
 in prolonged slow HD, 601
- Census
 census population as base for computing ESRD incidence and prevalence, S1:163
 of ESRD network facilities, S1:157
- Cerebral blood flow velocity, orthostatic, HD for diabetes mellitus and reduction of, 1096-1104
- Cerebral embolism after mechanical thrombolysis of clotted HD access grafts, 341-343, 362-363
- cGMP (cyclic guanosine monophosphate) on HD, indices of activity of, 228-234
- CGN, *see* Crescentic glomerulonephritis
- Chemokines
 role of, in neutrophil-induced renal injury in ARF, 390-391
 as therapeutic targets in renal inflammation, 761-767
- Chemotherapy, pediatric FS secondary to, mtDNA deletions and decreased oxidative phosphorylation in, 98-106
- Children, *see* Pediatric population
- Chlorambucil, steroids or, for stage II and III IMN, long-term follow-up on, 911-917
- Chloride, *see* Cl
- Cholesterol
 in HTN with MA, atherosclerosis and, 998

- total, in CAD, 920
see also Cholesterol emboli; Cholesterol in ESRD patients;
 Serum cholesterol
- Cholesterol emboli in renal AED, 161-165
- Cholesterol in ESRD patients
 fasting plasma, in CAPD patients with NIDDM, 516, 517
see also Cholesterol in ESRD patients on HD
- Cholesterol in ESRD patients on HD
 hypercholesterolemia and atherosclerotic vascular disease
 and, 671
 total, CVD and, 440, 441
- Chronic allograft nephropathy, de novo FSGS and, and graft
 survival, 731-738
- Chronic glomerulonephritis (GN)
 plasma and urinary AM and PAMP in, 114-119
 as primary disease, 434, 435, 1107
 Chronic hemodialysis (HD) for ESRD
 effects of vascular access for, on venous histology, 702-705
 long-term, genomic damage to lymphocytes and, 433-437
see also Infection(s) in ESRD patients on chronic HD
- Chronic pyelonephritis, as primary disease, 435
- Chronic rejection, racial disparities in, 709
- Chronic renal failure, *see* End-stage renal disease
- Cigarette smoking, *see* Smoking
- Circulating antibody, monoclonal IgA- κ , recurrent Goodpas-
 ture's syndrome due to, 549-555, 565-568
- Citrulline, plasma, and NO activity on HD, 231
- Cl (chloride)
 R642C missense mutation of NaCl *TSC* gene in Gitel-
 man's syndrome, 845-853
 serum, *see* Serum Cl
- Claims
 HCFA records of paid, S1:156
 Medicare, S1:33, S1:174
- Classification
 lost-to-follow-up method of, S1:160-162
 of Medicare payments, S1:126-127
- Clinical features and presentation
 of IE, 406-408
 of IMN, 523
 of MGN and LMGN, 86
 of NIDDM ESRD, *see* Clinical features and presentation
 of NIDDM ESRD
 of TINU syndrome, 1016-1018
see also Symptoms and specific conditions
- Clinical features and presentation of NIDDM ESRD
 in CAPD patients, relationship between insulin require-
 ments and, 514-520
 international study on, 801-802
- Clinical judgment analysis, 569-575
- Clinical performance measure (CPM) of parenteral Fe therapy
 in ESRD patients, national perspective on, S2:5-11
- Clinical trials, comparative, of immunosuppressants, 8
- Clinicopathology, *see* Pathology
- Clostridium difficile* (*C. difficile*), IgAN associated with,
 4:E16
- Clotting, *see* Coagulation profile and entries beginning with
 element: Thromb-
- CMAS, *see* Case-Mix Adequacy Study, USRDS
- CME (continuing medical education), exercises on, 1:E2,
 2:E2, 3:E8, 4:E14, 5:E19, 6:E24
- CMSS (Case-Mix Severity Study), USRDS, S1:31
- CMV, *see* Cytomegalovirus infection in RTx recipients
- CO₂ (carbon dioxide)
 in nephrotic-range proteinuria, 136, 137
 total, *see* Total CO₂
- Coagulation profile
 and bleeding due to percutaneous renal biopsy and, 92-97
see also entries beginning with element: Thromb-
- Cobalt, tissue exposure to, and glucose transport regulation
 by hypoxia, 189-202
- COL4A5* gene, mutations of, in X-linked Alport's syndrome,
 RT-PCR and direct sequencing in detection of, 854-
 862
- Colonic diverticular disease with ADPKD without ESRD,
 863-868
- Committees, USRDS, S1:5-6, S1:22-23
- Comorbidity
 with anterior ischemic optic neuropathy, 1127
 with aPL syndrome in RTx for ESRD secondary to SLE,
 1043
 with ATN in diabetes mellitus, 1013
 with ESRD, Western Australian Health Services Research
 Linked Database on, 1035; *see also* Morbidity with
 ESRD
see also specific conditions
- Complement, *see* C1q; C3; C4; Hypocomplementemia; Hy-
 pocomplementemic urticarial vasculitis syndrome
- Compliance
 with ACE inhibition therapy by hypertensive IDDM pa-
 tients, 813
see also Noncompliance
- Complications, *see* specific conditions and treatment modal-
 ities
- Computer needed to use SAFs, S1:35
- Congestive heart failure, NIDDM and, 516, 517
- Conservative management of hyperleptinemia in CRF pa-
 tients on HD, 824-831, 947-950
- Contacts, USRDS, S1:22
- Contents, address and, of USRDS site on World Wide Web,
 S1:25
- Continuing medical education (CME), exercises on, 1:E2,
 2:E2, 3:E8, 4:E15, 5:E19, 6:E24
- Continuous ambulatory peritoneal dialysis (CAPD) for
 ESRD, 242-253
 ACKD in children on, 242-246
 asymptomatic ABD patients on, 688-693
 BD on, 155-160
 improvement of, HCFA Core Indicators Project on, 1075-
 1082
 independent effects of RRF and adequacy of, on patients'
 nutritional status, 1056-1064
 influence of preceding exchange on PET results, 247-253
 leptin in, *see* Leptin in ESRD patients on PD/CAPD
 mortality risks with, 1065-1074
 in NIDDM patients, relationship between insulin require-
 ments and clinical and biochemical characteristics of
 patients on, 514-520
 secondary to SLE, calciphylaxis in, due to UV light,
 932-936
 thoracoscopic surgery and pleurodesis for PPC and,
 170-172

- see also* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1999 ADR on; Duration of PD/CAPD; Recombinant human erythropoietin for anemic ESRD patients on PD/CAPD
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1999 ADR on
- CAPD and Peritonitis Rates Study, S1:31
- described, S1:52-53
- hospitalization for, S1:117-118
- Medicare expenditures for, S1:132-134, S1:138
- patient characteristics and utilization of, S1:56-58
- patient survival on, S1:55
- trends in utilization of, S1:53-56
- Continuous cycling peritoneal dialysis (CCPD) for ESRD
- mortality risks with, 1065-1074
- pediatric, with IP rHuEPO therapy, 651-656
- see also* Continuous cycling peritoneal dialysis for ESRD, USRDS 1999 ADR on
- Continuous cycling peritoneal dialysis (CCPD) for ESRD, USRDS 1999 ADR on
- described, S1:52-53
- hospitalization for, S1:117-118
- Medicare expenditures for, S1:132-134, S1:138
- patient characteristics and utilization of, S1:56-58
- patient survival on, S1:55
- trends in utilization of, S1:53-56
- Continuous renal replacement therapy, *see* Acute renal failure, CRRT of; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Continuous venovenous hemofiltration
- Continuous venovenous hemofiltration (CVVH), HD compared with, for severe ARF, 424-432
- Contrast echocardiography of bilateral renal infarction secondary to paradoxical embolism, 752-755
- Convective clearances during CRRT of ARF at various dialysate and ultrafiltration flow rates, 486-492
- Coordinating Center (CC) University of Michigan, USRDS, S1:4-5
- Core Standard Analysis File (SAF) CD-ROM, S1:27-28, S1:30
- Coronary angiography in detection of CAD, 918-925
- Coronary artery disease (CAD), microalbuminuria and insulin as predictors of, 918-925
- Corticosteroids
- effects of, on glycemic tolerance, 3-4
- prolonged FSGS therapy with, prognosis and, 618-625
- Cost
- of CDs, S1:34
- of parenteral Fe therapy, S2:43-44
- of SAFs, S1:35
- see also* Cost of ESRD care
- Cost of ESRD care
- with prolonged slow HD, 604
- see also* Cost of ESRD care, USRDS 1999 ADR on
- Cost of ESRD care, USRDS 1999 ADR on, S1:124-127
- data sources on, S1:126
- executive summary of, S1:27-28
- measurement of, S1:128-129
- see also* Cost reports of ESRD care facilities; Medicare expenditures for ESRD, USRDS 1999 ADR on
- Cost reports of ESRD care facilities, S1:157
- Course
- of drug-induced renal graft AIN, 540-548
- of IDDM with HTN, captopril effects on, 809-817
- outcome and, of TINU syndrome, 1016-1021
- of proteinuria and renal insufficiency due to MPGN after gastric lymphoma, 590
- see also* Progression of renal disease
- COX (cytochrome oxidase) in pediatric FS secondary to chemotherapy, 101
- C-peptide, fasting plasma, in NIDDM patients on CAPD for ESRD, S16, S17
- CPM (clinical performance measure) of parenteral Fe therapy in ESRD patients, national perspective on, S2:5-11
- Cr and CrCl, *see* Creatinine and creatinine clearance
- Creatinine and creatinine clearance (Cr and CrCl)
- in CAD, 920
- in diffusive and convective, on CRRT for ARF, 488, 491
- in DM patients, *see* Creatinine and creatinine clearance in DM patients
- in ESRD, VLPD and, 501; *see also* Creatinine and creatinine clearance in ESRD patients on HD; Creatinine and creatinine clearance in ESRD patients on PD/CAPD
- in hypokalemia, 109
- in IgAN, 906
- in MGN and LMGN, 86
- in MPDs, 890
- in nephrotic-range proteinuria, 136, 137
- in NS, 612
- plasma, *see* Plasma creatinine
- in proliferative GN, DSG effects on, 895, 897
- ratios of urinary excretion of urate and oxalate to, in healthy pediatric population, 2:E3
- in renal insufficiency, LVH and, 127-131
- in RTx, *see* Creatinine and creatinine clearance in RTx
- serum, *see* Serum creatinine
- Creatinine and creatinine clearance (Cr and CrCl) in DM patients
- with ATN, 1012
- on HD, and orthostatic hypotension and, 1100
- in NIDDM ESRD patients, 802
- Creatinine and creatinine clearance (Cr and CrCl) in ESRD patients on HD
- L-carnitine effects on, 683
- and CVD, 440
- in NIDDM ESRD patients, 802
- plasma, NO activity and, 231
- Radix angelicae sinensis* effects on, 350
- serum, *see* Serum creatinine in ESRD patients on HD
- Creatinine and creatinine clearance (Cr and CrCl) in ESRD patients on PD/CAPD
- aminoglycoside effects on, 16, 17
- increased generation of, and decline in RRF with time, 235-241
- measured-to-predicted Cr generation, duration of CAPD and increase in, 235-241
- in NIDDM ESRD patients, 802
- nutritional status and, 1059
- race, survival and, 715

- serum, *see* Serum creatinine in ESRD patients on PD/CAPD
- Creatinine and creatinine clearance (Cr and CrCl) in RTx and de novo FSGS in renal grafts, 735
- hypophosphatemia and, 876
- in NIDDM ESRD patients, 802
- for SAHS, 741
- see also* Serum creatinine in RTx
- Crescentic glomerulonephritis (CGN)
- as primary diagnosis, 138
- tropical myositis and, in RTx recipients, 6:E25
- CRF (chronic renal failure), *see* End-stage renal disease
- CRRT (continuous renal replacement therapy), *see* Acute renal failure, CRRT of; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Continuous venovenous hemofiltration
- CsA, *see* Cyclosporine
- Cuffed, tunneled, permanent hemodialysis (HD) catheters, bacteremia associated with, 1114-1124
- Cuprophane membranes, thrombogenicity of PGC membranes and, compared, 36-42
- CVD, *see* Cardiovascular disease
- CVVH (continuous venovenous hemofiltration) for severe ARF, HD compared with, 424-432
- Cyclic guanosine monophosphate (cGMP) on HD, indices of activity of, 228-234
- Cyclical edema, *see* Idiopathic edema
- Cyclophosphamide, pediatric FS secondary to, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Cyclosporine (CsA)
- for acute allograft rejection, 304-307
- effects of, on glycemic tolerance, 4-6, 8, 9
- levels of urinary SMA in RTx recipients correlated with nephrotoxicity of, 69-84
- oral, bioavailability of SGC formulation versus, 869-874
- Cyst(s) in ADPKD
- decompression of, for pain of pediatric ADPKD, 639-645, 4:E17
- ovarian, 120-124
- Cystic kidney disease, *see* Polycystic kidney disease
- Cystinosis, infantile nephropathic, FS and, 966-971
- Cytochrome oxidase (COX) in pediatric FS secondary to chemotherapy, 101
- Cytokines
- GFs and, in renal involvement of POEMS syndrome, 633-638
- SAHS in ESRD and, 739-744
- and survival of ESRD patients on RRTs, 1083-1088
- see also* specific cytokines
- Cytomegalovirus (CMV) infection in RTx recipients
- persistent abdominal pain in GI tract of RTx recipients and active, 65-68
- post-CMV infection RTx, de novo HUS following, 556-559
- renal graft dysfunction due to, 942-946
- Cytoplasmic autoantibodies, *see* Anti-neutrophil cytoplasmic autoantibody(ies); c-Anti-neutrophil cytoplasmic autoantibody-positive vasculitis
- Damage and injury
- genomic, in lymphocytes of ESRD patients on long-term maintenance HD, 433-437
- see also* Renal damage and injury
- Data, USRDS
- abstracts citing, S1:29
- on changes in RRT modalities, S1:53
- release of, S1:35-39
- requests for, S1:26
- see also* Data, USRDS 1999 ADR
- Data, USRDS 1999 ADR
- ascertaining accuracy of, S1:157-158
- FSD in, S1:157-158
- geographic, *see* Geographic data in USRDS 1999 ADR
- on number changes, S1:159-162
- sources of, *see* Data, in USRDS 1999 ADR, sources of on UNOS, S1:156-157
- see also* Database, USRDS
- Data, in USRDS 1999 ADR, sources of, S1:10
- on cost of ESRD care, S1:126
- on international RRT, S1:144-145
- for USRDS database, S1:154-157
- see also* specific data sources
- Data Request Review Committee (DRRC), USRDS, S1:6, S1:22
- Database, USRDS, S1:23-24
- Medicare EDB, S1:129, S1:156
- REBUS/PMMS database of HCFA, S1:155-160
- Researcher's Guide to the USRDS Database*, S1:23-24, S1:31, S1:35, S1:152, S1:169, S1:173
- year 2000 compliance of, S1:154
- see also* Analytical methods used in USRDS 1999 ADR; Data, USRDS 1999 ADR
- Daytime sleepiness, effects of rHuEPO for HD patients on, 1089-1095
- DBP (diastolic blood pressure), *see* Blood pressure
- Death, *see* Mortality
- Death Notification Form (HCFA-2746), S1:88, S1:155-156
- Decision-making, judgment analysis and, 569-575
- Decompression, cyst, for pain of pediatric ADPKD, 639-645, 4:E17
- Deferoxamine, effects of parenteral Fe on, in ESRD patients on HD on, S2:30-34
- Deletions, mtDNA, and decreased oxidative phosphorylation activity in children with FS secondary to chemotherapy, 98-106
- Demographic characteristics of ESRD patients
- USRDS 1999 ADR on, S1:63-65; *see also* Age of ESRD patients, USRDS 1999 ADR on; Race of ESRD patients, USRDS 1999 ADR on; Sex of ESRD patients, USRDS 1999 ADR on
- see also* Sex of ESRD patients and entries beginning with terms: Age of ESRD patients; Race of ESRD patients
- De novo augloid light chain amyloidosis, benign monoclonal gammopathy turning into, after RTx, 166-169
- De novo focal segmental glomerulosclerosis (FSGS) in renal grafts with chronic nephropathy, graft survival and, 731-738
- De novo hemolytic uremic syndrome (HUS), post-RTx, after CMV infection, 556-559
- Deoxyribonucleic acid, *see* DNA

- Deoxyspergualin (DSG), effects of, on proliferative GN, 894-901
- Department of Veterans Affairs (DVA) facilities for ESRD care, S1:143
- Dermatoses, bullous, in ESRD patients on CAPD, 155-160
- Desquamating erythema, streptococcal toxic shock syndrome with ARF and, 150-154
- DEXA (dual energy X-ray absorptiometry), outcome of body composition and nutritional status of ESRD patients on VLPD assessed with, 500-507
- Diabetes mellitus, *see* Captopril in IDDM; Diabetic end-stage renal disease, IDDM; Hemodialysis for DM; Non-insulin-dependent diabetes mellitus; Posttransplant diabetes mellitus and entries beginning with *term*: Diabetic
- Diabetic end-stage renal disease (ESRD), IDDM
aminoglycoside effects on RRF in PD patients with, 16, 17
HTN control with captopril and its effects on IDDM course, 809-817
RTx for, oral CsA versus SGC formulation and, 871
- Diabetic end-stage renal disease (ESRD), NIDDM
relationship between insulin requirements and clinical and biochemical characteristics of ESRD patients with, on CAPD, 514-520
see also Diabetic end-stage renal disease, NIDDM, international incidence and prevalence of treated
- Diabetic end-stage renal disease (ESRD), NIDDM, international incidence and prevalence of treated, 795-808
in Asia, 800-801
clinical presentation of, 801-802
prevention of, 804-805
reasons for increasing incidence and prevalence, 801
and RRT modalities, 802-803
survival, quality of life, and, 803-804
in U.S., 796-797
in Western Europe, 797-800
- Diabetic nephropathy, 5:E18
and CAD, 920
in ESRD patients on CAPD, nutritional status, 1058
in ESRD patients on HD, *see* Diabetic nephropathy in ESRD patients on HD
hyperhomocyst(e)inemia, atherosclerotic vascular disease and, 671, 674
and LVH in early renal disease, 127
nephrotic-range proteinuria and, 136-138
and RTx, *see* Diabetic nephropathy, and RTx
see also Diabetic end-stage renal disease, IDDM; Diabetic end-stage renal disease, NIDDM
- Diabetic nephropathy, and RTx
idiopathic nodular GS and, 560-564
oral CsA versus SGC formulation in, 871
Pi replacement therapy and, 876
race and RTx outcome, 708
- Diabetic nephropathy in ESRD patients on HD
and asymptomatic Al-related renal osteodystrophy, 690
association between acidosis, nutritional status and, 494
and CVD, 440, 442
Fe deficiency diagnosis and, 510
and genomic damage to lymphocytes, 434
PD, or treated conservatively, hyperleptinemia in, 825
race and, and HD outcome, 714, 716, 723, 728
and SAEG, 1107
serial VABF and, 472
serum Mg and PTH in, 44, 45
- Diabetic retinopathy
in IDDM with HTN, long-term renoprotective effects of captopril and, 820-821
NIDDM and, 516, 517
- Diagnosis
analysis of judgment on, 569-575
of bacteremia associated with tunneled, cuffed, permanent HD catheters, 1115-1116
differential, *see* Differential diagnosis
ESRD, patient mortality by year since, USRDS 1999 ADR on, S1:82-83
Fe deficiency, in ESRD, 508-513
of IE, 406, 408-410
ovarian cyst, in ADPKD, 122
primary, *see* Primary disease in ESRD, USRDS 1999 ADR on *and specific conditions*
and screening for MA in, 1139-1141
see also specific conditions and diagnostic techniques
- Dialysate, CAPD, leptin in, 832-838, 947-950
- Dialysate flow rates, diffusive and convective clearances during CRRT of ARF at various, 486-492
- Dialysate to plasma (D/P) ratios, PET measurement of, 247-253
- Dialysis Morbidity and Mortality Study (DMMS), USRDS, S1:32
available on CD, S1:34
- Dialysis and transplant centers, described, S1:141
- Dialysis unrelated (DU) deaths of ESRD patients, annual, S1:166-167
- Dialyzer(s) (dialysis membranes), HD
high-flux, *see* High-flux biocompatible membranes, HD for ESRD with
PGC, thrombogenicity of, and heparin requirements, 36-42
USRDS 1999 ADR on, S1:59-60
see also Cellulose membranes; Cuprophane membranes
- Dialyzer Standard Analysis File (SAF), USRDS, S1:32
- Diastolic blood pressure, *see* Blood pressure
- Diesel oil-polluted seawater, ARF due to immersion, 6:E26
- Dietary protein
intake of, and acidosis in ESRD patients on HD and, 495, 496
outcome of body composition and nutritional status of ESRD patients on VLPD, 500-507
- Differential diagnosis
between anti-tubular basement-membrane nephritis and partial pediatric FS, 184-188
between PCT and pseudoporphyria in ESRD patients on HD, 155-160
- Diffusive clearances, and CRRT of ARF
convective and, at various dialysate and ultrafiltration flow rates, 486-492
in CVVH for severe ARF, HD compared with, 424-432
1,25-Dihydroxyvitamin D₃ (calcitriol), effects of age and, on recovery from hypocalcemia in ESRD patients on HD, 456-463
- Direct DNA (deoxyribonucleic acid) sequencing in detection of *COL4A5* gene mutations in X-linked Alport's syndrome, 854-862

- Direct patient care, Medicare expenditures for, S1:129-131
- Discharge, effects of percutaneous renal biopsy with ultrasound-guided automated spring-loaded gun device on bleeding, and their implications for early, 92-97
- Discontinuation of dialysis treatment for abusive patients, 778-780, 783-784
- Disk storage drive needed to use SAFs, S1:35
- Disruptive end-stage renal disease patients, *see* Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD
- Diuretics, and IE, 412
- Diverticular disease, colonic, with ADPKD, 863-668
- DM (diabetes mellitus), *see* Captopril in IDDM; Diabetic end-stage renal disease, IDDM; Hemodialysis for DM; Non-insulin-dependent diabetes mellitus; Post-transplant diabetes mellitus *and entries beginning with term*: Diabetic
- DMMS, *see* Dialysis Morbidity and Mortality Study, US-RDS
- DNA (deoxyribonucleic acid)
- deletion of mitochondrial, and decreased oxidative phosphorylation in pediatric FS secondary to chemotherapy, 98-106
 - direct sequencing of, for detection of *COL4A5* gene mutation in X-linked Alport's syndrome, 854-862
 - see also* Reverse transcriptase-polymerase chain reaction
- Documentation for SAFs, S1:35
- Researcher's Guide to the USRDS Database as*, S1:23-24, S1:31, S1:35, S1:152, S1:169, S1:173
 - Dominant polycystic kidney disease, *see* Autosomal dominant polycystic kidney disease
- Dopamine in IE etiology, 415-417
- Doppler ultrasound (US)
- Doppler echocardiography of ESRD patients with ADPKD on HD, 264-272
- transcranial, of reduced orthostatic cerebral blood flow due to HD for DM, 1096-1104
 - Dose
 - HD, USRDS 1999 ADR on, 1:58-59; *see also* Kt/V
 - see also* Dose, rHuEPO
- Dose, IP rHuEPO
- "dry well" dosing technique for IP rHuEPO administration to CAPD patients, 657-662
 - for pediatric patients on CCPD, 653, 654
- Dose, rHuEPO
- parenteral, S2:42-43
 - see also* Dose, IP rHuEPO
- Doxorubicin-induced nephropathy, NaHCO₃ effects on renal injury, renal TGF- β production, urinary TGF- β excretion in, 328-337
- D/P (dialysate to plasma) ratios, PET measurement of, 247-253
- DRRC (Data Request Review Committee), USRDS, S1:6, S1:22
- Drug(s)
- renal allograft AIN induced by, histopathology and course of, 540-548
 - responsible for IE, 409
 - see also* specific drugs
- "Dry well" dosing technique for IP rHuEPO administration to CAPD patients, 657-662
- DSG (deoxyspergualin), effects of, on proliferative GN, 894-901
- DU (dialysis unrelated) deaths of ESRD patients, annual, S1:166-167
- Dual energy X-ray absorptiometry (DEXA), outcome of body composition and nutritional status of ESRD patients on VLPD assessed with, 500-507
- Duplication, elimination of, in USRDS 1999 ADR, S1:152-153
- Duration of HD
- and association between acidosis and nutritional status, 494, 496
 - on chronic HD, changes in venous histology and, 703
 - and CVD, *see* Duration on HD, CVD and
 - for DM, and reduced orthostatic cerebral blood flow due to HD, 1097
 - Fe deficiency diagnosis and, 510
 - and heart disease in patients with ADPKD, 267
 - hyperleptinemia and, 825-827
 - in ideal HD, 601
 - on prolonged slow HD, 601
 - race, HD outcome and, 723, 728
 - and recurrent FSGS after RTx, 1049, 1051, 1052
 - relationship between serum Mg and PTH and, 45, 46
- Duration of HD, CVD and
- atherosclerotic vascular disease, 671
 - CVD prediction and, 440
 - hyperleptinemia and, 827
- Duration of PD/CAPD
- APD and TPD, D/P ratio and, 248
 - Cr generation increase, RRF decrease and, 235-241
 - and Fe status, 31
 - leptin and, *see* Duration of PD/CAPD, leptin and
 - of pediatric ACKD patients, 243-244
- Duration of PD/CAPD, leptin and
- and hyperleptinemia, 825-827
 - leptin in dialysate and, 833
- DVA (Department of Veterans Affairs) facilities for ESRD care, S1:143
- Dyscrasia, plasma cell, nephrotic-range proteinuria in, 135-139
- Dyslipidemia, and CAD, 920, 922
- Early renal disease, Hb decline and LVH in, 125-134
- Eating disorders, and IE etiology, 418-419
- EC (Executive Committee), USRDS, S1:5, S1:22
- ECG (electrocardiogram), signal-averaged, in ESRD, HD effects on, 1105-1113
- Echocardiography
- of cardiac complications in ESRD patients with ADPKD on HD, 264-272
 - contrast, of bilateral renal infarction secondary to paradoxical embolism, 752-755
- Economic Scientific Advisory Committee (E-SAC), USRDS, S1:5-6
- EDB (Enrollment Database) of Medicare, S1:129, S1:156
- Edema, *see* Idiopathic edema
- Education
- continuing medical, exercises on, 1:E2, 2:E2, 3:E8, 4:E14, 5:E19, 6:E24
 - public, in prevention of NIDDM ESRD, 805

- Educational status, race and, and survival on PD, 714
- EIA (enzyme immunoassay), IWB analysis and, of HIV infection in ESRD patients on chronic HD, 146-149
- Electrocardiogram (ECG), signal-averaged, in ESRD, HD effects on, 1105-1113
- Electrophoresis, urine and serum protein, in evaluation of nephrotic-range proteinuria, 135-139
- Eligibility, patient, *see* Medicare eligibility criteria
- Embolism
- cholesterol, in renal AED, 161-165
 - paradoxical, *see* Paradoxical embolism
 - pulmonary, after percutaneous thrombolysis of clotted HD access grafts, ventilation-perfusion scintigraphy of, 207-211
- Embolization, transcatheter renal arterial, in ADPKD patients with ESRD on HD, 926-931
- Employment status of new ESRD patients, USRDS 1999 ADR on, S1:71-72
- Empty peritoneum, IP rHuEPO therapy to CAPD patients administered on, 657-662
- ENaC (epithelial sodium channel) β (beta) subunit, T594M mutation in, and low-renin HTN, race and, 579-587
- Enalapril, antioxidant defense level in ESRD patients on HD treated or not treated with, 445-455
- Endocarditis, aortic bacterial, due *S haemolyticus* catheter infection, inverse paradoxical embolism with, in chronic HD, 338-340, 362-363
- Endogenous nitric oxide synthases (NOS) inhibitors, and NO activity on HD, 228-234
- Endothelial growth factor, vascular, and renal involvement of POEMS syndrome, 633-638
- End-stage renal disease (ESRD)
- anemia of, *see* Iron deficiency in ESRD patients on HD; Iron deficiency in ESRD patients on PD/CAPD; Recombinant human erythropoietin for anemic ESRD patients
 - familial aggregation of, in HIVAN, race and, 254-258
 - incidence and prevalence of, *see* Incidence and prevalence of treated ESRD
 - pediatric, *see* entries beginning with terms: Pediatric end-stage renal disease
 - in sarcoidosis, 5:E21
 - see also* Cardiovascular disease in ESRD patients; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; End-stage renal disease Core Indicators Project of HCFA; Hemodialysis for ESRD; Outcome of ESRD; Peritoneal dialysis for ESRD; Progression to renal failure with ESRD; Renal transplantation for ESRD; United States Renal Data System, 1999 ADR of and entries beginning with terms: Diabetic end-stage renal disease
- End-stage renal disease (ESRD) Core Indicators Project of HCFA (1997)
- on improvement of dialysis therapy, 1075-1082
 - racial/ethnic analysis of HD outcome of, 721-730
- End-stage renal failure, bedside renal biopsy for, 956
- Enrollment Database (EDB) of Medicare, S1:129, S1:156
- Enzyme immunoassay (EIA), IWB analysis and, of HIV infection in ESRD patients on chronic HD, 146-149
- Epithelial sodium channel (ENaC) β (beta) subunit, T594M mutation in, low-renin HTN and, and race, 579-587
- EPO, *see* entries beginning with terms: Recombinant human erythropoietin
- EqKt/V, *see* Equilibrated Kt/V in ESRD patients on HD
- Equilibrated Kt/V in ESRD patients on HD
- acidosis, nutritional status and, 495, 496
 - in pediatric patients, evaluation and prediction of, 49-54
- Equipment needed to use SAFs, S1:35
- Erythema, desquamating, streptococcal toxic shock syndrome with ARF and, 150-154
- Erythrocyte(s) (red blood cell; RBC)
- in proliferative GN, DSG effects on, 897
 - see also* Erythrocyte ferritin; Erythrocyte folate; Erythrocyte glutathione; Pure red cell aplasia; Red blood cell count
- Erythrocyte (red blood cell; RBC) ferritin, diagnosis of Fe deficiency in ESRD with, 508-513
- Erythrocyte (red blood cell; RBC) folate, atherosclerotic vascular disease and, in ESRD patients on HD, 672
- Erythrocyte (red blood cell; RBC) glutathione (GSH), enalapril and, in ESRD patients on HD, 448
- Erythropoietin, *see* entries beginning with terms: Recombinant human erythropoietin
- E-SAC (Economic Scientific Advisory Committee) USRDS, S1:5-6
- ESRD, *see* End-stage renal disease
- Essential hypertension, *see* Hypertension
- Ethical considerations in dealing with abusive patients, physician's duties versus, 777-778, 785-786
- Ethnicity, *see* Race
- Etiology of IE, 410-420
- abnormal capillary permeability in, 417-418
 - ADH secretion and, 413
 - ANF levels and, 413-414
 - dopamine in, 415-417
 - eating disorders in, 418-419
 - hypothalamic disorders in, 414
 - postural abnormalities in, 410-411, 413
 - renin-aldosterone axis in, 411-413
 - thyroid disorders in, 414-415
- Exchange transfusion for neonatal ARF due to transplacental transfer of nephrotoxic paraprotein, 1129-1131
- Executive Committee (EC), USRDS, S1:5, S1:22
- Executive summary of USRDS 1999 ADR, S1:9-19
- Exercises, CME, 1:E2, 2:E2, 3:E8, 4:E15
- Exon loss mutations of *COL4A5* gene in X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of, 858
- Expected remaining years of life of ESRD patients, USRDS 1999 ADR on, S1:84-85, S1:173
- Extrarenal manifestations of ADPKD, 6: xlv-xlviii
- Facilities for ESRD care, USRDS 1999 ADR on, S1:140-143
- AFS of, S1:157, S1:159
 - cost reports and census of, S1:157
 - DVA, S1:143
 - executive summary of, S1:18
 - location of, S1:140-142
 - number, S1:140, S1:142-143
 - number of ESRD patients by type and location of, S1:140-142
 - number of treatments administered by, S1:142
 - SHR and SMR by, S1:25-26

- Facility Cost Report Standard Analysis File (SAF), S1:31
 Facility grievance procedures for patients, 783-784
 Facility Standard Analysis File (SAF), S1:31
 Factor VII, and CVD in ESRD patients on HD, 440, 441
 Familial aggregation of ESRD in HIVAN, race and, 254-258
 Familial systemic vasculitis (SV), RPGN and, 364-373
 Family history
 of CVD, CAD and, 920
 of HTN, 997, 999
 see also Siblings and entries beginning with term: Familial
 Fanconi's syndrome, *see* Pediatric Fanconi's syndrome
 Fasting glucose in CAD, 920
 Fasting plasma cholesterol in NIDDM patients on CAPD for ESRD, 516, 517
 Fasting plasma C-peptide in NIDDM patients on CAPD for ESRD, 516, 517
 Fasting plasma glucose in NIDDM, ACE and AGN genes and, 1004
 Fasting plasma glucose in NIDDM patients on CAPD for ESRD, 516, 517
 Fasting plasma insulin in NIDDM patients on CAPD for ESRD, 516, 517
 Fasting plasma triglycerides (TGs) in NIDDM patients on CAPD for ESRD, 516, 517
 Fatigue, postdialysis, 464-470
 Fc γ RIII, DSG effects on expression of, on monocytes/macrophages in proliferative GN, 894-901
 Fe, *see* Iron deficiency in ESRD patients on HD; Iron deficiency in ESRD patients on PD/CAPD
 Ferrihydrite, as Pi binder, calcium acetate versus, 324-327
 Ferritin
 Fe status of ESRD patients on PD/CAPD and, 29-35; *see also* Ferritin in ESRD patients on HD
 in pediatric patients on CCPD and rHuEPO therapy, 654
 in recurrent Goodpasture's syndrome, 551
 serum, *see* Serum ferritin
 Ferritin in ESRD patients on HD
 and effects of PGC membrane thrombogenicity on heparin requirements, 38
 race, HD outcome and, 724, 727, 728
 Radix angelicae sinensis effects on, 350
 Ferritin in ESRD patients on HD, Fe and parenteral Fe effects on, 21-28, 173-176
 serum, and diagnosis of Fe deficiency, 508-513
 FGF- β (fibroblast growth factor- β) in POEMS syndrome, 633-638
 Fibrils, microtubules versus, in NS, 1146-1151
 Fibrinogen
 and CVD in ESRD patients on HD, 440, 441
 in DM patients on HD, and orthostatic hypotension, 1100
 Fibroblast growth factor- β (FGF- β) in POEMS syndrome, 633-638
 Fibronectin glomerulopathy, 1146-1151
 Fibrosis
 amyloidosis complicating idiopathic myelofibrosis, 6:E27
 GS, obstructive uropathy, and tubulointerstitial, in PEPCK-TGF- β 1 transgenic subjects, 177-183
 juxtaglomerular cell tumor with retroperitoneal, and secondary IC-GN, role of renin-angiotensin system in, 3:E10
 First end-stage renal disease (ESRD) therapy, USRDS 1999 ADR on
 long-term patient survival from, S1:80-81
 SMR by year of, S1:83
 First service date (FSD) data, USRDS, S1:157-158
 First-year adjusted death rates of ESRD patients, USRDS 1999 ADR on, S1:74-80
 FK506, *see* Tacrolimus
 Fluid retention syndrome, *see* Idiopathic edema
 Focal segmental glomerulosclerosis (FSGS), 5:liv-lvi
 associated with myeloproliferative disorders, 889-893
 de novo, in renal grafts with chronic nephropathy, graft survival and, 731-738
 development of, in renal allograft of transplanted LN patients, 3:E13
 mechanisms of, 5:liv-lv
 nephrotic syndrome and, *see* Nephrotic syndrome, FSGS and as primary diagnosis, 16, 138, 542
 prognosis of, *see* Focal segmental glomerulosclerosis, prognosis of
 progression versus regression of, 5:liv
 proteinuria, renal insufficiency, and HTN in, 768-774
 recurrent, prediction and treatment of, after RTx for, in children, 1048-1055
 Focal segmental glomerulosclerosis (FSGS), prognosis of, 5:lv-lvi
 prolonged immunosuppression and, 618-625
 Folate in ESRD
 MTHFR gene and, 262
 RBC, in HD patients, atherosclerotic vascular disease and, 672
 resistance to rHuEPO and deficiency in, 352
 Follow-up, *see* Long-term follow-up and outcome
 Foramen ovale, *see* Patent foramen ovale, paradoxical embolism across
 Formats of SAFs, S1:34-35
 Frameshift mutations of COL4A5 gene in X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of, 857-858
 Free carnitine, serum, L-carnitine effects on, 682, 685
 Free radicals, OTZ and peritoneal mesothelial cell resistance to, 663-668
 Freestanding units for ESRD care, described, S1:140
 FS (Fanconi's syndrome), *see* Pediatric Fanconi's syndrome
 FSD (first service date) data, USRDS, S1:157-158
 FSGS, *see* Focal segmental glomerulosclerosis
 Full-text articles in online features of AJKD, 1137-1138
 Furosemide, response to, in Gitelman's syndrome, 848
 Gallium-67, uptake of, in renal AED, 161-165
 Gamma (γ)-trimethyl-ammonium- β -hydroxybutyrate (L-carnitine), effects of, on leukocyte phagocytic function and viability in ESRD patients on HD, 678-687
 Gammopathy, benign monoclonal, turning to de novo amyloid light chain amyloidosis after RTx, 166-169
 Ganciclovir for CMV infection, 556-559
 Gastric lymphoma, proteinuria and renal insufficiency due to MPGN after, 588-593
 Gastrointestinal (GI) tract of RTx recipients with persistent abdominal pain, prevalence of active CMV infection in, 65-68

- GCT (germ-cell tumor), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Gene therapy of inherited renal tubular disease, 374-379
- General renal community, USRDS products for, S1:24
- Genetics, *see* DNA; Family history; Gene therapy; Genomic damage; Immunophenotype; mRNA; Mutation(s); Polymorphism; Reverse transcriptase-polymerase chain reaction; Transgenic subjects *entries beginning with terms*: Autosomal, Recessive and specific genes
- Genomic damage in lymphocytes of ESRD patients on long-term maintenance HD, 433-437
- Gentamicin, pharmacokinetics of, in ESRD patients hemodialyzed with high-flux polysulfone membranes, 222-227
- Geographic data in USRDS 1999 ADR, S1:162
on location of ESRD care facilities, S1:140-142
on treated ESRD incidence and prevalence, S1:50
see also State(s)
- Germ-cell tumor (GCT), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- GF(s) (growth factors), and cytokines in renal involvement of POEMS syndrome, 633-638
- GFR, *see* Glomerular filtration rate
- GI (gastrointestinal) tract of RTx recipients with persistent abdominal pain, prevalence of active CMV infection in, 65-68
- Gitelman's syndrome, R642C missense mutation of *TSC* gene in, 845-853
- Glomerular filtration rate (GFR)
in doxorubicin-induced nephropathy, NaHCO₃ effects on, 331
in IDDM with HTN, ACE inhibition effects on IDDM course and, 811, 814
in LN, 317, 319
in types I and III MPGN, 1024, 1025, 1028
see also Glomerular filtration rate in ESRD
- Glomerular filtration rate (GFR) in ESRD
VLPD and, 501
see also Glomerular filtration rate in ESRD patients on RRT
- Glomerular filtration rate (GFR) in ESRD patients on PD/CAPD
Cr generation and, 237
in new ESRD patients, 696
nutritional status and, 1059
- Glomerular filtration rate (GFR) in ESRD patients on RRT
in new ESRD patients on HD, 696
serum hyaluronan and survival and, 1084
see also Glomerular filtration rate in ESRD patients on PD/CAPD
- Glomerulonephritis (GN)
bedside renal biopsy for, 956
see also Glomerulonephritis, as primary diagnosis and specific types of glomerulonephritis; for example: IgA nephropathy
- Glomerulonephritis (GN), as primary diagnosis
acidosis and nutritional status of ESRD patients on HD and, 494
in ESRD patients on CAPD, *see* Glomerulonephritis, as primary diagnosis in ESRD patients on PD/CAPD and LVH, 127
race and, 714, 723
and RTx, 542, 706, 876
serial VABF and, 472
- Glomerulonephritis (GN), as primary diagnosis in ESRD patients on PD/CAPD
effects of aminoglycosides on RRF and, 16
and IP rHuEPO therapy, 659
nutritional status and, 1058
- Glomerulopathy, *see* specific conditions
- Glomerulosclerosis (GS)
aging-related, sex and, 884-888
focal segmental, *see* Focal segmental glomerulosclerosis
idiopathic nodular, 560-564
tubulointerstitial fibrosis, obstructive uropathy and, in PEPCK-TGF- β 1 transgenic subjects, 177-183
- Glucocorticoids, role of, in acidosis, 960-965
- Glucose
and CVD in ESRD patients on HD, 440
fasting, in CAD, 920
in HTN with MA, atherosclerosis and, 998, 999
plasma, *see* Plasma glucose
reabsorption of, in pediatric FS secondary to chemotherapy, 100
in recurrent Goodpasture's syndrome, 551
regulation of transport of, by hypoxia, 189-202
toxicity of, to peritoneal mesothelial cells, OTZ effects of 663-668
see also Immunosuppressive agents, effects of, on glyce-mic tolerance
- Glut1 mRNA (messenger ribonucleic acid), and glucose transport regulation, 189-201
- Glut2, and glucose transport regulation, 189-201
- Glut3, and glucose transport regulation, 189-201
- Glutathione (GSH), RBC, in ESRD patients on HD, enalapril and, 448
- Glycemic tolerance, *see* Immunosuppressive agents, effects of, on glyce-mic tolerance
- Glycosylated Hb in IDDM with HTN, captopril and captopril effects on IDDM course, 811
and long-term renoprotective effects of captopril, 820, 821
- GMP (guanosine monophosphate), cyclic, indices of activity of, on HD, 228-234
- GN, *see* Glomerulonephritis
- Goodpasture's syndrome
recurrent, due to monoclonal IgA- κ circulating antibody, 549-555, 565-568
RPGN and, 364-373
- Grafts, *see* Grafts, renal; Vascular access grafts, HD
- Grafts, renal
drug-induced AIN in, histopathology and course of, 540-548
dysfunctional, associated with CMV infection, 942-946
loss of, racial disparities in, 708; *see also* Rejection
spontaneous rupture of, due to ATN, 355-358
see also Grafts, renal, survival of
- Grafts, renal, survival of
and de novo FSGS in renal grafts with chronic nephropathy, 731-738
MMF and, 296-303
see also Grafts, renal, survival of, USRDS 1999 ADR on

- Grafts, renal, survival of, USRDS 1999 ADR on, S1:10, S1:98-100
analytical methods applied to, S1:152, S1:173
in pediatric RTx, S1:111-112
- Granulomatosis, *see* Wegener's granulomatosis
- Grievance mechanisms, facility, for patients, 783-784
- Gross hematuria
percutaneous renal biopsy and, 92-97
in types I and III MPGN, 1024
- Growth factors (GFs)
and cytokines in renal involvement of POEMS syndrome, 633-638
IGF-I in hyperleptinemic CRF, 824-831, 947-950
see also Transforming growth factor- β ; Transforming growth factor- β 1
- GS, *see* Glomerulosclerosis
- GSH (glutathione), RBC, in ESRD patients on HD, enalapril and, 448
- Guanosine monophosphate (GMP), cyclic, indices of activity of, on HD, 228-234
- HA (hyaluronan), serum, and survival on RRTs for ESRD, 1083-1088
- Hb (hemoglobin)
LVH and decline of, in early renal disease, 125-134
in MPDs, 890
in recurrent Goodpasture's syndrome, 551
and SAHS in RTx recipients, 741
see also Hb in ESRD patients on HD; Hb in ESRD patients on PD/CAPD
- Hb (hemoglobin) in ESRD patients on HD
with ADPKD, cardiac complications and, 266, 267
L-carnitine effects on, 683
parenteral Fe therapy effects on, 24, S2:40-46
and PGC membrane thrombogenicity effects on heparin requirements, 38
resistant to rHuEPO, *Radix angelicae sinensis* effects on, 350
reticulocyte, 29-35
- Hb (hemoglobin) in ESRD patients on PD/CAPD
Fe deficiency and, 510
in NIDDM ESRD, 516, 517
- HbA_{1c} (hemoglobin A_{1c})
in CAD, 920
see also HbA_{1c} in NIDDM
- HbA_{1c} (hemoglobin A_{1c}) in NIDDM
ACE and AGN genes and, 1004
in NIDDM ESRD, 516, 517, 802
- HBV (hepatitis B virus) infection, PAN associated with, reversibility of bilateral hydronephrosis without obstruction in, 3:E11
- HCFA, *see* Health Care Financing Administration
- HCO₃, *see* NaHCO₃
- Hct, *see* Hematocrit
- HCV (hepatitis C virus) infection, ESRD patients on chronic HD with, IFN- α for, 55-60
- Hcy, *see* Homocysteine
- HD, *see* Hemodialysis
- HDL, *see* High-density lipoprotein
- HDL-C (high-density lipoprotein-cholesterol) in CAD, 920
- Health Care Financing Administration (HCFA), S1:4
- Death Notification Form of, S1:88, S1:155-156
- Medical Evidence Report Form of, *see* Medical Evidence Report Form
- racial/ethnic analysis of HD outcome of 1997 ESRD Core Indicators Project of, 721-730
- REBUS/PMMIS database of, S1:155-160
see also End-stage renal disease Core Indicators Project of HCFA and entries beginning with term: Medicare
- Healthy pediatric population, ratio of urinary excretion of urate and oxalate to Cr in, 2:E3
- Heart disease
ischemic, *see* Ischemic heart disease
valvular, in ESRD patients with ADPKD on HD, 264-272
- Heart failure, congestive, NIDDM and, 516, 517
- Heart rate (HR) in severe ARF, 427-430
- Height of hypokalemic patients, 109
- Hematocrit (Hct)
in DM patients on HD, and orthostatic hypotension, 1100
in LN, 536
in nephrotic-range proteinuria, 136, 137
in new ESRD patients on PD, 696-698; *see also* Hematocrit in ESRD patients on HD
in pediatric CCPD patients on IP rHuEPO therapy, 654
in recurrent Goodpasture's syndrome, 551
and SAHS in RTx recipients, 741
in severe ARF, 427-430
- Hematocrit (Hct) in ESRD patients on HD
L-carnitine effects on, 683
in new ESRD patients, 696-698
and parenteral Fe, S2:5-11, S2:22-23
race, HD outcome and, 724, 727, 728
rHuEPO effects on, 1092
resistant to rHuEPO, *Radix angelicae sinensis* effects on, 350
USRDS 1999 ADR on, S1:60-61
- Hematoma, percutaneous renal biopsy and, 92-97
- Hematuria
bedside renal biopsy for, 956
gross, percutaneous renal biopsy and, 92-97
macroscopic, IgAN and, 282
microscopic, in MGN and LMGN, 86
in POEMS syndrome, 634
in proliferative GN, DSG effects on, 895
in types I and III MPGN, 1024, 1025
- Hemodialysis (HD)
for DM, *see* Hemodialysis for DM
PDF and, 464-470
for severe ARF, CVVH compared with, 424-432
see also Hemodialysis for ESRD
- Hemodialysis (HD) for DM
with ATN, 1010-1015
orthostatic cerebral blood flow velocity reduction due to, 1096-1104
- Hemodialysis (HD) for ESRD, 43-54, 438-455, 688-701
activity of NO system on, 228-234
age and calcitriol effects on recovery from hypercalcemia on, 456-463; *see also* Age of ESRD patients on HD
antioxidant level in patients treated or not treated with enalapril, 445-455
association between acidosis and nutritional status on, 493-499
chronic, *see* Chronic hemodialysis for ESRD

- distinguishing PCT from pseudoporphyria in patients on, 155-160
- effects of, on SAECEG, 1105-1113
- hemostatic factors and serum MDA predictive of CVD on, 438-444
- hyperhomocyst(e)inemia and prevalence of atherosclerotic vascular disease in patients on, 669-677
- hyperleptinemia and, 824-831, 947-950
- ideal, *see* Prolonged slow hemodialysis for ESRD
- improvement of, HCFA Core Indicators Project on, 1075-1082
- influence of *MTHFR* gene polymorphism on plasma Hcy in patients on, 259-263
- initiation of, significance of SCr values in, 694-701
- outcome of, *see* Hemodialysis for ESRD, outcome of plasma AI in relation to ABD in asymptomatic patients on, 688-693
- serum Mg and PTH levels on, 43-48
- UF for HTN on, 218-221, 359-361
- vascular access for, *see* Vascular access, HD
- Western Australian Health Services Research Linked Database on, 1033-1039
- see also* Autosomal dominant polycystic kidney disease, ESRD patients on HD with; Dialyzer(s), HD; Hemodialysis for ESRD, USRDS 1999 ADR on; Parenteral iron therapy in ESRD patients on HD; Pediatric end-stage renal disease, HD and/or CCPD for; Phagocytic properties of leukocytes in ESRD patients on HD; Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD; Recombinant human erythropoietin for anemic ESRD patients on
- Hemodialysis (HD) for ESRD, outcome of
- racial/ethnic analysis of, 721-730
- see also* Mortality of ESRD patients on HD
- Hemodialysis (HD) for ESRD, USRDS 1999 ADR on
- causes of mortality on, S1:88-91
- described, S1:52-53
- dialysis dose on, S1:58-59
- Hct in patients on, S1:60-61
- history of, S1:51
- Medicare expenditures for, S1:132-134, S1:138
- membrane types in, S1:59-60
- patient characteristics and utilization of, S1:56-58
- patient survival on, S1:55
- for pediatric ESRD, S1:108
- at start of ESRD, S1:64
- trends in utilization of, S1:53-56
- Hemodynamic paradigm of pathogenesis of MA in HTN, 976-977
- Hemofiltration, continuous venovenous, for severe ARF, HD compared with, 424-432
- Hemoglobin, *see* Hb
- Hemolytic uremic syndrome (HUS)
- de novo post-RTx, after CMV infection, 556-559
- as primary diagnosis, 16, 659
- Hemorrhage, pulmonary, and recurrent Goodpasture's syndrome due to monoclonal IgA- κ circulating antibody, 549-555, 565-568
- Hemostatic factors, serum MDA and, as predictive factors for CVD in ESRD patients on HD, 438-444
- Heparin, requirements of ESRD patients on HD for, thrombogenicity of PGC membranes and, 36-42
- Hepatitis
- IgAN with skin lesions and, renal biopsy of, 380-383
- see also* Hepatitis B virus infection; Hepatitis C virus infection
- Hepatitis B virus (HBV) infection, PAN associated with, reversibility of bilateral hydronephrosis without obstruction in, 3:E11
- Hepatitis C virus (HCV) infection in ESRD patients on chronic HD, IFN- α for, 55-60
- Herbal medicine, *Radix angelicae sinensis* as, for anemic ESRD patients resistant to rHuEPO, 349-354
- HIF-1 (hypoxia-inducible factor 1), regulation of glucose transport by, 189-202
- High-density lipoprotein (HDL)
- in ESRD patients on HD, CVD and, 440, 441
- in HTN with MA, atherosclerosis and, 998
- High-density lipoprotein-cholesterol (HDL-C) in CAD, 920
- High-flux biocompatible membranes, HD for ESRD with polysulfone, pharmacokinetics of gentamicin with, 222-227
- on prolonged slow HD, 601
- Hispanics, *see* Race
- Histocompatibility leukocyte antigen, *see* HLA
- Histology
- venous, chronic HD vascular access and changes in, 702-705
- see also* Histopathology; Renal histology
- Histopathology
- of drug-induced renal graft AIN, 540-548
- of pediatric NS, changing trends in, 646-650
- HIV-associated nephropathy, *see* HIVAN
- HIV (human immunodeficiency virus) infection in ESRD patients on chronic HD, IWB analysis and EIA of, 146-149
- HIVAN (HIV-associated nephropathy)
- familial aggregation of ESRD in, race and, 254-258
- as primary diagnosis, 11-7
- HLA (histocompatibility leukocyte antigen)
- in familial SV and RPGN, 364-374
- in TINU syndrome, 1018
- see also* HLA, and RTx
- HLA (histocompatibility leukocyte antigen), and RTx
- HLA mismatch and de novo FSGS in renal grafts, 733
- racial disparities in, and RTx outcome, 706-712, 756-758
- HMG-CoA (hydroxy-methylglutaryl-coenzyme A) reductase inhibitors, effects of, on biological response to lipid-associated renal injury, 2:xlvi
- Hodgkin's disease, pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- HOMA (homeostasis model analysis) of pancreatic β -cell function in NIDDM patients on CAPD for ESRD, 514-520
- Homeostasis, acid/base, effects of Pi replacement for hypophosphatemia on, in RTx recipients, 875-883; *see also* pH
- Homeostasis model analysis (HOMA) of pancreatic β -cell function in NIDDM patients on CAPD for ESRD, 514-520

- Homocysteine (Hcy)
 hyperhomocyst(e)inemia and prevalence of atherosclerotic vascular disease in ESRD patients on HD, 669-677
 plasma, in ESRD, influence of *MTHFR* gene polymorphism on, 259-263
- Hospital centers for ESRD care, described, S1:140
- Hospital days, hospitalization rates for ESRD based on, S1:117-119
- Hospital facilities for ESRD care, described, S1:140
- Hospitalization
 early discharge from, effects of using ultrasound-guided automated spring-loaded gun device on, 92-97
 for LVH in renal insufficiency, 129-130
see also Hospitalization for ESRD, USRDS 1999 ADR on entries beginning with term: Hospital and specific conditions
- Hospitalization for ESRD, USRDS 1999 ADR on, S1:114-123, S1:153-154
 annual, S1:166-171
 executive summary of, S1:16-17
 and hospitalization CD, S1:33
 Medicare eligibility criteria for, S1:114-115
 for pediatric ESRD, S1:112
 rates of, based on hospital days and/or total admissions, S1:117-119
 SHR and, *see* Standard Hospitalization Ratio
 trends in, S1:115-117
- HR (heart rate) in severe ARF, 427-430
- HTN, *see* Hypertension
- Human immunodeficiency virus infection, *see* HIV-associated nephropathy; HIV infection
- HUS, *see* Hemolytic uremic syndrome
- HUVS (hypocomplementemic urticarial vasculitis syndrome), distinguishing between SLE and, 745-751
- Hyaluronan (HA), serum, and survival on RRTs for ESRD, 1083-1088
- Hydronephrosis, bilateral, without obstruction, HBV infection-associated PAN and reversibility of, 3:E11
- Hydrothorax, PPC and, in ESRD patients on CAPD, 170-172
- Hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, effects of, on biological response to lipid-associated renal injury, 2:xlx
- Hypercholesterolemia in ESRD patients on HD, atherosclerotic vascular disease and, 671
- Hyperhomocyst(e)inemia, and prevalence of atherosclerotic vascular disease in ESRD patients on HD, 669-677
- Hyperinsulinemia
 CAD and, 920
 and MA in HTN, 979-981
- Hyperleptinemia in CRF patients on conservative therapy, HD, or PD, 824-831, 947-950
- Hypermagnesemia, relationship between PTH levels and, in ESRD patients on HD, 43-48
- Hyperparathyroidism in CAPD patients with ESRD secondary to SLE, calciphylaxis due to UV light in, 932-936
- Hypertension (HTN)
 antihypertensives for, *see* Antihypertensive drugs
 and CAD, 920, 922
 in FSGS, 620
 and IP rHuEPO therapy, 659
 in LN, 317, 319, 536
 low-renin, T594M mutation in ENaC β subunit, race and, 579-587
 and LVH, 127, 129-131
 malignant, 1:E1
 in pediatric ADPKD, 639-645, 4:E17
 proteinuria and, *see* Hypertension, proteinuria and
 race, *see* Hypertension, race and
see also Hypertension in ESRD patients on HD; Hypertension in ESRD patients on PD/CAPD
see also Microalbuminuria in HTN
- Hypertension (HTN), proteinuria and
 nephrotic-range proteinuria, 136
 with renal insufficiency, renal biopsy of, 768-774
- Hypertension (HTN), race and
 and HD outcome, 723
 and RTx outcome, 708
- Hypertension (HTN) in ESRD patients on HD
 and ACE gene polymorphism in ADPKD patients, 273-278
 atherosclerotic vascular disease and, 671
 cardiac dilatation and time factor in therapy of, 218-221, 359-361
 leukocyte phagocytic function and viability and, 681
 NO system on HD and, 228-234
 and SAEG, 1107
 serial VABF and, 472
 UF for, 218-221, 359-361
- Hypertension (HTN) in ESRD patients on PD/CAPD
 aminoglycoside effects on, 16, 17
 with NIDDM, 516, 517
- Hypertensive nephrosclerosis, as primary diagnosis, 138, 494
- Hypertrophy, left ventricular, in early renal disease, Hb decline and, 125-134
- Hyperuricemia, renal insufficiency and, associated with tumor lysis syndrome, urate oxidase for, 5:E20
- Hypoapnea syndrome, reversal of sleep apnea, following RTx for ESRD, 739-744
- Hypocalcemia, effects of age and calcitriol on recovery from, in ESRD patients on HD, 456-463
- Hypocomplementemia in LN, 536
- Hypocomplementemic urticarial vasculitis syndrome (HUVS), distinguishing between SLE and, 745-751
- Hypokalemia, thiazide-induced, K Mg citrate effects on, 107-113
- Hypoparathyroidism, relationship between serum Mg levels and, in ESRD patients on HD and, 43-48
- Hypophosphatemia in RTx recipients, effects of Pi replacement therapy of, on muscular Pi content, mineral metabolism, and acid/base homeostasis, 875-883
- Hypotension
 orthostatic, due to HD for DM, 1096-1104
 in pediatric ARPKD, acute vision loss and, 1125-1128
- Hypothalamic disorders in IE etiology, 414
- Hypotonic saline, response to, in Gitelman's syndrome, 848
- Hypoxia, regulation of glucose transport by, 189-202
- Hypoxia-inducible factor 1 (HIF-1), regulation of glucose transport by, 189-202

- Hypoxia-signaling pathway, and glucose transport regulation, 192-194
- Hysteresis, and recovery from hypocalcemia in ESRD patients on HD with calcitriol, 456-463
- Iberoamerica, renal osteodystrophy in, 4:lviii-lx
- IC-GN (immune complex glomerulonephritis), secondary, role of renin-angiotensin system in juxtaglomerular cell tumor with retroperitoneal fibrosis and, 3:E10
- I/D (insertion/deletion) polymorphisms of *ACE*, *ATI*, *ATG*, and *PAI-1* genes, scarring in VUR and, 140-145
- IDDM (insulin-dependent diabetes mellitus) *see* Captopril in IDDM; Diabetic end-stage renal disease, IDDM
- Ideal hemodialysis, *see* Prolonged slow hemodialysis for ESRD
- Idiopathic edema (IE), 405-423
clinical features of, 406-408
diagnosis of, 406, 408-410
etiology of, *see* Etiology of IE
therapy of, 420-421
- Idiopathic membranous nephropathy (IMN), steroids for and/or chlorambucil for stage II and III IMN, long-term follow-up of, 911-917
prednisolone and azathioprine effects on IMN progression, 521-529
- Idiopathic myelofibrosis, amyloidosis complicating, 6:E27
- Idiopathic nodular glomerulosclerosis (GS), 560-564
- IE, *see* Idiopathic edema
- IFN- α (interferon- α) for HCV infection in ESRD patients on chronic HD, 55-60
- Ifosfamide, pediatric FS secondary to, mtDNA deletions and decreased oxidative phosphorylation in, 98-106
- IgA- κ (immunoglobulin- κ) circulating antibody, monoclonal, recurrent Goodpasture's syndrome due to, 549-555, 565-568
- IgA nephropathy (IgAN; Berger's disease)
C difficile associated with, 4:E16
with hepatitis and skin lesions, renal biopsy of, 380-383
mesangial cell α -SMA expression and progression of, 902-910
as primary disease, 16, 138, 612, 1107
and recurrent Goodpasture's syndrome due to monoclonal IgA- κ circulating antibody, 549-555, 565-568
see also IgA nephropathy in Japanese patients
IgA nephropathy (IgAN; Berger's disease) in Japanese patients, 279-295
in pediatric patients, role of *PAF-AH* gene mutation in, 289-295
TCR C α gene polymorphism and progression of, 279-288
- IgAN, *see* IgA nephropathy
- IGF-1 (insulin-like growth factor-1) in hyperleptinemic CRF, 824-831, 947-950
- IgG (immunoglobulin G), serum, in TINU syndrome, 1017
- IL-1 (interleukin-1) in POEMS syndrome, 633-638
- IL-6 (interleukin-6) in POEMS syndrome, 633-638
- Immersion in seawater polluted by diesel oil, ARF due to, 6:E26
- Immune complex glomerulonephritis (IC-GN), secondary, juxtaglomerular cell tumor with retroperitoneal fibrosis and, role of renin-angiotensin system in, 3:E10
- Immune deposits, subepithelial, in MGN and LMGN and, spatial arrangements of, 85-91
- Immune dysfunction, cell-mediated, serum and urinary NP and, in NS, 611-617
- Immunoglobulin, *see* entries beginning with acronym: Ig
- Immunohistochemistry of doxorubicin-induced nephropathy, NaHCO₃ effects on, 331-333
- Immunophenotype of mononuclear cells in peripheral blood and renal interstitium in TINU syndrome, 1018, 1020
- Immunosuppression
in LN, 530-539
prolonged FSGS, improved prognosis and, 618-625
see also Immunosuppressive agents, effects of, on glyce-mic tolerance and specific immunosuppressants
- Immunosuppressive agents, effects of, on glycemic toler-ance, 1-13
comparative clinical trials of, 8
of corticosteroids, 3-4
of cyclosporine, 4-6, 8, 9
of tacrolimus, 6-9
- Immunotactoid glomerulopathy, 1146-1151
- IMN, *see* Idiopathic membranous nephropathy, steroids for IN, *see* Interstitial nephritis
- INC (infantile nephropathic cystinosis), FS and, 966-971
- Incidence and prevalence
of active CMV infection in GI tract of RTx recipients, persistent abdominal pain, 65-68
of atherosclerotic vascular disease in ESRD patients on HD, hyperhomocyst(e)inemia and, 669-677
of bacteremia associated with tunneled, cuffed, permanent HD catheters, 1117
of ESRD, *see* Incidence and prevalence of treated ESRD of PTDM, 2, 8
see also specific conditions
- Incidence and prevalence of treated ESRD
according to Western Australian Health Services Research Linked Database, 1033-1039
see also Diabetic end-stage renal disease, NIDDM, interna-tional incidence and prevalence of treated; Incidence and prevalence of treated ESRD, USRDS 1999 ADR on
- Incidence and prevalence of treated ESRD, USRDS 1999 ADR on, S1:11-13, S1:40-50
by age, S1:11, S1:42-45, S1:47-49
executive summary of, S1:12-13
international, S1:145-146
measurement of, S1:40-41, S1:162-164
overall, S1:41-44
patient characteristics and, S1:44-50
by primary disease, S1:11, S1:42, S1:43, S1:47, S1:48
by race, S1:11, S1:42-49
of reported pediatric ESRD, S1:102-103, S1:107-108
by sex, S1:11, S1:42-45, S1:47-49
summary statistics on, S1:11
- Independently-supported research, SAFs used in, S1:28
- Indeterminate Western blot (IWB) analysis, EIA and, of HIV infection in ESRD patients on chronic HD, 146-149
- Infantile nephropathic cystinosis (INC), FS and, 966-971
- Infarction, bilateral renal, secondary to paradoxical embolism, 752-755
- Infection(s)
hepatitis as, *see* Hepatitis

- HIV, *see* HIV-associated nephropathy; HIV infection
- PAN associated with HBV, reversibility of bilateral hydro-nephrosis without obstruction in, 3:E11
- parvovirus B19, PRCA in RTx recipients on tacrolimus due to, 1132-1136
- risks of, Fe and, S2:33, S2:49-50
- see also* Cytomegalovirus infection in RTx recipients;
- Infection(s) in ESRD patients on HD *specific infections and microorganisms*
- Infection(s) in ESRD patients on chronic HD
- HCV, IFN- α for, 55-60
- HIV, EIA and IWB analysis of, 146-149
- S haemolyticus* catheter, bacterial endocarditis due to inverse paradoxical embolism with, 338-340, 362-363
- Infection(s) in ESRD patients on HD
- bacteremia as, due to tunneled, cuffed, permanent catheters, 1114-1124
- parenteral Fe therapy role in, S2:25-34, S2:44, S2:47-52
- see also* Infection(s) in ESRD patients on chronic HD
- Inflammation, renal
- chemokines as therapeutic targets in, 761-667
- in ESRD, survival on RRTs and, 1083-1088
- Inherited renal tubular disease, gene therapy of, 374-379
- Initiation of dialysis for new ESRD patients
- significance of SCr in, 694-701
- see also* Initiation of dialysis for new ESRD patients, USRDS 1999 ADR on
- Initiation of dialysis for new ESRD patients, USRDS 1999 ADR on, S1:70-72
- employment status prior to, S1:71-72
- timing of, S1:70-71
- Injury, *see* Damage and injury
- Insertion/deletion (I/D) polymorphisms of *ACE*, *AT1*, *ATG*, and *PAI-1* genes, scarring in VUR and, 140-145
- Inside-outside signaling by integrins, and neutrophils in ARF, 394
- Insulin
- microalbuminuria and, as predictors of CAD, 918-925
- relationship between clinical and biochemical characteristics of NIDDM in ESRD patients on CAPD and their requirements for, 514-520
- see also* Hyperinsulinemia; Insulin resistance
- Insulin-dependent diabetes mellitus, *see* Captopril in IDDM; Diabetic end-stage renal disease, IDDM
- Insulin-like growth factor-1 (IGF-1) in hyperleptinemic CRF, 824-831, 947-950
- Insulin resistance, and MA in hypertension, 979-981
- Intact parathyroid hormone (iPTH)
- in renal insufficiency, LVH and, 127, 129
- see also* Intact parathyroid hormone in ESRD patients on HD/PD
- Intact parathyroid hormone (iPTH) in ESRD patients on HD/PD
- asymptomatic AI-related renal osteodystrophy and, 690
- and Fe status, 31
- hyperleptinemia and, 826, 827
- Integrins, role of, in activation of neutrophils, renal injury and, 393-395
- Intent-to-treat model of Medicare expenditures for ESRD, USRDS 1999 ADR on, S1:127-128, S1:133-135
- analytical method applied to, S1:174-176
- Interferon- α (IFN- α) for HCV infection in ESRD patients on chronic HD, 55-60
- Interleukin-1 (IL-1) in POEMS syndrome, 633-638
- Interleukin-6 (IL-6) in POEMS syndrome, 633-638
- International incidence and prevalence of treated ESRD in USRDS 1999 ADR, S1:144-145
- see also* Diabetic end-stage renal disease, NIDDM, international incidence and prevalence of treated
- International renal replacement therapy (RRT) for ESRD, USRDS 1999 ADR on, S1:144-151
- data source on, S1:144-145
- incidence and prevalence of, *see* International incidence and prevalence of treated ESRD
- patient survival in, S1:149-150
- PD as, S1:146-148
- RTx as, S1:148-149
- Internet World Wide Web, USRDS products on, S1:24-25
- Interstate differences in Medicare expenditures for ESRD, S1:138-139
- Interstitial nephritis (IN)
- acute, *see* Acute interstitial nephritis
- allergic, differentiation between renal AED and, with gallium-67 scan, 161-165
- as primary diagnosis, 138, 876, 1107
- Interstitialium
- immunophenotype of mononuclear cells in, in TINU syndrome, 1018, 1020
- see also* entries beginning with terms: Interstitial, Tubulointerstitial
- Intradialytic serial vascular access blood flow (VABF), measurements of, 471-477
- Intraperitoneal recombinant human erythropoietin (IP rHuEPO) therapy, 651-662
- "dry well" dosing technique of, 657-662
- for pediatric patients, 651-656
- Intravenous iron therapy, *see* Parenteral iron therapy in ESRD patients on HD
- Inverse paradoxical embolism in chronic HD patient with aortic bacterial endocarditis due *S haemolyticus* catheter infection, 338-340, 362-363
- Investigator-initiated research, policy on USRDS data release for, S1:35-36
- IP, *see* Intraperitoneal recombinant human erythropoietin therapy
- iPTH, *see* Intact parathyroid hormone
- Iron, *see* Parenteral iron therapy in ESRD patients on HD and entries beginning with terms: Iron deficiency
- Iron (Fe) deficiency in ESRD patients on HD
- diagnosis of, 508-513
- Radix angelicae sinensis* effects on, 350
- see also* Iron deficiency in ESRD patients on PD/CAPD; Parenteral iron therapy in ESRD patients on HD
- Iron (Fe) deficiency in ESRD patients on PD/CAPD
- diagnosis of, 508-513
- indices of, 29-35
- Ischemic heart disease
- in ESRD patients on HD, hyperhomocyst(e)nia and prevalence of, 669-677
- NIDDM and, 516, 517
- Ischemic optic neuropathy, anterior, and acute vision loss in pediatric ARPKD, 1125-1128

- IWB (indeterminate Western blot) analysis, EIA and, of HIV infection in ESRD patients on chronic HD, 146-149
- Japanese patients, *see* IgA nephropathy in Japanese patients
- Judgment analysis, 569-575
- Juxtaglomerular cell tumor with retroperitoneal fibrosis and secondary IC-GN, role of renin-angiotensin system in, 3:E10
- K (potassium)
- in DM patients on HD, and orthostatic hypotension and, 1100
 - in nephrotic-range proteinuria, 136, 137
 - in recurrent Goodpasture's syndrome, 551
 - serum, *see* Serum K
 - see also* Hypokalemia; K in ESRD patients on HD
- K (potassium) in ESRD patients on HD
- and CVD, 440
 - plasma, and NO activity, 231
 - Radix angelicae sinensis* effects on, 350
 - SAECG and, 1108
- K Mg (potassium magnesium) citrate, effects of, on thiazide-induced hypokalemia and Mg loss, 107-113
- Kinetics, urea
- and acidosis in ESRD patients on HD and, 495
 - see also* entries beginning with: Kt/V
- Kt/V in ESRD patients on HD
- acidosis, nutritional status and, 495
 - equilibrated, *see* Equilibrated kt/V in ESRD patients on HD
 - hyperleptinemia and, 826, 827
 - on prolonged slow HD, 600-601
 - race, HD outcome and, 724, 727, 728
 - Radix angelicae sinensis* effects on, 350
- Kt/V in ESRD patients on PD/CAPD
- and Cr generation, 237
 - hyperleptinemia and, 826, 827
 - with NIDDM, 517
 - race, survival and, 715
- Lactate dehydrogenase (LDH)
- in severe ARF, 427-430
 - see also* Lactate dehydrogenase in ESRD patients on HD
- Lactate dehydrogenase (LDH) in ESRD patients on HD
- L-carnitine effects on release of, 683-684
 - Radix angelicae sinensis* effects on, 350
- Laxatives, and IE, 412
- LBM (lean body mass) in ESRD patients, VLPD and, 501, 503
- LDH, *see* Lactate dehydrogenase
- LDL, *see* Low-density lipoprotein
- LDL-C (low-density lipoprotein-cholesterol) in CAD, 920
- Lean body mass (LBM) in ESRD patients, VLPD and, 501, 503
- Left ventricular hypertrophy (LVH) in early renal disease, Hb decline and, 125-134
- Legal aspects of discontinuing dialysis treatment for abusive patients, physician's duties versus, 778-780, 783-784
- Leptin in ESRD patients
- undergoing conservative therapy or HD, hyperleptinemia in, 824-831, 947-950
 - see also* Leptin in ESRD patients on PD/CAPD
- Leptin in ESRD patients on PD/CAPD, 824-844
- hyperleptinemia in patients undergoing conservative treatment, HD, or PD, 824-831, 947-950
 - and leptin dialysate from CAPD patients, 832-838, 947-950
 - peritoneal clearance of, 839-844, 947-950
- Leukocyte(s) (white blood cells)
- Fe status effects on function of, S2:48-49
 - in nephrotic-range proteinuria, 136
 - in recurrent Goodpasture's syndrome, 551
 - see also* HLA; Leukocyturia; Phagocytic properties of leukocytes in ESRD patients on HD; White blood cell count and specific leukocytes
- Leukocyturia in POEMS syndrome, 634
- Light, UV, light, calciphylaxis in CAPD patients with ESRD secondary to SLE due to, 932-936
- Light chain amyloidosis, de novo angiod, benign monoclonal gammopathy turning into, after RTx, 166-169
- Light microscopy of doxorubicin-induced nephropathy, NaHCO₃ effects on, 331-333
- Limb movements in sleep, periodic, effects of rHuEPO for ESRD patients on HD on, 1089-1095
- Lipid(s)
- and de novo FSGS in renal grafts with chronic allograft nephropathy, graft survival and, 731-738
 - and progression of renal disease, 2:xlili-xlvi
 - serum, and MA in hypertension, 978-979
- Lipid-soluble antioxidants, plasma, in ESRD patients on HD, enalapril and, 448-449
- Lipoprotein, *see* High-density lipoprotein; Low-density lipoprotein; Very-low-density lipoprotein
- Lithiasis (urolithiasis and nephrolithiasis), as primary diagnosis, 138, 434, 1058, 1107
- Liver disease
- and renal function recovery with severe ARF treated with CVVH or HD, 424-432
 - see also* Hepatitis
- LMGN (lupus membranous glomerulonephritis), spatial arrangements of subepithelial immune deposits in, 85-91
- LN, *see* Lupus nephritis
- Lobular glomerulonephritis (GN), idiopathic nodular GS and, 560-564
- Location of ESRD care facilities, S1:140-142
- Long-term follow-up and outcome
- of LN, 315-323
 - of stage II and III IMN treated with steroids and/or chlorambucil, 911-917
- Long-term maintenance hemodialysis (HD) for ESRD, genomic damage to lymphocytes and, 433-437
- Long-term renoprotection in IDDM, correlation between captopril effects on serum TGF- β 1 and, 818-823, 951-954
- Long-term survival with ESRD from first ESRD treatment, USRDS 1999 ADR on, S1:80-81
- Lost-to-follow-up classification methods in USRDS 1999 ADR, S1:160-162
- Low-density lipoprotein (LDL)
- in ESRD patients on HD, CVD and, 440, 441
 - in HTN with MA, atherosclerosis and, 998
- Low-density lipoprotein-cholesterol (LDL-C) in CAD, 920
- Low-renin hypertension (HTN), race and, and T594M mutation in ENaC β subunit, 579-587

- Lupus membranous glomerulonephritis (LMGN), spatial arrangements of subepithelial immune deposits in, 85-91
- Lupus nephritis (LN)
 as primary diagnosis, 16, 138
 repeated renal biopsies in, 530-539
 RTx for, FSGS development in allograft and, 3:E13
 in Southern Chinese patients, clinicopathologic findings on, and long-term outcome with, 315-323
see also Systemic lupus erythematosus
- LVH (left ventricular hypertrophy) in early renal disease, Hb decline and, 125-134
- Lymphocytes, genomic damage to, in ESRD patients on long-term maintenance HD, 433-437
- Lymphoma, gastric, proteinuria and renal insufficiency after, due to MPGN, 588-593
- Lymphoproliferative disorder, rapidly developing T-cell post-transplantation, 1:E3
- β_2 -M, *see* β_2 -Microglobulin
- MA, *see* Microalbuminuria
- Macrophages, *see* Monocytes/macrophages
- Macroscopic hematuria, IgAN and, 282
- Magnesium, *see* Mg
- Maintenance hemodialysis, *see* Chronic hemodialysis for ESRD
- Malignancy
 IE and, 408
see also specific malignancies
- Malignant hypertension (HTN), 1:E1
- Malnutrition, *see* entries beginning with terms: Nutritional status
- Malondialdehyde (MDA), serum, hemostatic factors and, as predictive factors for CVD in ESRD patients on HD, 438-444
- Manuscript tracking in online features of *AJKD*, 1137-1138
- MB (medulloblastoma), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- MDA (malondialdehyde), serum, hemostatic factors and, as predictive factors for CVD in ESRD patients on HD, 438-444
- Measured-to-predicted creatinine (Cr), duration of CAPD and increased generation of, 235-241
- Mechanical thrombolysis of clotted HD access grafts, cerebral embolism after, 341-343, 362-363
- Mechanical ventilation of severe ARF patients on HD or CVVH, 427-430
- Media, SAFs, S1:34-35
- Medical education, continuing, exercises on, 1:E2, 2:E2, 3:E8, 4:E14, 5:E15, 6:E24
- Medical Evidence Report Form (HCFA-2728), S1:28, S1:155, S1:158-162, S1:164
 new, S1:63-64
 new reference tables based on, S1:152
see also Patient characteristics at start of ESRD, USRDS 1999 ADR on
- Medical practice considerations in dealing with abusive patients, 779-780
- Medicare, *see* Medicare claims; Medicare eligibility criteria; Medicare expenditures for ESRD, USRDS 1999 ADR on
- Medicare claims, S1:33, S1:174
- Medicare eligibility criteria
 for hospitalization, S1:114-115
- Medicare expenditures and, S1:127-128
- Medicare Enrollment Database (EDB), S1:129, S1:156
- Medicare expenditures for ESRD, USRDS 1999 ADR on, S1:33-34, S1:127-139
 analytical data on Medicare claims, S1:174
 for direct patient care, S1:129-131
 EDB of, S1:129, S1:156
 executive summary of, S1:27-28
 intent-to-treat model applied to, *see* Intent-to-treat model of Medicare expenditures for ESRD, USRDS 1999 ADR on
 interstate differences in, S1:138-139
 and patient eligibility, S1:127-128
 payments and, *see* Payment(s), Medicare
 by physician specialty and supplier type, S1:135-138
 by treatment modality, S1:131-135, S1:138
- Medulloblastoma (MB), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Membranes, HD, *see* Dialyzer(s), HD; Dialyzer Standard Analysis File
- Membranoproliferative glomerulonephritis (MPGN)
 differences between types I and III, in response to alternate-day prednisone, 1022-1032
 as histopathologic subtype of NS, 646-650
 as primary diagnosis, 16, 138
 proteinuria and renal insufficiency after gastric lymphoma due to, 588-593
- Membranoproliferative glomerulonephritis (MPGN)-like glomerulonephritis (GN) in POEMS syndrome, 633-638
- Membranous glomerulonephritis (MGN)
 differentiating between partial pediatric FS and, 184-188
 with hepatitis and skin lesions, secondary syphilis and, 380-383
 lupus, spatial arrangements of subepithelial immune deposits in, 85-91
 as primary diagnosis, 16, 138
 and SLE in remission, NS associated with FSGS in, 5:E22
- Membranous nephropathy (MN)
 idiopathic, *see* Idiopathic membranous nephropathy, steroids for
 as primary disease, 612
- Mesangial cell α -smooth muscle actin (α -SMA), expression of, and IgAN progression, 902-910
- Mesangial proliferation in IgAN with *PAF-AH* gene mutation, 289-295
- Mesangial proliferative glomerulonephritis (GN)
 as histopathologic subtype of NS, 646-650
 as primary disease, 612
- Mesangial sclerosis associated with myeloproliferative disorders, 889-893
- Mesangiolytic glomerulonephritis (GN) in POEMS syndrome, 633-638
- Mesothelial cells, resistance of peritoneal, to free radicals, OTZ effects on, 663-668

- Messenger ribonucleic acid, *see* mRNA
- Metabolic acidosis, and nutritional status of ESRD patients on HD, 493-499
- Methylprednisolone, time course of response to pulse, for acute allograft rejection, 304-307
- Mg (magnesium)
relationship between PTH levels and hypermagnesemia in ESRD patients on HD, 43-48
and SAHS in RTx recipients, 741
see also K Mg citrate; Serum Mg
- MGN, *see* Membranous glomerulonephritis
- MH (microscopic hematuria) in MGN and LMGN, 86
- Microalbuminuria (MA)
insulin and, as predictors of CAD, 918-925
in siblings with NIDDM, ACE and AGN genes in, 1002-1009
see also Microalbuminuria in HTN
- Microalbuminuria (MA) in HTN, 973-995
atherosclerosis and, 996-1001
CVD and, 982-983
effects of antihypertensive drugs on, 984-985
insulin resistance, hyperinsulinemia and, 979-981
measurements of, 974
nephroangiosclerosis and, 983-984
pathogenesis of, 976-979
prevalence and relationship of, to BP level, 974-976
screening for, 1139-1141
serum lipids and, 978-979
- Microangiopathy, *see* Thrombotic microangiopathy
- Microbiology
of bacteremia associated with tunneled cuffed permanent HD catheters, 1117, 1118
see also specific microorganisms; for example: *Clostridium difficile*
 β_2 (beta₂)-Microglobulin (β_2 M)
diffusive and convective clearances of, during CRRT at various dialysate and ultrafiltration rates, 486-492
in TINU syndrome, 1016-1021
see also β_2 -Microglobulin, and leptin in CAPD patients
 β_2 (beta₂)-Microglobulin (β_2 M), and leptin in CAPD patients
leptin in peritoneal dialysate, 834, 836
peritoneal clearance of leptin, 839-844, 947-950
- Micronuclei, evaluation of, in assessment of genomic damage to lymphocytes in ESRD patients on long-term maintenance HD, 433-437
- Microscopic hematuria (MH) in MGN and LMGN, 86
- Microscopic polyangiitis (MPA), RPGN and, 364-373
- Microtubules, fibrils versus, in NS, 1146-1151
- Middle molecules in prolonged slow HD, 601
- Mineral metabolism, effects of Pi replacement for hypophosphatemia in RTx recipients on, 875-883
- Minimal change disease
as histopathological subtype of NS, 646-650
as primary disease, 612
- Minimum aggregation size in USRDS 1999 ADR analytical methods, S1:154
- Missense mutation, R642C, of *TSC* gene in Gitelman's syndrome, 845-853
- Mitochondrial DNA (mtDNA), deletions in, and decreased oxidative phosphorylation activity in children with FS secondary to chemotherapy, 98-106
- MM, *see* Multiple myeloma
- MMF, *see* Mycophenolate mofetil
- MN, *see* Membranous nephropathy
- Modality(ies), RRT, for ESRD
international incidence and prevalence of NIDDM ESRD and, 802-803
see also Hemodialysis for ESRD; Incidence and prevalence of treated ESRD; Modality(ies), RRT, USRDS 1999 ADR on; Peritoneal dialysis for ESRD; Renal transplantation for ESRD
- Modality(ies), RRT, USRDS 1999 ADR on, S1:51-53
analytical method applied to, S1:173-174
changes in, S1:53
described, S1:52-53
history of, S1:51
- Medicare expenditures by, S1:131-135, S1:138
trends in utilization of, S1:53-56
see also Hemodialysis for ESRD, USRDS 1999 ADR on; Peritoneal dialysis for ESRD, USRDS 1999 ADR on; Renal transplantation for ESRD, USRDS 1999 ADR on
- Modality Sequence File (Treatment History File), S1:28
- Monitoring of HD access graft venous pressure at high blood flow in prediction of graft survival, 212-217
- Monoclonal gammopathy, benign, turning to de novo amyloid light chain amyloidosis after RTx, 166-169
- Monoclonal IgA- κ circulating antibody, recurrent Goodpasture's syndrome due to, 549-555, 565-568
- Monocytes/macrophages
and cell-mediated immune dysfunction in NS, 611-617
immunophenotype of peripheral blood, in TINU syndrome, 1018, 1020
in proliferative GN, DSG effects on expression of Fc γ RIII on, 894-901
- Mononuclear cells, *see* Monocytes/macrophages
- Morbidity, *see* Comorbidity; Morbidity with ESRD
- Morbidity with ESRD
in CAPD patients, 1060
in HD patients, parenteral Fe therapy and, S2:44
in new ESRD patients, USRDS 1999 ADR on, S1:66-70
see also Dialysis Morbidity and Mortality Study, USRDS and specific conditions
- Morning-evening differences in BW of IE patients, 416
- Mortality
with ATN in DM, 1010-1015
with LN, 315-323
see also Mortality of ESRD patients
- Mortality of ESRD patients
on CAPD and CCPD, compared, 1065-1074
on HD, *see* Mortality of ESRD patients on HD
of new patients, SCr levels and, 694-701
see also Mortality of ESRD patients, USRDS 1999 ADR on
- Mortality of ESRD patients, cause(s) of, USRDS 1999 ADR on, S1:87-94
adjusted first-year death rates by cause, S1:78-79
by age, S1:88-89, S1:91-93
determination of, S1:87-88, S1:153

- executive summary of, S1:14-15
 among PD and HD patients, S1:88-91
 of pediatric patients, S1:112-113
 by race, S1:90-93
 with RTx, S1:91-92
 by sex, S1:89-90, S1:92, S1:93
 withdrawal from dialysis as, S1:92-93
- Mortality of ESRD patients, USRDS 1999 ADR on, S1:74-80
 executive summary of, S1:14
 national death rates, S1:85
 of pediatric patients, S1:112-113
 of RTx, S1:91-92, S1:170-171
 SMRs and, *see* Standard Mortality Ratio
 by year since diagnosis, S1:82-83
see also Adjusted death rates of ESRD patients, USRDS 1999 ADR on; Dialysis Morbidity and Mortality Study, USRDS; Mortality of ESRD patients, cause(s) of, USRDS 1999 ADR on
- Mortality of ESRD patients on HD
 mortality on CAPD, CCPD, and HD, compared, 1065-1074
 parenteral Fe therapy and, S2:44
- MPA (microscopic polyangiitis), RPGN and, 364-373
- MPDs (myeloproliferative disorders), FSGS and mesangial sclerosis associated with, 889-893
- MPGN, *see* Membrano- proliferative glomerulonephritis
- mRNA (messenger ribonucleic acid)
 Glut1, and glucose transport regulation, 189-101
 mesangial cell α -SMA, and IgAN progression, 902-910
 TGF- β , in doxorubicin-induced nephropathy, 333
- mtDNA (mitochondrial deoxyribonucleic acid), deletions in, and decreased oxidative phosphorylation activity in children with FS secondary to chemotherapy, 98-106
- MTHFR* gene, influence of polymorphism of, on plasma Hcy in ESRD patients on HD, 259-263
- Multinucleated podocytes in pediatric FS with NS, 966-971
- Multiple myeloma (MM)
 benign monoclonal gammopathy turning into, 166-169
 nephrotic-range proteinuria in, 135-139
 as primary diagnosis, 138
- Muscle actin, *see* Smooth muscle actin; α -Smooth muscle actin
- Muscle cramps in ESRD patients on HD, L-carnitine effects on, 683
- Muscular phosphate (Pi), effects of Pi replacement for hypophosphatemia in RTx recipients on content of, 875-883
- Mutation(s), 845-862
COL4A5 gene, in X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of, 854-862
 R642C missense, of *TSC* gene in Gitelman's syndrome, 845-853
 role of *PAF-AH* gene, in Japanese pediatric IgAN, 289-295
 T594M, in ENaC β subunit, race and, and low-renin HTN, 579-587
see also Polymorphism
- Mycophenolate mofetil (MMF), 296-303
 for acute c-ANCA-positive vasculitis, 3:E9
 and persistent abdominal pain in RTx recipients, prevalence of active CMV infection in GI tract and, 65-68
- Myelofibrosis, idiopathic, amyloidosis complicating, 6:E27
- Myeloma, *see* Multiple myeloma
- Myeloproliferative disorders (MPDs), FSGS and mesangial sclerosis associated with, 889-893
- Myositis, tropical, CGN and, in RTx recipients, 6:E25
- N (nitrogen), *see* BUN
- Na (sodium)
 plasma, and NO activity on HD, 231
 in recurrent Goodpasture's syndrome, 551
 serum, *see* Serum Na
see also Na channel β subunit; NaCl *TSC* gene; NaHCO₃; Natriuresis
- Na (sodium) channel β (beta) subunit, epithelial, race and T594M mutation in, low-renin HTN and, 579-587
- NaCl (sodium chloride) *TSC* gene, R642C missense mutation of, in Gitelman's syndrome, 845-853
- NAD-NCCR (nicotinamide adenine dinucleotide-reduced cytochrome-c reductase) in pediatric FS secondary to chemotherapy, 101
- NaHCO₃ (sodium bicarbonate)
 effects of, on renal injury, renal TGF- β production, urinary TGF- β excretion in doxorubicin-induced nephropathy, 328-337
 in recurrent Goodpasture's syndrome, 551
 and SAHS in RTx recipients, 741
 serum, *see* Serum NaHCO₃
- National death rates of ESRD patients, S1:85
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), USRDS, S1:4
- Native Americans, *see* Race
- Natriuresis
 urinary excretion of PAMP and AM in chronic GN and, 114-119
see also Natriuretic factor; Natriuretic peptide
- Natriuretic factor, atrial, levels of, and etiology of IE, 413-414
- Natriuretic peptide, atrial, proadrenomedullin N-terminal 20 as, plasma and urinary AM and, in chronic GN, 114-119
- NB (neuroblastoma), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Necrosis, *see* Acute tubular necrosis
- Neonatal acute renal failure (ARF) due to transplacental transfer of nephrotoxic paraprotein, exchange transfusion for, 1129-1131
- Neopterin (NP), serum and urinary, cell-mediated immune dysfunction in NS and, 611-617
- Nephritis, *see* specific types of nephritis
- Nephroangiosclerosis, and MA in hypertension, 983-984
- Nephrocalcinosis, as primary diagnosis, 434
- Nephrolithiasis and urolithiasis, as primary diagnosis, 138, 434, 1058, 1107
- Nephropathic cystinosis, infantile, FS and, 966-971
- Nephropathy, *see* Renal disease
- Nephrosclerosis, as primary diagnosis, 434, 494, 1058
- Nephrotic-range proteinuria, UPEP and SPEP in evaluation of, 135-139
- Nephrotic syndrome (NS)
 bedside renal biopsy for, 956
 chronic GN and, 114-119
 fibrils versus microtubules in, 1146-1151
 FSGS and, *see* Nephrotic syndrome, FSGS and

- in IDDM, remission of, with captopril, 308-314
- LN and, 530-539
- pediatric, *see* Pediatric nephrotic syndrome
- as primary diagnosis, 659
- serum and urinary NP in cell-mediated immune dysfunction in, 611-617
- in types I and III MPGN, 1022-1032
- Nephrotic syndrome (NS), FSGS and
- FSGS as histopathologic subtype, 618-625
- in patient with SLE and MGN in remission, 5:E22
- Nephrotoxic paraprotein, neonatal ARF due to transplacental transfer of, exchange transfusion for, 1129-1131
- Nephrotoxicity of CsA or tacrolimus, levels of urinary SMA in RTx recipients correlated with, 69-84
- Networks, ESRD
- census of ESRD network facilities, S1:157
- patient survival by RRT modality and, S1:55
- and their states, S1:6
- Neuroblastoma (NB), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Neuropathy, anterior ischemic optic, and acute vision loss in pediatric ARPKD, 1125-1128
- Neutrophils (polymorphonuclear leukocytes; PMNs) in ARF, 387-395
- renal injury and, *see* Renal injury in ARF, neutrophil-induced
- role of integrins in activation of neutrophils, 393-395
- Neutrophils (polymorphonuclear leukocytes; PMNs) in ESRD patients on HD
- effects of parenteral Fe therapy on phagocytic properties of, S2:27-28, S2:30-34
- ESRD effects on neutrophil functions, 395-396
- see also* entries beginning with term: Anti-neutrophil
- New end-stage renal disease patients, *see* Initiation of dialysis for new ESRD patients; New end-stage renal disease patients, USRDS 1999 ADR on
- New end-stage renal disease (ESRD) patients, USRDS 1999 ADR on, S1:65-72
- comorbid conditions in, S1:66-70
- employment status of, S1:71-72
- initiation of dialysis for, *see* Initiation of dialysis for new ESRD patients, USRDS 1999 ADR on
- predialysis rHuEPO utilization among, S1:71
- primary disease in, S1:65
- see also* Patient characteristics at start of ESRD, USRDS 1999 ADR on
- NHL (non-Hodgkin's lymphoma), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Nicotinamide adenine dinucleotide (NAD)-reduced cytochrome-c reductase (NCCR) in pediatric FS secondary to chemotherapy, 101
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), USRDS, S1:4
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nitric oxide (NO)
- on HD, indices of activity of, 228-234
- in normal pregnancy, 1142-1145
- Nitric oxide synthase (NOS) inhibitors, endogenous, and NO activity on HD, 228-234
- Nitrogen, *see* BUN
- NO, *see* Nitric oxide
- Nodular glomerulosclerosis (GS), idiopathic, 560-564
- Noncardiovascular conditions in new ESRD patients, USRDS 1999 ADR on, S1:67-69
- Noncompliance
- by abusive and/or disruptive patients, 778, 780-783
- and outcome of RTx, racial disparities in, 709
- Noncompliance by abusive ESRD patients, 778-783
- addressing, 782-783
- regimen complexity and, 780-781
- and treatment termination, 778-779
- Nonhemodynamic paradigm of pathogenesis of MA in HTN, 978
- Non-Hodgkin's lymphoma (NHL), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Non-insulin-dependent diabetes mellitus (NIDDM)
- in siblings, *ACE* and *AGN* genes in, MA and, 1002-1009
- see also* Diabetic end-stage renal disease, NIDDM
- Nonoxidative mechanisms in neutrophil-induced renal injury of ARF, 387-389
- Nonsense mutations of *COL4A5* gene in X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of, 857
- Normal pregnancy, relaxin as renal vasodilatory agent in, 1142-1145
- Normalized protein catabolic rate in ESRD patients on CAPD
- Cr generation and, 237
- nutritional status and, 1060
- Normalized protein catabolic rate in ESRD patients on HD
- acidosis, nutritional status and, 495, 496
- Radix angelicae sinensis* effects on, 350
- NOS (nitric oxide synthase) inhibitors, endogenous, and NO activity on HD, 228-234
- NP (neopterin), serum and urinary, cell-mediated immune dysfunction in NS and, 611-617
- NS, *see* Nephrotic syndrome
- Number of ESRD care facilities, USRDS 1999 ADR on, S1:140, S1:142-143
- Nutritional status of ESRD patients
- on CAPD, independent effects of RRF and adequacy of CAPD on, 1056-1064
- on HD and, *see* Nutritional status of ESRD patients on HD
- VLPD and outcome of body composition and, DEXA assessment of, 500-507
- Nutritional status of ESRD patients on HD
- acidosis and, 493-499
- on prolonged slow HD, 601-602
- O₂ (oxygen) saturation, and SAHS in RTx recipients, 741
- Obstruction, reversibility of bilateral hydronephrosis without, HBV infection-associated PAN and, 3:E11
- Obstructive uropathy, GS, and tubulointerstitial fibrosis in PEPCK-TGF- β 1 transgenic subjects, 177-183
- 1,25(OH)₂D₃ (1,25-dihydroxyvitamin D₃; calcitriol), effects of age and, on recovery from hypocalcemia in ESRD patients on HD, 456-463
- OKT3 for acute allograft rejection, 304-307
- Oncotic pressure in IE, 408

- Online features of *AJKD*
 full-text articles, manuscript tracking, and automated literature search in, 1137-1138
see also specific online features
- Optic neuropathy, anterior ischemic, and acute vision loss in pediatric ARPKD, 1125-1128
- Oral CsA, bioavailability of SGC formulation versus, 869-874
- Organizational structure of USRDS, S1:21
- Orthostatic cerebral blood flow velocity, HD for diabetes mellitus and reduction of, 1096-1104
- Orthostatic edema, *see* Idiopathic edema
- Osteodystrophy, renal, *see* Renal osteodystrophy in ESRD patients on HD
- OTZ (L-2-oxothiazolidine-4-carboxylic acid), effects of, on peritoneal mesothelial cells, 663-668
- Outcome
 of ATN in diabetes mellitus, 1010-1015
 of bacteremia associated with tunneled, cuffed, permanent HD catheters, 1116-1119
 of bedside renal biopsy with ultrasound guidance, 955-959
 course and, of TINU syndrome, 1016-1021
 of ESRD, *see* Outcome of ESRD
 long-term LN, 315-323
 of PTDM, 2-3
 of RTx, *see* Outcome of RTx
 severe ARF, with HD or CVVH, 426, 427
see also Long-term follow-up and outcome; Mortality; Prognosis and specific conditions
- Outcome of ESRD
 body composition and nutritional status outcome with VLPD, 500-507
 on HD, *see* Hemodialysis for ESRD, outcome of
see also Mortality with ESRD; Patient survival with ESRD
- Outcome of RTx
 racial disparities in, 706-712, 756-758
see also Grafts, renal, survival of; Patient survival with RTx; Rejection
- Outside-inside signaling by integrins, and neutrophils in ARF, 394-395
- Ovarian cysts in ADPKD, 120-124
- Overall incidence and prevalence of treated ESRD, USRDS 1999 ADR on, S1:41-44
- Oxalate, ratios of urinary excretion urate and, to Cr, in healthy pediatric population, 2:E3
- Oxidative mechanisms of neutrophil-induced injury, 385-387
- Oxidative phosphorylation
 and glucose transport regulation by hypoxia, 189-202
 mtDNA deletions and decreased activity in, in children with FS secondary to chemotherapy, 98-106
- Oxidative stress, HD and, 438-455
 HD effects on, 445-455
 MDA as marker of, 438-444
 parenteral Fe and, S2:18-19, S2:21-22
 L-2-Oxothiazolidine-4-carboxylic acid (OTZ), effects of, on peritoneal mesothelial cells, 663-668
- Oxygen (O₂) saturation, and SAHS in RTx recipients, 741
- P (phosphorus)
 in ADPKD HD patients, 266
 diffusive and convective clearances of, during CRRT for ARF, 488, 491
 serum, *see* Serum P
see also P in ESRD patients on HD
- P (phosphorus) in ESRD patients on HD
 L-carnitine effects on, 683
 and CVD, 440
 serum, *see* Serum P in ESRD patients on HD
- PaCO₂ in DM patients on HD, and orthostatic hypotension and, 1100
- PAF-AH gene mutation, role of, in Japanese pediatric IgAN, 289-295
- PAI-1 gene, scarring in VUR and, 140-145
- Paid claims, *see* Payment(s)
- Pain
 in pediatric ADPKD, cyst decompression for, 639-645, 4:E17
 persistent abdominal, and prevalence of active of CMV infection in GI tract of RTx recipients, 65-68
- PAMP (proadrenomedullin N-terminal 20 peptide), plasma and urinary AM and, in chronic GN, 114-119
- Panarteritis, *see* Polyarteritis nodosa
- Paradoxical embolism
 inverse, in chronic HD patient with aortic bacterial endocarditis due *S. haemolyticus* catheter infection, 338-340, 362-363
 across patent foramen ovale, *see* Patent foramen ovale, paradoxical embolism across
- Paraprotein, nephrotoxic, neonatal ARF due to transplacental transfer of, exchange transfusion for, 1129-1131
- Parathyroid hormone (PTH)
 effects of Pi replacement for hypophosphatemia in RTx recipients on, 875-883
see also Hyperparathyroidism; Hypoparathyroidism; Intact parathyroid hormone; Parathyroid hormone in ESRD patients on HD
- Parathyroid hormone (PTH) in ESRD patients on HD
 with ADPKD, 266, 267
 age and calcitriol effects on recovery from hypocalcemia and, 456-463
 and CVD, 440, 441
 relationship between serum Mg levels and, 43-48
 and rHuEPO therapy, parenteral Fe therapy effects on, 24
- Parenteral iron (Fe) therapy in ESRD patients on HD, S2:5-52
 benefits of, S2:40-46
 as CPM, national perspective on, S2:5-11
 and CVD, S2:18-24
 infections and, S2:25-34, S2:44, S2:47-52
 rHuEPO and, *see* Parenteral iron therapy in ESRD patients on HD, rHuEPO therapy and
 serum ferritin and, *see* Parenteral iron therapy in ESRD patients on HD, serum ferritin and
 systemic inflammatory response and, S2:35-39
- Parenteral iron (Fe) therapy in ESRD patients on HD, rHuEPO therapy and, 21-28, 173-176
 and benefits of parenteral Fe, S2:40-46
 rHuEPO role in infections due to Fe therapy, S2:30-34
- Parenteral iron (Fe) therapy in ESRD patients on HD, serum ferritin and

- effects of, on serum ferritin, S2:7, S2:42, S2:43
 serum ferritin as marker of Fe status, 508-513, S2:12-17
 Partial Fanconi's syndrome (FS), pediatric, renal biopsy of, 184-188
 Parvovirus B19 infection, PRCA in RTx recipients on tacrolimus due to, 1132-1136
 Patent foramen ovale (PFO), paradoxical embolism across bilateral renal infarction secondary to, 752-755
 after mechanical thrombolysis of clotted HD access grafts, 341-343, 362-363
 Pathobiologic character of Fe role in infections, S2:25-29, S2:47-48
 Pathogenesis of MA in hypertension, 976-979
 Pathology
 LN, 315-323
see also Pathology, renal and specific conditions
 Pathology, renal
 atlas of, 1:E1, 2:E1, 3:E7, 4:E14, 5:E18, 6:E23
 in TINU syndrome, 1018
see also Renal disease
 Patient(s), role of, in preventing NIDDM ESRD, 805
 Patient characteristics, ESRD patients, USRDS 1999 ADR on demographic, S1:64-65; *see also* Age of ESRD patients, USRDS 1999 ADR on; Race of ESRD patients, USRDS 1999 ADR on; Sex of ESRD patients, USRDS 1999 ADR on
 incidence and prevalence of ESRD and, S1:44-50
 RRT modality utilization by, S1:56-58
see also Patient characteristics at start of ESRD, USRDS 1999 ADR on
 Patient characteristics at start of ESRD, USRDS 1999 ADR on, S1:63-65
 executive summary of, S1:13-14
 and new Medical Evidence Report Form, S1:63-64
 RRT modality distribution and, S1:64-65
see also New end-stage renal disease patients, USRDS 1999 ADR on
 Patient rehabilitation, ESRD patient on prolonged slow HD, 603-604
 Patient selection for prolonged slow HD, 605
 Patient Standard Analysis File (SAF), S1:28
 Patient survival with ESRD
 due to NIDDM, 803-804
 on prolonged slow HD, 603
 on RRT, serum HA and, 1083-1088
see also Patient survival with ESRD on PD/CAPD; Patient survival with ESRD, USRDS 1999 ADR on; Patient survival with RTx
 Patient survival with ESRD, USRDS 1999 ADR on, S1:10
 by age, S1:172-173
 analytical method applied to, S1:152, S1:171-173
 with CAPD and CCPD, S1:55
 executive summary of, S1:14
 and expected remaining years of life, S1:84-85, S1:173
 on HD, S1:55
 international, S1:149-150
 long-term, from first ESRD treatment, S1:80-81
 of pediatric patients, S1:110-111
 by race, S1:172-173
 with RTx, S1:55, S1:95, S1:98-100, S1:110-111
 by sex, S1:98-99, S1:172-173
 Patient survival with ESRD on PD/CAPD
 nutritional status and, 1060
 race and, 713-720
 Patient survival with RTx
 MMF and, 296-303
 USRDS 1999 ADR on, S1:55, S1:95, S1:98-100, S1:110-111
 Payment(s)
 records of paid HCFA claims, S1:156
see also Payment(s), Medicare
 Payment(s), Medicare
 claims and, S1:33, S1:174
 classification, S1:126-127
see also Medicare expenditures for ESRD, USRDS 1999 ADR on
 Payment Data Standard Analysis File (SAF), S1:33-34
 PCO₂, and SAHS in RTx recipients, 741
 PCR (polymerase chain reaction) *see* Reverse transcriptase-polymerase chain reaction
 PCT (porphyria cutanea tarda), distinguishing pseudoporphyria from, in ESRD patients on HD, 155-160
 PD, *see* Peritoneal dialysis for ESRD
 PDF (postdialysis fatigue), 464-470
 PDGF (platelet-derived growth factor) in POEMS syndrome, 633-638
 Pediatric autosomal polycystic kidney disease (ADPKD), renal asymmetry in, 639-645, 4:E17
 Pediatric end-stage renal disease (ESRD), HD and/or CCPD for
 evaluation and prediction of urea rebound and eqKt/V in, 49-54
 with IP rHuEPO therapy, 651-656
 USRDS 1999 ADR on, S1:108
 Pediatric end-stage renal disease (ESRD), RRT of, USRDS 1999 ADR on, S1:108-111
 with HD and PD, S1:108
 patient survival and, S1:110-111
see also Renal transplantation for pediatric ESRD, USRDS 1999 ADR on
 Pediatric end-stage renal disease (ESRD), USRDS 1999 ADR on, S1:102-113
 causes of, S1:104-107
 executive summary of, S1:16
 Growth and Development Study on, S1:31-32
 hospitalization for, S1:112
 incidence and prevalence of reported, S1:102-103, S1:107-108
 mortality with, S1:112-113
 RRT of, *see* Pediatric end-stage renal disease, RRT of, USRDS 1999 ADR on
 Pediatric Fanconi's syndrome (FS)
 INC with NS, multinucleated podocytes in, 966-971
 partial, renal biopsy of, 184-188
 secondary to chemotherapy, mtDNA deletions and decreased oxidative phosphorylation in, 98-106
 Pediatric Growth and Development Study, USRDS, S1:31-32
 Pediatric IgA nephropathy (IgAN), Japanese patients with, role of *PAF-AH* gene mutation in, 289-295
 Pediatric nephrotic syndrome (NS)
 changing histopathology of, 646-650

- with Fanconi's syndrome, multi-nucleated podocytes in, 966-971
- Pediatric population
 - acute vision loss with ARPKD in, 1125-1128
 - healthy, ratios of urinary excretion of urate and oxalate to Cr in, 2:E3
 - neonatal ARF due to transplacental transfer of nephrotoxic paraprotein, exchange transfusion for, 1129-1131
 - prediction and treatment of recurrent FSGS in, after RTx, 1048-1055
 - see also* entries beginning with term: Pediatric
- Pediatric renal transplantation (RT; RTx)
 - prediction and treatment of recurrent FSGS after, 1048-1055
 - see also* Renal transplantation for pediatric ESRD, USRDS 1999 ADR on
- PEPCK-TGF- β 1 (phosphoenolpyruvate carboxykinase-transforming growth factor- β -1) transgenic subjects, GS, tubulointerstitial fibrosis, and obstructive uropathy in, 177-183
- Peptide(s), atrial natriuretic, proadrenomedullin N-terminal 20 as, plasma and urinary AM and, in chronic GN, 114-119
- Percutaneous renal biopsy with ultrasound-guided automated spring-loaded gun device, effects of, on bleeding, and implications for early hospital discharge, 92-97
- Percutaneous thrombolysis of clotted HD, pulmonary thrombi after ventilation-perfusion scintigraphy of, 207-211
- Perforation, colonic, diverticular disease with ADPKD and, 863-868
- Perfusion-ventilation scintigraphy of pulmonary clots after percutaneous thrombolysis of clotted HD access grafts, 207-211
- Periodic edema, *see* Idiopathic edema
- Periodic limb movements in sleep (PLMS), effects of rHuEPO for ESRD patients on HD, 1089-1095
- Peripheral blood mononuclear cells, immunophenotype of, in TINU syndrome, 1018, 1020
- Peritoneal dialysis (PD) for ESRD, 688-701
 - automated, *see* Automated peritoneal dialysis for ESRD
 - effects of aminoglycosides on RRF of patients on, 14-20
 - initiation of, for new patients, significance of SCr values in, 694-701
 - leptin and, *see* Leptin in ESRD patients on PD/CAPD
 - patient survival on, race and, 713-720
- PET on, effects of preceding exchange on results of, 247-253
- plasma Al in relation to ABD in asymptomatic patients on, 688-693
- see also* Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Duration of PD/CAPD; Peritoneal dialysis for ESRD, USRDS 1999 ADR on; Recombinant human erythropoietin for anemic ESRD patients on PD/CAPD
- Peritoneal dialysis (PD) for ESRD, USRDS 1999 ADR on
 - causes of mortality on, S1:88-91
 - described, S1:52-53
 - history of, S1:51
 - international utilization of, S1:146-148
 - patient characteristics and utilization of, S1:56-58
 - patient survival on, S1:55
 - for pediatric ESRD, S1:108
 - at start of ESRD, S1:64
 - trends in utilization of, S1:53-56
 - see also* Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1999 ADR on; Continuous cycling peritoneal dialysis for ESRD, USRDS 1999 ADR on
- Peritoneal equilibration test (PET), effects of preceding exchange on results of, 247-253
- Peritoneal mesothelial cells, OTZ effects on, 663-668
- Peritoneum, *see* Peritonitis on CAPD and entries beginning with terms: Intraperitoneal, Peritoneal
- Peritonitis on CAPD
 - CAPD and Peritonitis Rates Study, USRDS, S1:31
 - effects of aminoglycosides for, on RRF, 14-20
- Permanent hemodialysis (HD) catheters, tunneled, cuffed, bacteremia associated with, 1114-1124
- Permeability, abnormal capillary, IE etiology and, 417-418
- Permeability factors in recurrent FSGS in children after RTx, 1048-1055
- Persistent abdominal pain, and prevalence of active CMV infection in GI tract of RTx recipients, 65-68
- PET (peritoneal equilibration test), effects of preceding exchange on results of, 247-253
- PFO, *see* Patent foramen ovale, paradoxical embolism across
- PGC (polyethylene glycol-grafted cellulose) membranes, thrombogenicity of, and heparin requirements of ESRD patients on HD, 36-42
- pH
 - in DM patients on HD, and orthostatic hypotension and, 1100
 - in hypokalemia, 109
 - in RTx recipients, SAHS and, 741
- Phagocytic properties of leukocytes in ESRD patients on HD
 - L-carnitine effects on viability and, 678-687
 - of PMNLs, effects of parenteral Fe on, S2:27-28, S2:30-34
- Pharmacokinetics
 - of gentamicin in ESRD patients hemodialyzed with high-flux polysulfone membranes, 222-227
 - see also* Pharmacokinetics of IP rHuEPO
- Pharmacokinetics of IP rHuEPO, 651-662
 - in CAPD patients, "dry well" dosing technique for, 657-662
 - in pediatric patients on CCPD, 651-656
- Phosphate, *see* Pi
- Phosphoenolpyruvate carboxykinase-transforming growth factor- β 1 (PEPCK-TGF- β 1) transgenic subjects, GS, tubulointerstitial fibrosis, and obstructive uropathy in, 177-183
- Phospholipase products in neutrophil-induced renal injury in ARF, 389-390
- Phosphorus, *see* P
- Phosphorylation, *see* Oxidative phosphorylation
- Physical strength of ESRD patients on HD, L-carnitine effects on, 683
- Physician(s)
 - role of, in preventing NIDDM ESRD, 804-805
 - see also* Physician specialty; Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD
- Physician specialty, Medicare expenditures by, S1:135-138

- Physician's duties to abusive, aggressive, or disruptive ESRD patients on HD, 759-761, 775-789
 approaches to, 776-786
 case presentation, 775-776
 discussion on, 786-788
- Pi (phosphate)
 in ESRD patients on HD or PD, asymptomatic Al-related renal osteodystrophy and, 690
 ferrihydrite versus calcium acetate as binders of, 324-327
 in nephrotic-range proteinuria, 136, 137
 reabsorption of, in pediatric FS secondary to chemotherapy, 100
see also Pi in RTx recipients
- Pi (phosphate) in RTx recipients
 effects of Pi replacement therapy for hypophosphatemia in, on muscular Pi content, mineral metabolism, and acid/base homeostasis, 875-883
 and SAHS, 741
- PKD, *see* Polycystic kidney disease
- Plasma, PET measurement of D/P ratios, 247-253
- Plasma adrenomedullin (AM), PAMP and, in chronic GN, 114-119
- Plasma albumin
 in doxorubicin-induced nephropathy, NaHCO₃ effects on, 331, 334
 of NIDDM patients on CAPD for ESRD, 516, 517
- Plasma aldosterone
 in chronic GN, 115-117
 in Gitelman's syndrome, 846
 in low-renin HTN, 581
- Plasma aluminum (Al) in relation to ABD in asymptomatic ESRD patients on HD, 688-693
- Plasma arginine (Arg), and NO activity on HD, 231
- Plasma atrial natriuretic peptides (ANPs) in chronic GN, 115-117
- Plasma cell dyscrasia, nephrotic-range proteinuria in, 135-139
- Plasma cGMP (cyclic guanosine monophosphate), and NO activity on HD, 231
- Plasma cholesterol
 fasting, in NIDDM patients on CAPD for ESRD, 516, 517
 in FSGS, 620
- Plasma citrulline, and NO activity on HD, 231
- Plasma C-peptide, fasting, in NIDDM patients on CAPD for ESRD, 516, 517
- Plasma creatinine (Cr)
 in doxorubicin-induced nephropathy, NaHCO₃ effects on, 331
 in FSGS, 620
 in LN, 534
 of NIDDM patients on CAPD for ESRD, 516, 517
 and NO activity on HD, 231
- Plasma glucose
 fasting, in NIDDM, *ACE* and *AGN* genes and, 1004
see also Plasma glucose in ESRD patients on CAPD
- Plasma glucose in ESRD patients on CAPD
 leptin and, 833
 in NIDDM ESRD patients, 516, 517
- Plasma homocysteine (Hcy) in ESRD patients on HD, influence of *MTHFR* gene polymorphism on, 259-263
- Plasma insulin in ESRD patients on CAPD
 leptin and, 833, 834
 in NIDDM ESRD patients, 516, 517
- Plasma K (potassium), and NO activity on HD, 231
- Plasma lipid-soluble antioxidants in ESRD patients on HD, enalapril and, 448-449
- Plasma Na (sodium), and NO activity on HD, 231
- Plasma nitric oxide (NO) oxidation products, and NO activity on HD, 231
- Plasma renin activity (PRA)
 in chronic GN, 115-117
 and de novo FSGS in renal grafts, 733
 in Gitelman's syndrome, 846
 in low-renin HTN, 581
- Plasma thiobarbituric acid reactive substance (TBARS) in ESRD patients on HD, enalapril and, 449-450
- Plasma triglycerides, fasting, in NIDDM patients on CAPD for ESRD, 516, 517
- Plasminogen activator, tissue, in ESRD patients on HD, CVD and, 440, 441
- Platelet(s)
 in MPDs, 890
 in nephrotic-range proteinuria, 136, 137
- Platelet count
 and bleeding due to percutaneous renal biopsy, 93
 in ESRD patients resistant to rHuEPO, *Radix angelicae sinensis* effects on, 350
 in proliferative GN, DSG effects and, 897
 in severe ARF, 427-430
- Platelet-derived growth factor (PDGF) in POEMS syndrome, 633-638
- Platinum compounds, pediatric FS secondary to, mtDNA deletions and decreased oxidative phosphorylation in, 98-106
- Pleurodesis, thoracoscopic surgery and, for PPC in ESRD patients on CAPD, 170-172
- Pleuroperitoneal communication (PPC), thoracoscopic surgery and pleurodesis for, in ESRD patients on CAPD, 170-172
- PLMS (periodic limb movements in sleep), effects of rHuEPO for ESRD patients on HD, 1089-1095
- PMNLs (polymorphonuclear leukocytes), *seentries* beginning with term: Neutrophils
- PO₂, and SAHS in RTx recipients, 741
- Podocytes, multinucleated, in pediatric FS with NS, 966-971
- POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, GFs and cytokines in renal involvement of, 633-638
- Policy on USRDS data release for investigator-initiated research, S1:35-36
- Polyangiitis, microscopic, RPGN and, 364-373
- Polyarteritis (panarteritis) nodosa
 HBV infection-associated, reversibility of bilateral hydro-nephrosis without obstruction in, 3:E11
 RPGN and, 364-373
- Polycystic kidney disease (PKD)
 as primary diagnosis, 16, 127, 138, 434, 435, 494, 1058, 1107
see also Acquired cystic kidney disease; Autosomal dominant polycystic kidney disease; Autosomal recessive polycystic kidney disease

- Polyethylene glycol-grafted cellulose (PGC) membranes, thrombogenicity of, and heparin requirements of ESRD patients on HD, 36-42
- Polymerase chain reaction, *see* Reverse transcriptase-polymerase chain reaction
- Polymorphism
ACE gene, *see* Polymorphism of *ACE* gene
 I/D, of *AT1*, *ATG*, and *PAI-1* genes, and scarring in VUR, 140-145
 of *MTHFR* gene, influence of, on plasma Hcy in ESRD patients on HD,
TCR C α gene, IgAN progression in Japanese subjects and, 279-288
- Polymorphism of *ACE* gene
 I/D, and scarring in VUR, 140-145
 and progression of renal failure in ADPKD, 273-278
- Polymorphonuclear leukocytes, *see* entries beginning with term: Neutrophils
- Polyneuropathy, organomegaly, endocrinopathy, and skin changes (POEMS) syndrome, GFs and cytokines in renal involvement of, 633-638
- Polysulfone membranes, HD for ESRD with high-flux biocompatible, pharmacokinetics of gentamicin with, 222-227
- Population in USRDS 1999 ADR
 census, as basis for computing ESRD incidence and prevalence, S1:163
 standard, for adjustment, 1:153
- Porphyria cutanea tarda (PCT), distinguishing pseudoporphyria from, in ESRD patients on HD, 155-160
- Porphyrins in BD, 155-160
- Postdialysis fatigue (PDF), 464-470
- Postmenopausal women, IE in, 407
- Posttransplant diabetes mellitus (PTDM), 1-13
 defined, 1-2
 and effects of immunosuppressive agents on glycemic tolerance, *see* Immunosuppressive agents, effects of, on glycemic tolerance
 future issues, 9-10
 incidence of, 2, 8
 outcome of, 2-3
 risk factors for, 2, 8-9
- Posttransplantation lymphoproliferative disorder (PTLD), rapidly developing T cell, 1:E3
- Postural abnormalities in etiology of IE, 410-411, 413
- Potassium, *see* K
- PPC (pleuroperitoneal communication), thoracoscopic surgery and pleurodesis for, in ESRD patients on CAPD, 170-172
- PRA, *see* Plasma renin activity
- PRCA (pure red cell aplasia), parvovirus B19 infection causing, in RTx recipients on tacrolimus, 1132-1136
- Prealbumin in ESRD
 treated conservatively, with HD, or PD, hyperleptinemia and, 826, 827
 VLPD and, 501
- Predialysis employment status of new ESRD patients, USRDS 1999 ADR on, S1:71-72
- Predialysis left ventricular hypertrophy (LVH), Hb decline and, 125-134
- Predialysis recombinant human erythropoietin (rHuEPO) utilization among new ESRD patients, USRDS 1999 ADR on, S1:71
- Prednisolone, effects of azathioprine and, on progression of IMN, 521-529
- Prednisone, alternate-day, differences between types I and III MPGN in response to, 1022-1032
- Pregnancy, normal, relaxin as renal vasodilatory agent in, 1142-1145
- Premenopausal women, IE in, 407
- Prevalence
 of MA in hypertension, 974-976
see also Incidence and prevalence
- Prevention of NIDDM ESRD, 804-805
- Primary disease, *see* Primary disease in ESRD, USRDS 1999 ADR on *and specific conditions*
- Primary disease in ESRD, USRDS 1999 ADR on
 incidence and prevalence of treated ESRD by, S1:11, S1:42, S1:43, S1:47, S1:48
 in new ESRD patients, S1:65
 in pediatric patients, S1:104-107
- Proadrenomedullin N-terminal 20 peptide (PAMP), plasma and urinary AM and, in chronic GN, 114-119
- Products, USRDS, S1:11-12, S1:20
 database and, *see* Database, USRDS
 on Internet World Wide Web, S1:24-25
 for researchers, S1:24
see also United States Renal Data System, 1998 ADR of; United States Renal Data System, 1999 ADR of *and specific USRDS products*
- Prognosis
 analysis of judgment on, 573
 FSGS, *see* Focal segmental glomerulosclerosis, prognosis of
 LN, repeated renal biopsies and, 530-539
see also Outcome
- Progression
 of IDDM with HTN, ACE inhibition effects on, 809-817
see also Progression of renal disease; Progression of renal failure
- Progression of renal disease
 ACE inhibition effects on, 626-632
 of FSGS, regression versus, 5:liv
 of IMN, effects of prednisolone and azathioprine on, 521-529
 lipids and, 2:xliii-xlvi
 mesangial cell α -SMA expression and progression of IgAN, 902-910
 reciprocal graph to plot reciprocal serum Cr over time and understanding of, 576-578
- Progression to renal failure
 in IgAN, *TCR C α* gene polymorphism and, 279-288
see also Progression to renal failure with ESRD
- Progression to renal failure with ESRD
 and ADPKD in HD patients, *ACE* gene polymorphism and, 273-278
 reciprocal serum Cr and, 576-578
- Proinflammatory cytokines, *see* Cytokines
- Proliferative glomerulonephritis (GN)
 DSG effects on, 894-901
 as primary diagnosis, 1107

- see also* Membranoproliferative glomerulonephritis; Mesangial proliferative glomerulonephritis and specific forms of proliferative glomerulonephritis; *for example*: IgA nephropathy
- Prolonged immunosuppression, and improved prognosis of FSGS, 618-625
- Prolonged slow hemodialysis (HD) for ESRD, 597-610
adequacy of, 599-601
blood pressure and CV morbidity on, 602-603
cost effectiveness of, 604
nutritional status on, 601-602
and patient rehabilitation, 603-604
patient selection for, 605
patient survival and, 603
principle of, 598-599
risks of, 604-605
techniques of, 598
treatment duration, middle molecules, cellulose and high-flux biocompatible membranes and, 601
- Protein
dietary, *see* Dietary protein
electrophoresis of urine and serum, in evaluation of nephrotic-range proteinuria, 135-139
retinol binding, in ESRD patients, VLPD and, 501
total, *see* Total protein
see also Normalized protein catabolic rate in ESRD patients on HD; Normalized protein catabolic rate in ESRD patients on PD/CAPD; Proteinuria
- Proteinuria
ACE inhibition and, *see* Proteinuria, ACE inhibition and bedside renal biopsy for, 956
in ESRD, *see* Proteinuria in ESRD
in FSGS, *see* Proteinuria in FSGS
in IgAN, 906
in IMN, effects of prednisolone and azathioprine on, 521-529
in LN, 317, 534, 536
in MPDs, 890
nephrotic-range, UPEP and SPEP in evaluation of, 135-139
in POEMS syndrome, 634
in proliferative GN, DSG effects on, 895
in recurrent Goodpasture's syndrome, 551
renal insufficiency and, *see* Proteinuria, and renal insufficiency in stage II and III IMN, steroids and/or chlorambucil effects on, 914
in types I and III MPGN, 1024, 1025
see also Microalbuminuria; Proteinuria; Proteinuria in IgAN
- Proteinuria, ACE inhibition and
ACE inhibition effects on progression of renal disease and proteinuria, 626-632
with captopril, NS remission in IDDM and, 310; *see also* Proteinuria in IDDM with HTN, captopril and
- Proteinuria, and renal insufficiency
after gastric lymphoma due to, MPGN, 588-593
with HTN, 768-774
- Proteinuria in ESRD
hyperleptinemia and, 826, 827
in NIDDM ESRD, 802
- Proteinuria in FSGS
de novo FSGS in renal grafts, 735
prolonged immunosuppression and, 620, 622
- Proteinuria in IDDM with HTN, captopril and
captopril effects on IDDM course and, 811, 813, 814
and long-term renoprotective effects of captopril, 820
- Proteinuria in IgAN
in pediatric IgAN, 289-295
with TCR α gene polymorphism, 282
- Prothrombin time (PT), and bleeding due to percutaneous renal biopsy, 93
- Pruritus in ESRD patients on HD, L-carnitine effects on, 683
- Pseudoporphyria, distinguishing PCT from, in ESRD patients on HD, 155-160
- PT (prothrombin time), and bleeding due to percutaneous renal biopsy, 93
- PTDM, *see* Posttransplant diabetes mellitus
- PTH, *see* Parathyroid hormone
- PTLD (posttransplantation lymphoproliferative disorder), rapidly developing T-cell, 1:E3
- Public education in prevention of NIDDM ESRD, 805
- Pulmonary clots after percutaneous thrombolysis of clotted HD access grafts, ventilation-perfusion scintigraphy of, 207-211
- Pulmonary hemorrhage, and recurrent Goodpasture's syndrome due to monoclonal IgA- κ circulating antibody, 549-555, 565-568
- Pulmonary-renal syndrome with anti-glomerular basement membrane nephritis and ANCA-associated pauci-immune GN, 344-348
- Pulse methylprednisolone for acute allograft rejection, time course of response to, 304-307
- Pure red cell aplasia (PRCA), parvovirus B19 infection causing, in RTx recipients on tacrolimus, 1132-1136
- Pyelonephritis, as primary disease, 434, 435
- Quality improvement of ESRD care, ESRD Core Indicators Project report on, 1075-1082
- Quality of life
of ESRD patients on HD, effects of rHuEPO on HD, 1089-1095
with NIDDM ESRD, 803-804
RTx and, 61-64
- R642C missense mutation of TSC gene in Gitelman's syndrome, 845-853
- Race (and ethnicity)
and diabetes mellitus with ATN, 1012
of early renal disease patients, LVH and, 127, 129, 131
of ESRD patients, *see* Race of ESRD patients, USRDS 1999 ADR on; Race of ESRD patients on HD; Race of ESRD patients on PD/CAPD; Race of RTx recipients
and familial aggregation of ESRD in HIVAN, 254-258
of IDDM patients with HTN, ACE inhibition effects on IDDM course and, 811
of nephrotic-range proteinuria patients, 136, 137
and renal osteodystrophy in Iberoamerica, 4:lviii-lx
Southern Chinese patients with LN, 315-323
and T594M mutation in ENaC β subunit, low-renin HTN and, 579-587
see also IgA nephropathy in Japanese patients
- Race (and ethnicity) of ESRD patients, USRDS 1999 ADR on

- adjusted first-year death rates by, S1:78
and cause of mortality, S1:90-93
expected remaining years of life by, S1:84-85
incidence and prevalence of treated ESRD by, S1:11,
S1:42-49
Medicare expenditures by, S1:132-135
of new ESRD patients, S1:64-65
patient survival by, S1:172-173
of pediatric patients, S1:102-107, S1:111-112
race codes used, S1:163-165
RRT modality use by, S1:57
Race (and ethnicity) of ESRD patients on HD
and association between acidosis and nutritional status,
494
ESRD Core Indicators Project analysis of HD outcome by,
721-730,
of new patients, SCr levels and, 696-698
rHuEPO and, 1091
SAEG and, 1107
serial VABF and, 472
Race (and ethnicity) of ESRD patients on PD/CAPD
effects of aminoglycosides on CRF and, 16
of new patients, SCr levels and, 696-698
patient survival and, 713-720
Race (and ethnicity) of RTx recipients
and drug-induced renal graft AIN, 542
outcome and, 706-712, 756-758
PTDM and, 2, 9
quality of life and, 62
Radix angelicae sinensis for anemic ESRD patients resistant
to rHuEPO, 349-354
Rapidly developing T cell posttransplantation lymphoprolif-
erative disorder (PTLD), 1:E3
Rapidly progressive glomerulonephritis (RPGN), familial
SV and, 364-373
Rate of adjustment, *see* Adjustment, rate, in USRDS 1999
ADR
RBCs (red blood cells), *see* Erythrocyte(s); Pure red cell
aplasia; Red blood cell count
RBP (retinol binding protein) in ESRD patients, VLPD
and, 501
RCC (Renal Community Council), USRDS, S1:22
Rebound phenomenon, and pharmacokinetics of gentamicin
in HD with high-flux polysulfone membranes,
222-227
REBUS/PMMIS database, S1:155-160
Recessive polycystic kidney disease, pediatric autosomal,
acute vision loss in, 1125-1128
Reciprocal serum creatinine (SCr) over time in ESRD,
reciprocal graph to plot, 576-578
Recombinant human erythropoietin (rHuEPO) for anemic
ESRD patients
effects of, on serum ferritin, S2:12-17
predialysis utilization of, among new ESRD patients,
USRDS 1999 ADR on, S1:71
see also Recombinant human erythropoietin for anemic
ESRD patients on HD; Recombinant human erythro-
poietin for anemic ESRD patients on PD/CAPD
Recombinant human erythropoietin (rHuEPO) for anemic
ESRD patients on HD
with ADPKD, 266
effects of, on sleep, sleep disorders, and daytime sleepi-
ness, 1089-1095
and effects of thrombogenicity of PGC membranes on
heparin requirements, 38
for new ESRD patients, 696, 697
race, HD outcome and, 724, 727
Radix angelicae sinensis for resistance to, 349-354
see also Parenteral iron therapy in ESRD patients on HD,
rHuEPO therapy and
Recombinant human erythropoietin (rHuEPO) for anemic
ESRD patients on PD/CAPD
Fe status and, 29-35
IP, *see* Intraperitoneal recombinant human erythropoietin
therapy
for new ESRD patients, 696, 697
Recovery
from hypocalcemia in ESRD patients on HD, effects of
age and calcitriol on, 456-463
of renal function with severe ARF treated with CVVH or
HD, liver disease and, 424-432
Recurrent focal segmental glomerulosclerosis (FSGS), pre-
diction and treatment of, after RTx for, in children,
1048-1055
Recurrent Goodpasture's syndrome due to monoclonal IgA- κ
circulating antibody, 549-555, 565-568
Red blood cell(s), *see* Erythrocyte(s); Pure red cell aplasia;
Red blood cell count
Red blood cell (RBC) count in ESRD patients on rHuEPO
therapy, *Radix angelicae sinensis* effects on, 350
Red cell aplasia, pure, parvovirus B19 infection causing, in
RTx recipients on tacrolimus, 1132-1136
Reflux, vesicoureteric, ACE gene and scarring in, 140-145
Regimen complexity, and noncompliance by abusive pa-
tients, 780-781
Regression, FSGS, progression versus, 5:liv
Rehabilitation of ESRD patient on prolonged slow HD,
603-604
Rejection
acute, *see* Acute rejection
and drug-induced renal allograft AIN, 540-548
racial disparities in, 708
Relaxin, as renal vasodilatory agent in normal pregnancy,
1142-1145
Release of USRDS data, S1:35-39
Remaining years of life, expected, of ESRD patients, USRDS
1999 ADR on, S1:84-85, S1:173
Remission
of FSGS, prolonged immunosuppression and, 618-625
of NS in IDDM with captopril, 308-314
SLE and MGN in, NS associated with FSGS in, 5:E22
Renal arterial embolization, transcatheter, in ADPKD patients
with ESRD on HD, 926-931
Renal asymmetry in children with ADPKD, 639-645, 4:E17
Renal atheroembolic disease (AED) with ARF, gallium-67
uptake in, 161-165
Renal biopsy
analysis of judgment in presence of, 569-575
for CsA or tacrolimus nephrotoxicity, 69-84
of dysfunctional renal graft due to CMV infection, 942-946
of IgAN with hepatitis and skin lesions, 380-383
of LN, *see* Renal biopsy of LN

- of NS, 1146-1151
- of partial pediatric FS, 184-188
- for proteinuria in renal insufficiency, *see* Renal biopsy for renal insufficiency with proteinuria
- see also* Renal histology; Ultrasound-guided renal biopsy
- Renal biopsy of LN, 315-323
- repeated, 530-539
- Renal biopsy for renal insufficiency with proteinuria due to MPGN after gastric lymphoma, 588-593
- HTN and, 768-774
- Renal cell carcinoma, and ACKD in ESRD children on CAPD, 242-246
- Renal Community Council (RCC), USRDS, S1:22
- Renal damage and injury
 - ACE inhibition effects on progression of renal disease and, 626-632
 - in doxorubicin-induced nephropathy, NaHCO_3 effects on, 328-337
 - lipid-associated, 2:xliv-xlvi
 - see also* Renal injury in ARF, neutrophil-induced and specific conditions
- Renal disease
 - chronic, de novo FSGS in renal grafts with, graft survival and, 731-738
 - early, Hb decline and LVH in, 125-134
 - see also* Pathology, renal and specific conditions
- Renal failure, *see* Acute renal failure; End-stage renal disease; Progression to renal failure
- Renal function
 - ACE inhibition effects on, in IDDM with HTN, 811
 - in ADPKD with colonic diverticular disease, 865
 - of allograft, MMF effects on, 299
 - in doxorubicin-induced nephropathy, NaHCO_3 effects on, 334
 - in ESRD, VLPD and, 502
 - in IMN, effects of prednisolone and azathioprine on, 521-529
 - recovery of, with severe ARF treated with CVVH or HD, liver disease and, 424-432
 - residual, *see* Residual renal function on PD/CAPD
 - see also* Renal insufficiency specific conditions and specific aspects of renal function
- Renal histology
 - in LMGN, 88
 - in MGN, 87
 - see also* Renal biopsy
- Renal infarction, bilateral, secondary to paradoxical embolism, 752-755
- Renal inflammation, *see* Inflammation, renal
- Renal injury in ARF, neutrophil-induced, 385-393
 - adhesion molecules in, 391-393
 - chemokines in, 390-391
 - evidence of, 385
 - nonoxidative mechanisms in, 387-389
 - oxidative mechanisms in, 385-387
 - phospholipase products and, 389-390
- Renal insufficiency
 - hyperuricemia and, associated with tumor lysis syndrome, urate oxidase for, 5:E20
 - see also* Proteinuria, and renal insufficiency and specific conditions
- Renal interstitium, *see* Interstitium
- Renal involvement of POEMS syndrome, GFs and cytokines in, 633-638
- Renal osteodystrophy (bone disease) in ESRD patients on HD
 - adynamic, serum Mg and PTH levels in, 43-48
 - Al-related, in asymptomatic ESRD patients on HD or CAPD, 688-693
 - in Iberoamerica, 4:lviii-lx
- Renal pathology, *see* Pathology, renal
- Renal replacement therapy(ies) (RRT)
 - for ESRD, serum hyaluronan and survival on, 1083-1088; *see also* Continuous cycling peritoneal dialysis for ESRD; Hemodialysis for ESRD; Peritoneal dialysis for ESRD; Renal replacement therapy(ies) for ESRD, USRDS 1999 ADR on; Renal transplantation for ESRD
 - see also* Acute renal failure, CRRT of; Continuous venovenous hemofiltration; Hemodialysis; Renal transplantation and entries beginning with term: Modality(ies)
- Renal replacement therapy(ies) (RRT) for ESRD, USRDS 1999 ADR on
 - acceptance into, S1:162-164
 - executive summary of, S1:13
 - options in, *see* Modality(ies), RRT, USRDS 1999 ADR on
 - summary statistics on, S1:10, S1:11
 - see also* First end-stage renal disease therapy, USRDS 1999 ADR on; International renal replacement therapy for ESRD, USRDS 1999 ADR on
- Renal transforming growth factor- β (TGF- β) in doxorubicin-induced nephropathy, NaHCO_3 effects on production of, 328-337
- Renal transplantation (RT; RTx)
 - for ADPKD, colonic diverticular disease and, 863-868
 - for LN, FSGS development in allograft and, 3:E13
 - pediatric, *see* Pediatric renal transplantation
 - tropical myositis and CGN in recipients of, 6:E25
 - see also* Renal transplantation for ESRD
- Renal transplantation (RT; RTx) for ESRD
 - benign monoclonal gammopathy turning to de novo aglycid light chain amyloidosis after, 166-169
 - CMV infection and, *see* Cytomegalovirus infection in RTx recipients
 - hypophosphatemia in, effects of Pi replacement therapy on muscular Pi content, mineral metabolism, and acid-base homeostasis, 875-883
 - outcome of, racial disparities in, 706-712, 756-758; *see also* Grafts, renal, survival of; Patient survival with RTx; Rejection
 - parvovirus B19 infection causing PRCA in recipients of, on tacrolimus, 1132-1136
 - patient survival with, *see* Patient survival with RTx
 - reversal of SAHS following, 739-744
 - secondary to SLE, aPL antibody syndrome in, 1040-1047
 - and spontaneous graft rupture due to ATN, 355-358
 - successful, 61-64
 - Western Australian Health Services Research Linked Database on, 1035, 1036
 - see also* Grafts, renal; Posttransplant diabetes mellitus; Posttransplantation lymphoproliferative disorders; Renal transplantation for ESRD, USRDS 1999 ADR on and specific immunosuppressive agents

- Renal transplantation (RT; RTx) for ESRD, USRDS 1999 ADR on, S1:15-16, S1:95-101, S1:153-154
 ABO blood group and, S1:98
 access to, *see* Access to RTx, USRDS 1999 ADR on described, S1:51-52
 history of, S1:51
 international, S1:148-149
 and kidney supply, S1:95-96
 mortality with, S1:91-92, S1:170-171
 patient characteristics and utilization of, S1:56-58
 patient survival with, S1:55, S1:95, S1:98-100, S1:110-111
 summary statistics on, S1:11
 and transplant CD, S1:32-33
see also Renal transplantation for pediatric ESRD, USRDS 1999 ADR on
- Renal transplantation (RT; RTx) for pediatric ESRD, USRDS 1999 ADR on, S1:108-111
 access to, S1:109-110
 graft survival and, S1:111-112
 patient survival and, S1:110-111
- Renal tubules, *see* entries beginning with element: Tubul-
- Renal vasodilatory agent in normal pregnancy, relaxin as, 1142-1145
- Renin
 race, T594M mutation in ENaC β subunit, and low-renin HTN, 579-587
see also Plasma renin activity; Renin-aldosterone axis; Renin-angiotensin system
- Renin-aldosterone axis in etiology of IE, 411-413
- Renin-angiotensin system
 role of, in retroperitoneal fibrosis associated with secondary IC-GN and juxtaglomerular cell tumor, 3:E10
 in siblings with NIDDM, MA and, 1002-1009
- Renoprotection, long-term, in IDDM, correlation between captopril effects on serum TGF- β 1 and, 818-823, 951-954
- Repeated renal biopsies for LN, 530-539
- Reported comorbid conditions by new ESRD patients, USRDS 1999 ADR on, S1:67, S1:69-70
- Reported incidence and prevalence of pediatric ESRD, S1:102-103, S1:107-108
- Requests for USRDS data, S1:26
- Research
 independently-supported, SAFs used in, S1:28
 investigator-initiated, policy on USRDS data release for, S1:35-36
- Research proposal to USRDS, suggested outline for, S1:38
- Researchers
 USRDS analysis files for, S1:26-35; *see also* specific analysis files
 USRDS products for, S1:24
- Researcher's Guide to the USRDS Database*, S1:23-24, S1:31, S1:35, S1:152, S1:169, S1:173
- Residence Standard Analysis File (SAF), S1:28
- Residual renal function (RRF) on PD/CAPD
 effects of aminoglycosides on, 14-20
 increase in Cr generation and decline of, time and, 235-241
 independent effects of adequacy of CAPD and, on patients' nutritional status, 1056-1064
- Resistance
 peritoneal mesothelial cell, to free radicals, OTZ and, 663-668
 to rHuEPO, *Radix angelicae sinensis* for anemic ESRD patients with, 349-354
- Reticulocyte count in ESRD patients on HD, L-carnitine effects on, 683
- Reticulocyte Hb (hemoglobin) in ESRD patients on CAPD, 29-35
- Retinol binding protein (RBP) in ESRD patients, VLPD and, 501
- Retinopathy, diabetic, NIDDM and, 516, 517
- Retroperitoneal fibrosis, juxtaglomerular cell tumor with, and secondary IC-GN, role of renin-angiotensin system in, 3:E10
- Reversal of SAHS following RTx for ESRD, 739-744
- Reverse transcriptase-polymerase chain reaction (RT-PCR) in detection of *COL4A5* gene mutations in X-linked Alport's syndrome, 854-862
 gene polymorphisms in VUR identified with, 140-145
 of mtDNA deletions in pediatric FS secondary to chemotherapy, 101-102
- Reversibility of bilateral hydronephrosis without obstruction in HBV infection-associated PAN, 3:E11
- Rhabdomyosarcoma (RMS), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
 rHuEPO, *see* entries beginning with terms: Recombinant human erythropoietin
- Risk(s)
 of infections, Fe and, S2:33, S2:49-50
 of mortality on CAPD, CCPD, and/or HD for ESRD, compared, 1065-1074
 of prolonged slow HD, 604-605
see also Risk factors for PTDM
- Risk factors for PTDM, 2, 8-10
 clinical trials of immunosuppressants and, 8-9
 patient management with regard to, 10
- RMS (rhabdomyosarcoma), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Rosai-Dorfman disease, ARF with, 3:E12
- RPGN (rapidly progressive glomerulonephritis), familial SV and, 364-373
- RRF, *see* Residual renal function on PD/CAPD
- RRT, *see* Renal replacement therapy(ies)
- RT (RTx), *see* Renal transplantation
- RT-PCR, *see* Reverse transcriptase-polymerase chain reaction
- Rupture, spontaneous graft, due to ATN, 355-358
- S haemolyticus* (*Staphylococcus haemolyticus*) infection of catheter in chronic HD, inverse paradoxical embolism with aortic bacterial endocarditis due to, 338-340, 362-363
- SACs (Scientific Advisory Committees), USRDS, S1:22
- SAECG (signal-averaged electrocardiogram) in ESRD, HD effects on, 1105-1113
- Safety of MMF, 299-301
- SAHS (sleep apnea hypoapnea syndrome), reversal of, following RTx for ESRD, 739-744
- Sarcoidosis, ESRD in, 5:E21
- SBP (systolic blood pressure), *see* Blood pressure

- Scarring in VUR, *ACE* gene and, 140-145
- SCCR (succinate cytochrome-c reductase) in pediatric FS secondary to chemotherapy, 101
- Scientific Advisory Committees (SACs), USRDS, S1:22
- Scintigraphy, ventilation-perfusion, of pulmonary clots after percutaneous thrombolysis of clotted HD access grafts, 207-211
- Scleroderma kidney, as primary diagnosis, 138
- Scleroderma renal crisis (SRC), sclerosis and, associated with breast cancer, 937-941
- Sclerosis
- mesangial, associated with myeloproliferative disorders, 889-893
 - systemic, scleroderma renal crisis and, associated with breast cancer, 937-941
 - see also* Atherosclerosis; Glomerulosclerosis; Nephroangiosclerosis
- SCr, *see* Serum creatinine
- Screening
- for MA in hypertension, 1139-1141
 - see also* Diagnosis
- Seawater polluted by diesel oil, ARF due to immersion, 6:E26
- Secondary immune complex glomerulonephritis (IC-GN), juxtaglomerular cell tumor with retroperitoneal fibrosis and, role of renin-angiotensin system in, 3:E10
- Secondary syphilis, and IgAN with hepatitis and skin lesions, 380-383
- Selection, patient, for prolonged slow HD, 605
- Serial vascular access blood flow (VABF), intradialytic, measurements of, 471-477
- Serum acylcarnitine, L-carnitine effects on, 682, 685
- Serum albumin
- in chronic GN, 115
 - in ESRD patients, *see* Serum albumin in ESRD patients on RRT
 - in FSGS, 620
 - in IMN, 523
 - in LN, 317
 - in recurrent Goodpasture's syndrome, 551
 - in severe ARF, 427-430
 - in types I and III MPGN, 1024
- Serum albumin in ESRD patients on HD
- acidosis and nutritional status and, 495-497
 - iron status and, 31
 - race and HD outcome, 724, 727, 728
 - relationship between serum Mg and PTH and, 44, 45
- Serum albumin in ESRD patients on PD/CAPD
- Cr generation over time and, 237
 - nutritional status and, 1060
- Serum albumin in ESRD patients on RRT
- serum hyaluronan and survival and, 1084, 1085
 - see also* Serum albumin in ESRD patients on HD; Serum albumin in ESRD patients on PD/CAPD
- Serum aluminum (Al) in ESRD patients on HD, relationship between serum Mg and PTH and, 44, 45
- Serum angiotensin-converting enzyme (ACE), activity of, in NIDDM ESRD patients on CAPD, 514-520
- Serum C3 (complement 3) in LN, 317
- Serum C4 (complement 4) in LN, 317
- Serum Ca (calcium)
- in ESRD patients on HD, relationship between serum Mg, PTH and, 44, 45
 - in Gitelman's syndrome, 846
- Serum carnitine, total and free, L-carnitine effects on, 682, 685
- Serum cholesterol
- and de novo FSGS in renal grafts, 734
 - in NIDDM, *ACE* and *AGN* genes and, 1004
 - in NIDDM ESRD, 802
- Serum Cl (chloride)
- in Gitelman's syndrome, 846
 - in IE, 416
- Serum creatinine (SCr)
- in ADPKD patients with colonic diverticular disease, 865
 - in chronic GN, 115
 - in DM with ATN, 1012
 - in ESRD, *see* Serum creatinine in ESRD patients on RRT
 - in IDDM, *see* Serum creatinine in IDDM with HTN, captopril and
 - in IgAN, *see* Serum creatinine in IgAN
 - in IMN, 523
 - in LN, 317, 536
 - in MGN and LMGN, 86
 - in NIDDM, *ACE* and *AGN* genes and, 1004
 - in NS, 612
 - and pulse methylprednisolone for acute allograft rejection, 304-307
 - reciprocal graph to plot reciprocal, over time, 576-578
 - in recurrent Goodpasture's syndrome, 551
 - and remission of NS in IDDM with captopril, 310
 - in RTx, *see* Serum creatinine in RTx
 - in severe ARF, 427-430
 - in stage II and III IMN, steroids and/or chlorambucil effects on, 914
 - in types I and III MPGN, 1024, 1025, 1028
- Serum creatinine (SCr) in ESRD patients on HD
- acidosis, nutritional status and, 495-497
 - levels of, in new ESRD patients, significance of, 694-701
 - in NIDDM ESRD patients, 802
- Serum creatinine (SCr) in ESRD patients on PD/CAPD
- on CAPD, generation of, over time, 237
 - and leptin in dialysate, 833
 - levels of, in new ESRD patients, significance of, 694-701
 - race, survival and, 715
- Serum creatinine (SCr) in ESRD patients on RRT
- serum hyaluronan and survival and, 1084, 1085
 - see also* Serum creatinine in ESRD patients on HD; Serum creatinine in ESRD patients on PD/CAPD; Serum creatinine in RTx
- Serum creatinine (SCr) in IDDM with HTN, captopril and captopril effects of IDDM course, 811, 814
- and long-term renoprotective effects of captopril, 820
- Serum creatinine (SCr) in IgAN
- with *PAF-AH* gene mutation, 292
 - with *TCR C α* gene polymorphism, 282
- Serum creatinine (SCr) in RTx
- and drug-induced renal graft AIN, 543
 - oral CsA versus SGC formulation and, 871
- Serum Fe (iron) in recurrent Goodpasture's syndrome, 551
- Serum ferritin
- and Fe deficiency in ESRD, 508-513, S2:12-17

- parenteral Fe therapy effects on, S2:7, S2:42, S2:43
and rHuEPO effects on sleep, sleep disorders, and daytime sleepiness in ESRD patients on HD, 1092
- Serum hyaluronan (HA), and survival on RRTs for ESRD, 1083-1088
- Serum IgG (immunoglobulin G) in TINU syndrome, 1017
- Serum K (potassium)
acidosis and nutritional status and, in ESRD patients on HD, 495-497
in Gitelman's syndrome, 846
in hypokalemia, 109-110
in IE, 416
- Serum lipids, and MA in hypertension, 978-979
- Serum malondialdehyde (MDA), hemostatic factors and, as predictive factors for CVD in ESRD patients on HD, 438-444
- Serum Mg (magnesium)
in ESRD patients on HD, relationship between serum Mg and PTH and, 44, 45
in Gitelman's syndrome, 846
in hypokalemia, 109-110
- Serum Na (sodium)
in Gitelman's syndrome, 846
in IE, 416
- Serum NaHCO₃ (sodium bicarbonate)
hyperleptinemia and, 826
in IE, 416
in pediatric FS secondary to chemotherapy, 100
- Serum neopterin (NP), cell-mediated immune dysfunction in NS and, 611-617
- Serum P (phosphorus)
in Gitelman's syndrome, 846
see also Serum P in ESRD patients on HD
- Serum P (phosphorus) in ESRD patients on HD
acidosis and nutritional status and, 495-497
relationship between serum Mg and PTH and, 44, 45
- Serum protein
in recurrent Goodpasture's syndrome, 551
total, *see* Total serum protein
- Serum protein electrophoresis (SPEP), UPEP and, in evaluation of nephrotic-range proteinuria, 135-139
- Serum transforming growth factor- β 1 (TGF- β 1), correlation between captopril effects on, and long-term renoprotection in IDDM, 818-823, 951-954
- Serum triglycerides
and de novo FSGS in renal grafts, 734
in NIDDM, ACE and AGN genes and, 1004
- Serum urea
and Cr generation on CAPD, over time, 237
in IgAN with PAF-AH gene mutation, 292
in NIDDM ESRD, 802
- Severe acute renal failure (ARF), HD and CVVH for, compared, 424-432
- Severity of infections in ESRD patients on HD, parenteral Fe effects on, S2:26-27
- Sex
of ADPKD patients, *see* Sex of ADPKD patients
of bedside renal biopsy patients, 956
of CAD patients, 920, 922
of chronic GN patients, 115
of DM patients, *see* Sex of DM patients
of early renal disease patients, LVH and, 127, 129, 131
of ESRD patients, *see* Sex of ESRD patients
of FS patients, 99
of GS patients, *see* Sex of GS patients
of HTN patients, *see* Sex of HTN patients
of hypokalemic patients, 109
of IgAN patients, *see* Sex of IgAN patients
of IMN patients, 523
of LN patients, 317, 319, 536
of MGN and LMGN patients, 86
of MPGN patients, 1024
of NS patients, *see* Sex of NS patients
of proliferative GN patients, DSG effects and, 895
of recurrent Goodpasture's syndrome, 554
of severe ARF patients, 426, 428, 429
of TINU syndrome patients, 1017
- Sex of ADPKD patients
ACE gene polymorphism and, 275
with colonic diverticular disease, 865
- Sex of DM patients
with ATN, 1012
and reduced orthostatic cerebral blood flow due to HD, 1097
see also Sex of IDDM patients with HTN, captopril and
- Sex of ESRD patients
and outcome of nutritional status and body composition with VLPD, 501
race and, familial aggregation of ESRD in HIVAN and, 248
see also Sex of ESRD patients, USRDS 1999 ADR on;
Sex of ESRD patients on HD; Sex of ESRD patients on PD/CAPD; Sex of RTx recipients
- Sex of ESRD patients, USRDS 1999 ADR on
adjusted first-year death rates by, S1:79
cause of mortality by, S1:89-90, S1:92, S1:93
expected remaining years of life by, USRDS 1999 ADR on, S1:84-85
incidence and prevalence of treated ESRD by, S1:11, S1:42-45, S1:47-49
Medicare expenditures by, S1:132-135
of new ESRD patients, S1:64
patient survival by, S1:98-99, S1:172-173
of pediatric patients, S1:105-107
RRT modality use by, S1:57
- Sex of ESRD patients on HD
with ADPKD, valvular heart disease and, 266
and association between acidosis and nutritional status, 494
with asymptomatic AI-related renal osteodystrophy, 690
atherosclerotic vascular disease and, 671, 674
and CVD, 440
gentamicin pharmacokinetics and, 223
hyperleptinemic patients, 825, 828
leukocyte phagocytic function and viability and, 681
on long-term maintenance HD, genomic damage to lymphocytes and, 434, 435
of new patients, SCr levels and, 696-698
race and, and outcome of HD, 723, 728
and relationship between serum Mg and PTH, 44, 45
rHuEPO and, 24, 1091
- SAEG and, 1107
serial VABF and, 472

- Sex of ESRD patients on PD/CAPD
 with asymptomatic Al-related renal osteodystrophy, 690
 Cr generation and, over time, 236
 and effects of aminoglycosides on RRF, 16, 17
 and Fe status, 31
 and IP rHuEPO therapy, "dry well" dosing technique and, 659
 leptin and, *see* Sex of ESRD patients on PD/CAPD, leptin and
 of new patients, SCr levels and, 696-698
 with NIDDM, 516, 517
 nutritional status and, 1058
 PET measurement of D/P ratio and, 248
 race, survival and, 714
- Sex of ESRD patients on PD/CAPD, leptin and
 hyperleptinemic patients, 825
 and leptin in dialysate, 833, 834
 peritoneal leptin clearance, 840
- Sex of ESRD patients on RRT
 of pediatric patients on CCPD, 654
 serum hyaluronan, survival and, 1085
see also Sex of ESRD patients on HD; Sex of ESRD patients on PD/CAPD; Sex of RTx recipients
- Sex of GS patients
 of aging-related GS patients, 884-888
 of FSGS patients, 620
- Sex of HTN patients
 with low-renin HTN, 581, 584
 with MA, 997
see also Sex of IDDM patients with HTN, captopril and
- Sex of IDDM patients with HTN, captopril and
 captopril effects of IDDM course, 811
 and long-term renoprotective effects of captopril, 820
- Sex of IgAN patients, 906
 with *PAF-AH* gene mutation, 292
 with *TCR* α gene polymorphism, 282
- Sex of NS patients
 cell-mediated immune dysfunction and, 612
 and remission of NS in IDDM with captopril, 310
- Sex of RTx recipients
 de novo FSGS in renal graft and, 733, 735
 and drug-induced renal graft AIN, 542
 for FSGS, 1049
 with gastric CMV infection, persistent abdominal pain and, 66
 hypophosphatemic, 876
 oral CsA versus SGC formulation and, 871
 parvovirus B19 infection and PRCA and, 1134, 1135
 quality of life and, 62
 race, RTx outcome and, 708
- SGC (soft gelatin capsule) versus oral CsA formulation, bioavailability of, 869-874
- Shock, streptococcal toxic shock syndrome with desquamating erythema and, 150-154
- SHR, *see* Standard Hospitalization Ratio
- Siblings with NIDDM, *ACE* and *AGN* genes in, MA and, 1002-1009
- Signal-averaged electrocardiogram (SAECG) in ESRD, HD effects on, 1105-1113
- Silent mutations of *COL4A5* gene in X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of, 858
 60-day rule, defined, S1:174
- Skin lesions, IgAN with hepatitis and, renal biopsy of, 380-383
- SLE, *see* Systemic lupus erythematosus
- Sleep, effects of rHuEPO in HD patients on, 1089-1095
- Sleep apnea, effects of rHuEPO in HD patients on HD, 1089-1095
- Sleep apnea hypoapnea syndrome (SAHS), reversal of, following RTx for ESRD, 739-744
- Sleep disorders, effects of rHuEPO in HD patients on HD, 1089-1095
- Sleepiness, daytime, effects of rHuEPO for HD patients on HD, 1089-1095
- Slow hemodialysis, *see* Prolonged slow hemodialysis for ESRD
- SMA, *see* Smooth muscle actin; α -Smooth muscle actin
- Smoking
 and CAD, 920
 by ESRD patients on HD, atherosclerotic vascular disease, 671, 674
 and HTN with MA, 997
- Smooth muscle actin (SMA), levels of urinary, in RTx recipients, correlated with CsA or tacrolimus nephrotoxicity, 69-84
 α (alpha)-Smooth muscle actin (α -SMA), expression of mesangial cell, and IgAN progression, 902-910
- SMR, *see* Standard Mortality Ratio
- Socioeconomic factors
 role of, in RTx outcome, 706-712, 756-758
see also Race
- Sodium, *see* Na
- Sodium bicarbonate, *see* NaHCO_3
- Sodium chloride (NaCl) *TSC* gene, R642C missense mutation of, in Gitelman's syndrome, 845-853
- Soft gelatin capsule (SGC) versus oral CsA formulation, bioavailability of, 869-874
- Software experience needed to use SAFs, S1:35
- Software needed to use SAFs, S1:35
- Soluble receptor of transferrin in diagnosis of Fe deficiency in ESRD patients on HD, 508-513
- Southern blot analysis of mtDNA deletions in pediatric FS secondary to chemotherapy, 101-102
- Southern Chinese patients with LN, clinicopathologic findings on, and long-term outcome with, 315-323
- Spatial arrangements of subepithelial immune deposits in MGN and LMGN, 85-91
- Special Studies, USRDS, S1:31
- Special Studies Review and Implementation Committee (SSRIC), USRDS, S1:6, S1:22-23
- Specialty, medical, Medicare expenditures by, S1:135-138
- SPEP (serum protein electrophoresis), UPEP and, in evaluation of nephrotic-range proteinuria, 135-139
- Spontaneous graft rupture due to ATN, 355-358
- Spring-loaded gun device, automated ultrasound-guided, for renal biopsy, effects of, on bleeding and early discharge, 92-97
- SRC (scleroderma renal crisis), sclerosis and, associated with breast cancer, 937-941

- SSc (systemic sclerosis), scleroderma renal crisis and, associated with breast cancer, 937-941
- SSRIC (Special Studies Review and Implementation Committee), USRDS, S1:6, S1:22-23
- Stage II (and III) idiopathic membranous nephropathy (IMN), steroid and/or chlorambucil therapy for, long-term follow-up of, 911-917
- Stainless steel coil, renal TAE in ADPKD patients with ESRD on HD with, 926-931
- Standard Analysis Files (SAFs), S1:27
- core SAF CD-ROM, S1:27-28, S1:30
- cost of, S1:35
- documentation for, *see* Documentation for SAFs
- equipment needed to use, S1:35
- media and formats of, S1:34-35
- see also* specific Standard Analysis Files
- Standard Hospitalization Ratio (SHR), S1:25, S1:119-122
- by ESRD care facilities, S1:25-26
- by states, S1:121-122
- time trends in, S1:122
- Standard Mortality Ratio (SMR), S1:25, S1:82-S1:83
- by ESRD care facilities, S1:25-26
- by state, S1:83
- by year of first treatment, S1:83
- Standard population for adjustment, S1:153
- Standard Transplantation Ratio (STR), S1:25
- Standardization, rate, *see* Adjustment, rate, in USRDS 1999 ADR
- Staphylococcus haemolyticus* (*S. haemolyticus*) infection of catheter in chronic HD, inverse paradoxical embolism with aortic bacterial endocarditis due to, 338-340, 362-363
- Start of ESRD, *see* Patient characteristics at start of ESRD, USRDS 1999 ADR on
- State(s)
- interstate differences in Medicare expenditures for ESRD, S1:138-139
- SMR by, S1:83
- USRDS networks and their, S1:6
- Statistics, USRDS 1999 ADR
- summary, on RRTs for ESRD, S1:10, S1:11
- see also* specific aspects of USRDS 1999 ADR
- Stenosis, HD vascular graft, 478-485
- Steroids
- for cell-mediated immune dysfunction in NS, 611-617
- for TINU syndrome, 1016-1021
- see also* Glucocorticoids; Idiopathic membranous nephropathy, steroids for; Prednisolone; Prednisone
- Stones (urolithiasis and nephrolithiasis), as primary diagnosis, 138, 434, 1058, 1107
- STR (Standard Transplantation Ratio), S1:25
- Streptococcal toxic shock syndrome with ARF and desquamating erythema, 150-154
- Subepithelial immune deposits in MGN and LMGN and, spatial arrangements of, 85-91
- Succinate cytochrome-c reductase (SCCR) in pediatric FS secondary to chemotherapy, 101
- Supplier type, Medicare expenditures by, S1:135-138
- Surgery
- thoracoscopic pleurodesis and, for PPC in ESRD patients on CAPD, 170-172
- see also* Renal transplantation
- Survival
- HD vascular access graft, monitoring graft venous pressure at high blood flow in prediction of, 212-217
- see also* Grafts, renal, survival of; Patient survival with ESRD; Patient survival with RTx
- SV (systemic vasculitis), familial, RPGN and, 364-373
- Symptoms
- cardiac, in renal insufficiency, LVH and, 128-129
- HUVS and SLE, 750
- in IE, 406, 407
- of ovarian cysts in ADPKD, 122
- see also* Clinical features and presentation
- Synergism between oxidative and nonoxidative mechanisms of neutrophil-induced renal injury in ARF, 388-389
- Syphilis, secondary, and IgAN with hepatitis and skin lesions, 380-383
- Systemic amyloidosis, as primary diagnosis, 138
- Systemic inflammatory response, parenteral Fe in ESRD patients on HD and, S2:35-39
- Systemic lupus erythematosus (SLE)
- distinguishing between HUVS and, 745-751
- and MGN in remission, NS associated with FSGS in, S5:E22
- as primary diagnosis, 659, 1107
- see also* Lupus nephritis; Systemic lupus erythematosus, ESRD secondary to
- Systemic lupus erythematosus (SLE), ESRD secondary to
- aPL antibody syndrome in RTx for ESRD secondary to SLE, 1040-1047
- CAPD patients with ESRD secondary to, calciphylaxis due to UV light in, 932-936
- Systemic sclerosis (SSc), scleroderma renal crisis and, associated with breast cancer, 937-941
- Systemic vasculitis (SV), familial, RPGN and, 364-373
- Systolic blood pressure, *see* Blood pressure
- T cell(s) in cell-mediated immune dysfunction in NS, 611-617
- T cell posttransplantation lymphoproliferative disorder (PTLD), rapidly developing, 1:E3
- T594M mutation in ENaC β subunit, race and, and low-renin HTN, 579-587
- Tacrolimus (FK506)
- effects of, on glycemic tolerance, 6-9
- levels of urinary SMA in RTx recipients correlated with nephrotoxicity of, 69-84
- parvovirus B19 infection causing PRCA in RTx recipients on, 1132-1136
- TAE (transcatheter arterial embolization), renal, in ADPKD patients with ESRD on HD, 926-931
- TBARS (thiobarbituric acid reactive substance), plasma, in ESRD patients on HD, enalapril and, 449-450
- TCD (transcranial Doppler) of reduced orthostatic cerebral blood flow due to HD for DM, 1096-1104
- TCR α gene, polymorphism of, and IgAN progression in Japanese subjects, 279-288
- Telemedicine, dialysis patients and, 1:xxxvi-xxxviii
- Temperature, body, of severe ARF patients, 427-430
- Termination of dialysis treatment for abusive patients, 778-780, 783-784
- TGF- β , *see* Transforming growth factor- β

- TGF- β 1, *see* Transforming growth factor- β 1
- Therapy
 judgment on, analyzed, 573-574
 see also Renal replacement therapy(ies); Surgery *specific therapeutic modalities and specific conditions*
- Thiazides (TZs), K Mg citrate effects on Mg loss and hypokalemia induced by, 107-113
- Thiobarbituric acid reactive substance (TBARS), plasma, in ESRD patients on HD, enalapril and, 449-450
- Thoracoscopic surgery, pleurodesis and, for PPC in ESRD patients on CAPD, 170-172
 365-day period, lost-to-follow-up classification and, S1:160
- Thrombi, *see* Embolism
- Thrombogenicity of PGC membranes, influence of, on heparin requirements of ESRD patients on HD, 36-42
- Thrombolysis of clotted HD access grafts
 mechanical, cerebral embolism after, 341-343, 362-363
 percutaneous, pulmonary thrombi after ventilation-perfusion scintigraphy of, 207-211
- Thrombosis of HD vascular access grafts, 471-485
 BF as predictor of, 478-485
 intradialytic serial VABF and, 471-477
 outcome of RTx and, racial disparities in, 709
 see also Thrombolysis of clotted HD access grafts
- Thrombotic microangiopathy, 3:E7
 in POEMS syndrome, 633-638
- Thyroid disorders in IE etiology, 414-415
- TIBC (total iron binding capacity), effects of parenteral Fe on, 23, 24, 26
- Tidal peritoneal dialysis (TPD) for ESRD, influence of preceding exchange on PET results, 247-253
- Time course of response to pulse methylprednisolone for acute allograft rejection, 304-307
- Time on HD, *see* Duration of HD
- Time trends in SHR, S1:122
- Timing of dialysis initiation, S1:70-71
- TINU (tubulointerstitial nephritis and uveitis) syndrome, outcome and course of, 1016-1021
- Tissue exposure to azide and cobalt, and glucose transport regulation by hypoxia, 189-202
- Tissue plasminogen activator (TPA) in ESRD patients on HD, and CVD, 440, 441
- TMP-SMZ (trimethoprim-sulfamethoxazole) for drug-induced renal graft AIN, 540-548
- TNF (tumor necrosis factor), and systemic inflammatory response in ESRD patients on HD, parenteral Fe and, S2:35-39
- TNF- α , *see* Tumor necrosis factor- α
- Tobacco, *see* Smoking
- Total admissions, hospitalization rates for ESRD based on, S1:117-119
- Total bilirubin in severe ARF, 427-430
- Total body fat in ESRD patients, VLPD and, 501, 503-504
- Total cholesterol
 in CAD, 920
 and CVD in ESRD patients on HD, 440, 441
- Total CO₂ (carbon dioxide)
 acidosis and nutritional status in ESRD patients on HD and, 495
 in severe ARF, 427-430
- Total iron binding capacity (TIBC), effects of parenteral Fe on, 23, 24, 26
- Total protein
 in DM patients on HD, and orthostatic hypotension and, 1100
 in HD patients on ESRD, L-carnitine effects on, 683
 see also Total serum protein
- Total serum carnitine, L-carnitine effects on, 682, 685
- Total serum protein
 in chronic GN, 115
 in MGN and LMGN, 86
- Toxic shock syndrome, streptococcal, with ARF and desquamating erythema, 150-154
- TPA (tissue plasminogen activator) in ESRD patients on HD, CVD and, 440, 441
- TPD (tidal peritoneal dialysis) for ESRD, influence of preceding exchange on PET results, 247-253
- Transcatheter arterial embolization (TAE), renal, in ADPKD patients with ESRD on HD, 926-931
- Transcranial Doppler (TCD) of reduced orthostatic cerebral blood flow due to HD for DM, 1096-1104
- Transferrin in ESRD patients
 VLPD and, 501
 see also Transferrin saturation in ESRD patients on HD and rHuEPO therapy; Transferrin saturation in ESRD patients on PD/CAPD and rHuEPO therapy
- Transferrin saturation (TSAT) in ESRD patients on HD and rHuEPO therapy
 in diagnosis of Fe deficiency, 508-513
 and parenteral Fe, 21-28, 173-176, S2:5-11
 race, HD outcome and, 724, 727, 728
 Radix angelicae sinensis effects on, 350
 and rHuEPO effects on sleep, sleep disorders, and daytime sleepiness, 1092
- Transferrin saturation (TSAT) in ESRD patients on PD/CAPD and rHuEPO therapy
 iron deficiency diagnosis and, 508-513
 iron status and, 29-35
- Transforming growth factor- β (TGF- β)
 in doxorubicin-induced nephropathy, NaHCO₃ effects on renal production and urinary excretion of, 328-337
 in POEMS syndrome, 633-638
- Transforming growth factor- β 1 (TGF- β 1)
 serum, correlation between captopril effects on, and long-term renoprotection in IDDM, 818-823, 951-954
 tubulointerstitial fibrosis, GS, obstructive uropathy in PEPCK-TGF- β 1 transgenic subjects, 177-183
- Transfusion, exchange, for neonatal ARF due to transplacental transfer of nephrotoxic paraprotein, 1129-1131
- Transgenic subjects, PEPCK-TGF- β 1, tubulointerstitial fibrosis, GS, obstructive uropathy in, 177-183
- Transplacental transfer of nephrotoxic paraprotein, neonatal ARF due to, exchange transfusion for, 1129-1131
- Transplant centers, described, S1:140-141
- Transplant Standard Analysis File (SAF), S1:31
- Transplant Waiting List Standard Analysis File (SAF), S1:31
- Treatment, *see* Therapy
- Treatment History File (Modality Sequence File), S1:28
- Trends
 hospitalization, S1:115-117
 RRT utilization, S1:53-56
 time, in SHR, S1:122

- Triglycerides
 in CAD, 920
 in HTN with MA, atherosclerosis and, 998
see also Serum triglycerides; Triglycerides in ESRD patients
- Triglycerides in ESRD patients
 fasting plasma, in NIDDM patients on CAPD, 516, 517
 on HD, CVD and, 440, 441
- Trimethoprim-sulfamethoxazole (TMP-SMZ) for drug-induced renal graft AIN, 540-548
- γ (gamma)-Trimethyl-ammonium- β -hydroxybutyrate (L-carnitine), effects of, on leukocyte phagocytic function and viability in ESRD patients on HD, 678-687
- Tropical myositis, CGN and, in RTx recipients, 6:E25
- TSAT, *see* entries beginning with terms: Transferrin saturation in ESRD patients
- TSC gene, NaCl, R642C missense mutation of, in Gitelman's syndrome, 845-853
- Tubular disease
 inherited, gene therapy of, 374-379
see also specific conditions
- Tubular necrosis, *see* Acute tubular necrosis
- Tubulointerstitial damage in doxorubicin-induced nephropathy, NaHCO_3 effects on, 328-337
- Tubulointerstitial fibrosis, GS, obstructive uropathy and, in PEPCK-TGF- β 1 transgenic subjects, 177-183
- Tubulointerstitial nephritis and uveitis (TINU) syndrome, outcome and course of, 1016-1021
- Tumor lysis syndrome, hyperuricemia and renal insufficiency associated with, urate oxidase for, 5:E20
- Tumor necrosis factor- α (TNF- α)
 in POEMS syndrome, 633-638
 and systemic inflammatory response in ESRD patients on HD, parenteral Fe and, S2:35-39
- Tunneled, cuffed, permanent hemodialysis (HD) catheters, bacteremia associated with, 1114-1124
- Type 1 diabetes mellitus, *see* Captopril in IDDM; Diabetic end-stage renal disease, IDDM
- Type I membranoproliferative glomerulonephritis (MPGN), differences between type III and, in response to alternate-day prednisone, 1022-1032
- Type 2 diabetes mellitus, *see* Diabetic end-stage renal disease, NIDDM
- Type III membranoproliferative glomerulonephritis (MPGN), differences between type I and, in response to alternate-day prednisone, 1022-1032
- TZs (thiazides), K Mg citrate effects on Mg loss and hypokalemia induced by, 107-113
- UF, *see* Ultrafiltration
 Ultrafiltration (UF)
 flow rates of, diffusive and convective clearances during CRRT of ARF at various, 486-492
 and intradialytic serial VABF, 475
see also Ultrafiltration in ESRD patients on HD
- Ultrafiltration (UF) in ESRD patients on HD
 acidosis and, 495, 496
 for HTN, 218-221, 359-361
- Ultrasound, *see* Doppler ultrasound; Echocardiography; Ultrasound-guided renal biopsy
- Ultrasound (US)-guided renal biopsy
 bedside biopsy, 955-959
 effects of percutaneous biopsy with US-guided automated spring-loaded device on bleeding implications for early hospital discharge, 92-97
- Ultraviolet (UV) light, calciphylaxis in CAPD patients with ESRD secondary to SLE due to, 932-936
- United Network for Organ Sharing (UNOS) transplant data, S1:156-157
- United States (U.S.), incidence and prevalence of treated NIDDM ESRD in, 796-797
- United States (U.S.) population, expected remaining lifetimes for, USRDS 1999 ADR on, S1:85
- United States Renal Data System (USRDS)
 address of, on World Wide Web, S1:25
 committees of, S1:5-6, S1:22-23
 contacts of, S1:22
 organizational structure of, S1:21
 products of, *see* Products, USRDS
 project goals of, S1:21
 research proposal to, suggested outline for, S1:38
 who's who in, S1:4-6
see also United States Renal Data System, 1998 ADR of; United States Renal Data System, 1999 ADR of
- United States Renal Data System (USRDS), 1998 ADR of, errata to, S1:19
- United States Renal Data System (USRDS), 1999 ADR of
 abbreviations used in, S1:7-8
 executive summary of, S1:9-19
 functions of, S1:20
 introduction to, S1:1-3
 what's new in, S1:20
see also Analytical methods used in USRDS 1999 ADR; Cost of ESRD care, USRDS 1999 ADR on; Facilities for ESRD care, USRDS 1999 ADR on; Hospitalization for ESRD, USRDS 1999 ADR on; Incidence and prevalence of treated ESRD, USRDS 1999 ADR on; Mortality of ESRD patients, USRDS 1999 ADR on; Patient characteristics, ESRD patients, USRDS 1999 ADR on; Patient survival with ESRD, USRDS 1999 ADR on; Pediatric end-stage renal disease, USRDS 1999 ADR on; Renal replacement therapy(ies) for ESRD, USRDS 1999 ADR on
- UNOS (United Network for Organ Sharing) transplant data, S1:156-157
- UPEP (urinary protein electrophoresis), SPEP and, in evaluation of nephrotic-range proteinuria, 135-139
- Urate(s)
 diffusive and convective clearances of, during CRRT for ARF, 488, 491
 ratios of urinary excretion of oxalate and, to Cr, in healthy pediatric population, 2:E3
- Urate oxidase for hyperuricemia and renal insufficiency associated with tumor lysis syndrome, 5:E20
- Urea
 diffusive and convective clearances of, during CRRT for ARF, 488, 491
 in ESRD patients on HD, CVD and, 440
 kinetics of, *see* Kinetics, urea
 ratio of urinary excretion of oxalate and, to Cr, in healthy pediatric population, 2:E3
 serum, *see* Serum urea
see also BUN; Urea rebound; Urea reduction ratio

- Urea rebound in pediatric ESRD patients on HD, evaluation and prediction of, 49-54
- Urea reduction ratio (URR)
improvement of, ESRD Core Indicators Project report on, 1075-1082
race, HD outcome and, 724, 727, 728
rHuEPO effects on, in ESRD patients on HD, 1092
- Uremia, *see* End-stage renal disease
- Uremic syndrome, *see* Hemolytic uremic syndrome
- Uric acid
and CVD in ESRD patients on HD, 440
hyperuricemia and renal insufficiency associated with tumor lysis syndrome, 5:E20
- Urinary excretion
AM and PAMP, in chronic GN, 114-119
Cl and Ca, in Gitelman's syndrome, 846
K, *see* Urinary excretion, K
Mg, in hypokalemia, 109-111
Na, *see* Urinary excretion, Na
NP, cell-mediated immune dysfunction in NS and, 611-617
ratios of urea and oxalate to Cr, in healthy pediatric population 2:E3
TGF- β , in doxorubicin-induced nephropathy, NaHCO₃ effects on 328-337
see also entries ending with suffix: -uria
- Urinary excretion, K
in Gitelman's syndrome, 846
in hypokalemia, 109-111
in IE, 416
- Urinary excretion, Na
in Gitelman's syndrome, 846
in IE, 426
in low-renin HTN, 581
- Urinary smooth muscle (SMA) in RTx recipients correlated with CsA or tacrolimus nephrotoxicity, 69-84
- Urine volume of PD patients, effects of aminoglycosides on, 16, 17
- Urolithiasis and nephrolithiasis, as primary diagnosis, 138, 434, 1058, 1107
- Uropathy, GS, tubulointerstitial fibrosis, and obstructive, in PEPCK-TGF- β 1 transgenic subjects, 177-183
- Uroporphyrins in BD, 155-160
- URR, *see* Urea reduction ratio
- Urticarial vasculitis syndrome, hypocomplementemic, distinguishing between SLE and, 745-751
- US (ultrasound), *see* Doppler ultrasound; Echocardiography; Ultrasound-guided renal biopsy
- UV (ultraviolet) light, calciphylaxis in CAPD patients with ESRD secondary to SLE due to, 932-936
- Uveitis, outcome and course of TINU syndrome, 1016-1021
- VABF, *see* Vascular access blood flow, HD
- Valvular heart disease in ESRD patients with ADPKD on HD, 264-272
- Vascular access, HD
changes in venous histology and, 702-705
see also Catheters, HD; Vascular access blood flow, HD; Vascular access grafts, HD
- Vascular access blood flow (VABF), HD
intradialytic serial, measurements of, 471-477
see also Vascular access blood flow, HD, access graft failure prediction and
- Vascular access blood flow (VABF), HD, access graft failure prediction and, 478-485
by venous pressure monitoring at high VABF, 212-217
- Vascular access grafts, HD
complications of, 3:xxxviii-xl; *see also* Thrombosis of HD vascular access grafts
- failure of, *see* Vascular access blood flow, HD, access graft failure prediction and
- Vascular disease, atherosclerotic, hyperhomocyst(e)nia and prevalence of, in ESRD patients on HD, 669-677
- Vascular endothelial growth factor (VEGF), and renal involvement of POEMS syndrome, 633-638
- Vasculitis
acute c-ANCA-positive, MMF for, 3:E9
distinguishing between SLE and HUVS, 741-751
familial systemic, RPGN and, 364-373
as primary diagnosis, 16
- Vasodilatory agent, renal, in normal pregnancy, relaxin as, 1142-1145
- VEGF (vascular endothelial growth factor), and renal involvement of POEMS syndrome, 633-638
- Venous histology on chronic HD, vascular access and changes in, 702-705
- Venous pressure of HD access grafts, monitoring of, at high blood flow, and graft failure prediction, 212-217
- Venovenous hemofiltration, continuous, for severe ARF, HD compared with, 424-432
- Ventilation, mechanical, of severe ARF patients on HD or CVVH, 427-430
- Ventilation-perfusion scintigraphy of pulmonary clots after percutaneous thrombolysis of clotted HD access grafts, 207-211
- Very-low-density lipoprotein (VLDL) in HTN with MA, atherosclerosis and, 998
- Very low protein diet (VLPD), outcome of body composition and nutritional status of ESRD patients on, 500-507
- Vesicoureteric reflux (VUR), ACE gene and scarring in, 140-145
- Viability of leukocytes, L-carnitine effects on phagocytic function and, in ESRD patients on HD, 678-687
- Visceral fat, and leptin in dialysate from CAPD patients, 832-838, 947-950
- Vision loss, acute, with pediatric ARPKD, 1125-1128
- Vitamin B₁₂
deficiency in, and resistance to rHuEPO, 352
in ESRD, *see* Vitamin B₁₂ in ESRD
- Vitamin B₁
2 in ESRD
atherosclerotic vascular disease and, 672
MTHFR genotype and, 262
- VLDL (very-low-density lipoprotein) in HTN with MA, atherosclerosis and, 998
- VLPD (very low protein diet), outcome of body composition and nutritional status of ESRD patients on, 500-507
- Volume control, HTN treatment in ESRD patients on HD by, 218-221, 359-361
- VUR (vesicoureteric reflux), ACE gene and scarring in, 140-145

- Waiting time for RTx, Western Australian Health Services Research Linked Database on, 1035, 1036
- Water-loading test in IE, 410
- WBCs (white blood cells), *see* Leukocyte(s); White blood cell count
- Wegener's granulomatosis (WG)
as primary disease, 434
RPGN and, 364-373
- Western Australian Health Services Research Linked Database on incidence and prevalence of treated ESRD, 1033-1039
- Western blot analysis, indeterminate, EIA and, of HIV in ESRD patients on chronic HD, 146-149
- Western Europe, incidence and prevalence of treated NIDDM ESRD in, 797-800
- WG (Wegener's granulomatosis), RPGN and, 364-373
- White Americans, *see* Race
- White blood cell(s), *see* Leukocyte(s); White blood cell count
- White blood cell (WBC) count
in ESRD patients on rHuEPO therapy, *Radix angelicae sinensis* effects on, 350
in severe ARF, 427-430
- Who's who in USRDS, S1:4-6
- Wilms' tumor (WT), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- Withdrawal from dialysis, as cause of mortality, USRDS 1999 ADR on, S1:92-93
- World Wide Web, Internet, USRDS products on, S1:24-25
- WT (Wilms' tumor), pediatric FS secondary to chemotherapy for, mtDNA deletions and decreased oxidative phosphorylation in, 99
- X-linked Alport's syndrome, RT-PCR and direct sequencing in detection of *COL4A5* gene mutations in, 854-862
- Year 2000 (Y2K) compliance of USRDS database, S1:154

